Assessment of drug permeation: theory, methods and applications to skin and bacteria by Geinoz, S.
 FACULTE DES SCIENCES 
 
Institut de Chimie Thérapeutique 
 
 
 
 
 
Assessment of drug permeation: 
Theory, methods and applications to skin and bacteria. 
 
 
 
 
Thèse de doctorat 
 
 
présentée à la 
 
 
Faculté des Sciences de 
l’Université de Lausanne 
 
 
par 
 
 
Sandrine Geinoz 
 
 
 
Pharmacienne diplômée de la Confédération Helvétique 
Université de Lausanne 
 
 
Jury 
 
 
Prof. François Marillier, Président 
Prof. Bernard Testa, Directeur de thèse 
Dr. Pierre-Alain Carrupt, Expert 
Prof. Richard Guy, Expert 
Dr. Patrizia Crivori, Expert 
Dr. Michel Neuwels, Expert 
 
 
 
LAUSANNE 
2002 
 
  
I
Table of contents 
TABLE OF CONTENTS I 
LIST OF ABBREVIATIONS VII 
PART I:  SKIN PERMEATION: A REVIEW 1 
1 SKIN BARRIER FUNCTION 3 
1.1 Introduction 3 
1.2 The stratum corneum and routes of passive permeation 4 
1.3 Characterization of the passive transdermal route of polar/ionic 
permeants 8 
1.3.1 A dual-pathway model 8 
1.3.2 A domain mosaic model 11 
1.4 Factors influencing percutaneous absorption 15 
1.4.1 Physiological factors 15 
1.4.2 Extrinsic factors 18 
1.5 References 20 
2 BIOLOGICAL AND ARTIFICIAL MODELS TO STUDY SKIN 
PERMEATION 25 
2.1 In vivo models 25 
2.1.1 A pharmacokinetic approach to in vivo studies 25 
2.1.2 Skin permeation in humans 26 
2.1.3 Animal skin permeation 29 
2.1.4 “Hybrid” models 30 
2.2 In vitro models 31 
  
II 
2.2.1 Diffusion cells for measuring in vitro permeation 31 
2.2.2 Skin models 32 
2.2.3 Cell-culture techniques 35 
2.2.4 Artificial membranes 36 
2.3 Aims of the thesis 38 
2.4 References 39 
3 QUANTITATIVE STRUCTURE-PERMEATION RELATIONSHIPS 
(QSPERS) TO PREDICT SKIN PERMEATION: A CRITICAL REVIEW 47 
3.1 Introduction 47 
3.2 Statistical analysis 48 
3.3 Common molecular parameters used in QSPeRs 48 
3.3.1 Molecular weight and size 48 
3.3.2 Solvatochromic parameters 51 
3.3.3 Lipophilicity and related parameters 51 
3.4 Quantitative structure-permeation relationships: pre-1990 period 53 
3.5 Analyses based on Flynn’s dataset 54 
3.6 Other recent QSPeR analyses 63 
3.7 Conclusion 66 
3.8 References 67 
PART II:  EXPERIMENTAL STUDIES ON SKIN PERMEATION 73 
4 QUANTIFICATION OF LIPOPHILICITY 75 
4.1 Experimental measurements of lipophilicity 75 
4.1.1 Introduction 75 
4.1.2 The shake-flask method 76 
4.1.3 The potentiometric method 76 
4.1.4 Cyclic voltammetry at the interface between two immiscible 
electrolyte solutions (ITIES) 78 
  
III
4.2 Computational estimation of lipophilicity 83 
4.3 References 85 
5 SILICONE MEMBRANE: A MODEL FOR THE BARRIER FUNCTION 
OF SKIN 87 
5.1 Introduction 87 
5.2 Mathematical model 88 
5.3 Materials and methods 90 
5.3.1 Materials 90 
5.3.2 pKa measurements 91 
5.3.3 Partition coefficients measurements 91 
5.3.4 Assessment of hydrogen-bonding capacity 92 
5.3.5 Permeation experiments 92 
5.3.6 Adjustment for ionization 94 
5.4 Results and discussion 94 
5.4.1 Permeability of phenolic compounds across silicone membranes 96 
5.4.2 Permeability of selected drugs across silicone membranes 100 
5.4.3 Comparison with human skin permeation 103 
5.5 Conclusion 104 
5.6 Appendix: Development of the mathematical model 105 
5.7 References 108 
6 MOLECULAR FIELDS IN QUANTITATIVE STRUCTURE-
PERMEATION RELATIONSHIPS: THE VOLSURF APPROACH 111 
6.1 Introduction 111 
6.2 TLSER: a 2D-QSAR theoretical tool 111 
6.3 Molecular fields: 3D-QSAR theoretical tools 112 
6.3.1 The GRID force field 113 
6.3.2 The Molecular Lipophilicity Potential (MLP) 114 
6.3.3 The Molecular Hydrogen-Bonding Potential (MHBP) 115 
6.4 The VolSurf procedure 119 
  
IV
6.4.1 The water probe of GRID 120 
6.4.2 The amide and carbonyl probe of GRID 120 
6.4.3 The DRY probe of GRID 120 
6.4.4 VolSurf and the 1D descriptors 122 
6.5 Chemometrics tools 128 
6.5.1 Principal Component Analysis (PCA) 128 
6.5.2 Principal Component Regression (PCR) 130 
6.5.3 Partial Least Squares (PLS) 130 
6.5.4 Cross-validation 132 
6.6 Application of 2D and 3D-QSAR analysis to skin permeation 133 
6.6.1 Data validation criteria 134 
6.6.2 Material and methods 141 
6.6.3 Results and discussion 142 
6.6.4 Conclusion 163 
6.7 References 165 
PART III:  PARTITIONING OF IONS: INFLUENCE ON THE 
PERMEATION OF A SERIES OF SULFONAMIDES INTO BACTERIA 171 
7 SULFONAMIDES AND BACTERIA PERMEATION 173 
7.1 Classification and identification of bacteria 173 
7.1.1 Bacteria: a definition 173 
7.1.2 Taxonomy 173 
7.2 Antibacterial sulfonamides 175 
7.2.1 Historical background 175 
7.2.2 Chemotherapeutic agents 176 
7.2.3 Mechanism of action 177 
7.2.4 Therapeutic use 179 
7.2.5 Nomenclature and Classification 180 
7.2.6 Structure and biological activity of sulfonamides 181 
7.3 Materials and methods 183 
  
V
7.3.1 Chemical compounds and reagents 183 
7.3.2 Bacterial strain 184 
7.3.3 Determination of the minimal inhibitory concentration (MIC) 185 
7.3.4 pKa measurements 187 
7.3.5 Partition coefficients measurements 189 
7.3.6 Cyclic voltammetry measurements 189 
7.4 Results and discussion 191 
7.4.1 Viability of the microorganisms 191 
7.4.2 Antibacterial activity of sulfonamides 196 
7.4.3 Experimental versus theoretical lipophilicity 201 
7.5 Conclusion 203 
7.6 References 204 
CONCLUSION 209 
8 GENERAL CONCLUSION AND PERSPECTIVES 211 
SUMMARY 215 
RÉSUMÉ 216 
 
  
 
 
 
 
 
  
VII
List of abbreviations 
α, β  Scaled values of H-bond donor and acceptor capacity 
π∗  Solvatochromic parameter standing for the solute's 
dipolarity/polarizability 
Σfac-(ihb)  Sum of fragmental values (fβ) for H-bond acceptor 
capacity (taking into account intramolecular 
interactions) 
Σfdo-(ihb)  Sum of fragmental values (fα) for H-bond donor capacity 
  (taking into account intramolecular interactions) 
Σpi  Sum of fragmental π∗ values 
alk  n-alkane 
ATCC  American type culture collection, catalog of reference 
strains 
CFU  Colony forming units, number of bacterial colonies 
counted on a solid medium. 
dce  1,2-dichloroethane 
DM  Diffusion coefficient in membrane M 
F  Fischer's test 
GOLPE  Generating optimal linear PLS estimations 
h  Diffusional path length 
Kp  Permeability coefficient 
L  Membrane thickness 
log PI  Logarithm of the partition coefficient of the ionic form 
log PN  Logarithm of the partition coefficient of the neutral form 
log Pdce  Logarithm of the partition coefficient measured in the 
1,2-dichloroethane/water system 
log Poct  Logarithm of the partition coefficient measured in the 
octanol/water system 
0,I
dcelog P   Logarithm of the standard partition coefficient of the 
ionic form of an ionizable solute in the 
1,2-dichloroethane/water system 
  
VIII 
∆log P  Difference between the log P values of a solute present 
in a single electric state, measured in two distinct 
solvent systems 
diff( N-IlogP )  Difference between the log P values of the neutral and 
the ionized form of a given solute, measured in the same 
solvent system 
LSERs  Linear solvation energy relationships 
LV  Latent variable 
MHB  Mueller-Hinton broth used as culture medium for 
bacterial growth 
MHBPs  Molecular hydrogen-bonding potentials 
MHBPac(do)  Acceptor (donor) MHBP 
MIC  Minimal inhibitory concentration of an antibacterial 
agent to stop bacterial growth 
MIFs  Molecular interaction fields 
MLP  Molecular lipophilicity potential 
MLPhi(ho)  Hydrophilic (hydrophobic) part of the MLP 
MxPs  MHBPs or MLP fields 
oct  n-octanol 
PCA  Principal component analysis 
PC  Principal component 
PLS  Partial least squares 
q2  predictive correlation coefficient 
QSARs  Quantitative structure-activity relationships 
QSPeRs  Quantitative structure-permeation relationships 
r2  Square correlation coefficient  
s  Standard deviation 
SC  Stratum corneum 
SDEP  Standard deviation of error of predictions 
TLSERs  Theoretical linear solvation energy relationships 
VD  Volume of the diffusion cell donor compartment 
VR  Volume of the diffusion cell receptor compartment 
Vw  Van der Waals volume 
  
 
 
 
 
Part I: 
 
Skin permeation: a review 
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1 Skin barrier function 
1.1 Introduction 
Skin, the major function of which is to compartmentalize and protect 
an animal organism from its environment, was originally considered an 
essentially impermeable barrier. However, sensitive techniques of blood 
and urine analysis showed that the skin represents a potential portal of 
entry through which many chemicals can gain access to the systemic 
circulation. Consequently, much effort is currently directed towards 
utilizing the skin as a non-invasive route for drug administration [1]. One 
of the main advantages of transdermal drug delivery compared to oral 
administration is the avoidance of variability associated with the 
gastrointestinal tract (effects of pH, motility, transit time and food intake) 
and first-pass metabolism. Although these advantages are similar to those 
associated with intravenous infusion, transdermal drug delivery is a safer 
and more convenient method of drug administration [2]. 
During skin absorption, drugs have to pass a complex multilayer 
structure before reaching the blood [3]. Structurally, the skin can be 
viewed as a series of layers, the three major divisions being epidermis, 
dermis and hypodermis or subcutis (Fig. 1.1). The hypodermis lies below 
the dermis and functions as a fat-storage layer; being below the vascular 
system, this layer is not relevant to percutaneous penetration. The dermis 
(2 mm) is essentially an acellular collagen-based connective tissue that 
supports the many blood vessels, lymphatic channels and nerves of the 
skin. The extensive microvasculature network found in the dermis 
represents the site of resorption for drugs absorbed across the epidermis; 
at this point, transdermally absorbed molecules gain entry into the 
systemic circulation and access to their central targets. Hair follicles with 
their associated sebaceous glands, eccrine and apocrine sweat glands are 
skin appendages that originate in this layer. The avascular epidermis 
consists of stacked layers of cells whose thickness is about 0.2 mm but 
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varies between 0.1 mm (eyelids) and 0.8 mm (palms, soles) [4,5]. Cells, 
which provide the epidermal tissue, differ from those of all other organs in 
that they ascend from the proliferative layer of basal cells. They change in 
an ordered fashion from metabolically active and dividing cells to become 
dense, dead and keratinized [6]. The outermost layer of the epidermis, 
namely the stratum corneum, is composed of 10-15 layers (10-20 µm) of 
flat keratin-filled cells or corneocytes, closely packed in a nonpolar lipid 
matrix. As this horny layer and its components are continuously exposed 
to physical and chemical degradation, it is a requirement that the barrier 
is constantly renewed to maintain the homeostasis of the body.  
1 2 3 4 5
Nerve
Artery
Vein
Sebaceous gland
Eccrine sweat gland
Apocrine sweat gland
Hair follicle
Epidermis
Dermis
Hypodermis
Stratum corneum
 
Fig. 1.1. Structure of the skin and routes of passive permeation: (1) 
across the transcellular pathway, (2) via the intercellular 
pathway, (3) through the hair follicles and (4) their associated 
sebaceous glands, (5) via the sweat ducts (adapted from Ref. 
[7]). 
1.2 The stratum corneum and routes of passive 
permeation 
The skin is the largest organ of the body (1.5-2.0 m2 in man) and 
offers a very accessible surface for drug delivery [8]. To bypass this 
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biological barrier, two main routes of permeation are possible. The first 
involves diffusion through the intact epidermis and the other through the 
skin appendages, i.e. hair follicles and sweat glands, which form shunt 
pathways through the intact epidermis (Fig. 1.1). However, these skin 
appendages occupy only 0.1% of the total human skin surface and the 
contribution of this pathway is usually considered to be small, with only a 
few exceptions [9,10]. It is actually well established that drug permeation 
through the skin is limited by the stratum corneum [11,12]. Two pathways 
through the intact barrier may be identified (Fig. 1.2): the intercellular 
lipid route between the corneocytes and the transcellular route across the 
corneocytes and the intervening lipids. In both cases the permeant must 
diffuse at some point through the intercellular lipid matrix, which is now 
recognized as the major determinant of percutaneous transport rate [13]. 
Intercellular routeTranscellular route
Keratin Lipid Aqueous
Intercellular
space
Plasma 
membrane
Cell
cytoplasm
Lipid
Fatty acid Cholesterol
Aqueous Ceramide
 
Fig. 1.2. Permeation routes through the stratum corneum: (i) across the 
corneocytes and the intercellular lipid matrix (transcellular 
route) and (ii) via the lipid matrix between the corneocytes 
(intercullar route) (adapted from Ref. [14]). 
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As stated above, the barrier function of mammalian skin is 
principally attributed to the stratum corneum (SC). The barrier properties 
of this unique biomembrane are based on the specific content and 
composition of the intercellular lipid matrix which accounts for ~10% of 
the dry weight of this layer, 90% of which are intracellular proteins 
(mainly keratin) [15-17]. These lipids are distinctive in many respects: (1) 
they provide the only continuous phase from the skin surface to the base 
of the SC; (2) their composition (ceramides, free fatty acids and 
cholesterol, summarized in Table 1.1), is unique among biomembranes 
(particularly noteworthy is the absence of phospholipids); (3) despite this 
deficit of polar bilayer-forming lipids, the SC lipids exist as multilamellar 
sheets; and (4) the predominantly saturated, long-chain hydrocarbon tails 
facilite a highly ordered, interdigitated configuration and the formation of 
gel-phase membrane domains as opposed to the more usual liquid 
crystalline membrane systems [18]. 
 Table 1.1. Composition of mammalian epidermal lipids [19]. 
Lipid type Living layers 
(weight %) 
Stratum corneum 
(weight %) 
Phospholipids 40 Trace 
Sphingolipids  10 35 
Cholesterol 15 20 
Triglycerides 25 Trace 
Fatty acids 5 25 
Other 5 10 
 
To understand better the skin barrier function of the stratum 
corneum, structural characteristics of the intercellular lipids have to be 
considered closely. As indicated in Table 1.1, the major lipids are the 
sphingolipids (35%), which represent a structurally heterogeneous and 
complex group of at least six ceramides [20,21]. A ceramide is a 
  
7
combination of a fatty acid and a sphingoid base, joined by an amide bond 
between the carboxyl group of the fatty acid and the amino group of the 
base. The fatty acyl moiety is either non-hydroxylated or α-hydroxylated, 
while the sphingoid moiety is sphingosine or phytosphingosine. These 
compounds are optically active and are numbered from 1 to 6 in increasing 
order of polarity as determined by thin-layer chromatography [22,23]. Two 
examples of ceramides are depicted in Fig. 1.3.  
A
B
linoleate ester ω-hydroxy acid
sphingosine
O
O
HN
O
OH
OH
nonhydroxy acid
phytosphingosine
HN
O
OH
OH
OH
 
Fig. 1.3. Structural characterization of skin ceramides 1 (A) and 3 (B). 
Being the least abundant of the ceramides, ceramide 1 or 
acylceramide is thought to play a crucial role as a “molecular rivet” 
stabilizing the multilamellar lipid array in the stratum corneum. 
Interdigitated long-chain ω-hydroxy-ceramides provide cohesion between 
corneocytes by forming tight lipid envelopes around the corneocyte protein 
component [24-26]. Moreover, the barrier function of the skin appears to 
depend on the specific ratio of various lipid; studies in which non-polar 
and relatively polar lipids were selectively extracted with petroleum ether 
and acetone, respectively, indicate that the relative polar lipids are more 
crucial to skin barrier integrity [17]. 
It seems that the unusual lipid matrix alone cannot entirely explain 
the outstanding resistivity of the membrane, and the SC architecture as a 
whole has been proposed to play an instrumental role in the barrier 
function of the membrane. Hence, the staggered corneocyte arrangement 
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in a lipid continuum (similar to a brick and mortar assembly) [27,28] is 
suggested to bestow a highly tortuous lipoidal diffusion pathway rendering 
the membrane 1000-times less permeable to water relative to most other 
biomembranes [29]. The transport role of this sinuous pathway is further 
supported by visualization studies localizing several permeants in the 
intercellular channels [30,31], by kinetic analysis of the in vivo skin 
penetration rates of model compounds [32], and by evidence from 
thermotropic biophysical studies of lipid domains [33]. 
1.3 Characterization of the passive transdermal route of 
polar/ionic permeants 
The barrier properties of human skin, localized primarily in the 
stratum corneum, have been an area of focused research since at least 
three decades. This research has originated from diverse scientific fields, 
including pharmaceutics, dermatology, physiology, toxicology, and 
biochemistry. The pharmaceutical community has recently shown 
particular interest in this area. A fundamental understanding of the 
microenvironments encountered by drugs diffusing through the skin 
should help in the rational design and optimization of transdermal drug 
delivery systems. Despite substantial interest in this field, however, the 
complex heterogeneous structural properties of the skin have prevented 
the development of a universally accepted model describing transdermal 
diffusion of molecules.  
1.3.1 A dual-pathway model 
The concept of an alternative pathway in addition to the lipoidal 
pathway, existed for several years. The diffusional transport data for a 
series of steroid compounds revealed that much of the observed 
presteady-state flux was due to diffusion through “shunt” routes [34]. In 
discussing the transdermal permeation of polar permeants such as 
polyfunctional alcohols, it was noted that a finite limiting permeability 
may be reached [35]. A “limiting permeability” is expected, as the polarity 
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of the permeants increases, for a membrane with a porous pathway in 
parallel with a lipoidal pathway [36,37]. One of the primary sources of 
evidence cited in support of a porous pathway has been data of hairless 
mouse skin permeation for several permeants with a wide range of 
polarity and molecular weight (MW) [38]. The permeation characteristics 
of the moderately polar permeants within a homologous series of 
compounds (e.g., n-alkanols) were unquestionably consistent with 
transport through a lipoidal membrane. However, the more polar 
compounds showed a positive deviation from expectations based upon 
transport through a lipoidal membrane and reached a plateau at a 
permeability coefficient range of approximately 10-8 cm/s. This positive 
deviation from what is expected for permeability based strictly upon a 
lipid membrane partition/diffusion model has been viewed as evidence for 
a porous/polar pathway [3] (Fig. 1.4). 
Stratum corneum Epidermis-Dermis
Porous 
membrane
Lipid
Lipid
Lipid
Lipid
Aqueous pore
Aqueous pore
Aqueous pore
 
Fig. 1.4. Schematic diagram of the dual-pathway model. The stratum 
corneum consists of alternating parallel lipoidal and aqueous 
pores and is in series with the porous epidermis-dermis layer. 
However, the validity of this interpretation has been questioned since 
the analysis did not consider the influence of permeant molecular volume 
(MV) upon permeation [13].  
The strong MV dependence of permeation through lipid membranes 
is well established [39,40]. The first model that included a molecular 
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weight dependence in describing skin permeation through the lipoidal 
regions was based on the following equation [41]: 
p(lip) octlog K  a log P  - b MV + c= ⋅ ⋅  Eq. 1.1 
where Kp(lip) is the lipid pathway permeability coefficient, Poct is the 
octanol/water partition coefficient, and a, b, and c are constants. This 
model proposed an exponential dependence upon MV of the solute with 
regard to skin permeation. Later, other investigators fitted several data 
sets to a correlation similar to Eq. 1.1 [13]. 
Beside the previous studies cited in support of a porous pathway in 
parallel with a lipoidal one, further investigations on chemical permeation 
enhancers have reinforced the concept of a dual-pathway model [42-45]. In 
an attempt to better understand the different viewpoints of transdermal 
diffusion, a close examination of the permeants and data included in the 
development of Eq. 1.1 seems appropriate. 
Of the human skin permeation data that have been compiled [3] and 
analyzed [13], only six of the 92 compounds have log Poct values below 
zero, and only two of these six have log Poct values below –1. Clearly, the 
performed regression for human skin data was weighted almost entirely 
by relatively lipophilic permeants. Hence, it seems worthwhile to focus on 
the polar permeants included in the analysis to see how well the proposed 
correlation actually predicts their permeability coefficients. Of the 
permeants included in the human skin analysis, sucrose and water are the 
most polar (log Poct = -3.7 and -1.4, respectively). The correlation that 
results from the fit of the compiled data to the Eq. 1.1 predicts 
permeability coefficients for sucrose and water that are 150 and 3 times 
lower than the reported experimental values. The fit between predicted 
and experimental permeability of the compounds with log Poct values 
between –1 and 0 is more satisfactory. 
Raising these issues illustrates that there is experimental evidence 
that a single lipoidal pathway cannot sufficiently account for all 
permeation data. An objective assessment of the existing data, however, 
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also indicates that there is a definite need for additional systematic 
research focusing upon the porous/polar permeation pathway. Moreover, 
as previously noted, relatively little permeation data have been generated 
for polar permeants. The interest in performing permeation studies with 
polar and ionic solutes has been limited due to the inherently low 
permeability of skin to polar permeants. Also, factors such as skin 
sample-to-sample variability make it difficult to obtain data from passive 
permeation experiments with polar compounds that lead to quantitative 
conclusions [46,47]. Despite the difficulty of characterizing polar solute 
diffusion across the skin, the importance of a fundamental understanding 
of transdermal permeation pathways should not be overlooked. 
1.3.2 A domain mosaic model 
Lipids that can form biological membranes are characterized by a 
hydrophobic part, generally fatty acid hydrocarbon chains, and a more or 
less hydrophilic head. For thermodynamic reasons the hydrophobic parts 
of the lipid molecules are segregated to form a separate region, while the 
hydrophilic headgroups face the surrounding aqueous phase [48]. The 
cohesion of such aggregates, e.g. liposomes and bilamellar structures, 
depends on a number of factors such as the charge of the headgroup and 
its hydration sphere, the hydrocarbon chain length, the degree of 
unsaturation of the aliphatic chains, and temperature. The major forces 
involved in a bilamellar organization are hydrophobic interactions 
between the hydrocarbon tails which cause the molecules to associate, and 
also the hydrophilic character of the headgroups which requires that they 
remain in contact with the water phase. Lipids in lamellar bilayers of 
liposomes and membranes can be found to exist in either of two main 
states depending on the temperature of the system, a fluid crystalline 
state and a crystalline or a gel state (Fig 1.5). When the temperature is 
lowered, the lipids are forced into a crystalline state. When such 
crystalline bilayers have water on both sides they are termed a gel phase. 
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39 Å47 Å
A (solid) B (fluid)
phase transition
temperature
polar head
hydrophobic fatty acid chains
 
Fig. 1.5. Gel phase state (A) versus liquid crystalline phase (B) (adapted 
from Ref. [49]). 
The Singer-Nicholson model of the cell membrane [50] allows a free, 
bi-directional diffusion of water over the membrane bilayer. The osmotic 
control of intracellular water content is related to an active and passive 
transport of ions over the membrane of a living cell [51]. This is 
fundamentally different from the function of the stratum corneum barrier, 
which is designed to enclose the entire body system in a water-tight 
envelope. Consequently, if the barrier properties of the skin are such as to 
effectively prevent water from leaving the organism, the bulk of the lipids 
is expected to be in a crystalline or gel phase. It has been shown that lipid 
extracts from human skin have several transition temperatures [52,53], a 
lower one around 37°C to 40°C, i.e. above the normal temperature range of 
the skin, but still at a physiologically acceptable temperature. In addition 
there are further indications of hydrocarbon chain melting at higher 
(unphysiological) temperatures. It was also demonstrated that membrane 
lipids of the epidermis show increased fluidity in the basal layers 
compared to the horny layer. This corresponds to a dominance of shorter 
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aliphatic chains (< C20) in contrast to the much longer chains (C22 to 
> C30) of ceramides in the stratum corneum. 
Evidence for segregation of lipids in the skin barrier has accumulated 
in recent years [43,54-56]. Such a segregation may occur if there is a 
significant difference in the chain length of different lipid types in 
bilamellar structures. Undoubtedly influenced by the Singer-Nicholson 
model [50], dermatologists and scientists perceive the arrangement of the 
lipid units in the skin barrier as completely randomized (Fig. 1.6). If this 
were the correct model it would mean that diffusion in the plane of the 
lipid bilayers would be feasible, i.e. the bilayers would be in the fluid 
crystalline state. However, this is not compatible with the presence of long 
fatty acid chains in the barrier lipids; thus a crystalline or a gel phase 
would dominate the barrier. 
H2O
Lipid
Bilamellar 
structures of 
lipids
H2O
 
Fig. 1.6. Traditional model of “stochastic” lipid arrangement in 
bilamellar structures. There is a completely random 
distribution of the lipid units in the plane of the lipid bilayers 
(adapted from Ref. [57]). 
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To account for both the barrier function and the current concept of 
hydrophilic and hydrophobic pathways through this barrier, the “domain 
mosaic model” of the skin barrier has been proposed [57]. This model 
depicts the bulk of the lipids as segregated into crystalline/gel domains 
bordered by “grain borders” where lipids are in the fluid crystalline state 
(Fig. 1.7). Such an arrangement provides for an effective water-tight 
barrier that allows a controlled loss of water to keep the corneocytes 
moistened. In addition, the model provides for the necessary mechanical 
properties permitting bending and stress imposed on the skin surface. 
Furthermore, the fluid character of the “grain borders” represents areas 
where lipid and hydrophobic molecules may diffuse through the system on 
down-hill gradients. It is suggested that in the border areas between the 
crystalline domains, structural transformations of the lipid organization 
due to permeation enhancers may take place without structural changes 
in the bulk organization of lipids in the crystalline or gel phase. 
H2O
H2O
Open loosely packed 
grain border areas 
function as pores
"Grain" 
border
 
Fig. 1.7. The “domain mosaic model” including “grain borders”. Lipids 
with very long chain lengths are segregated into domains in the 
crystalline/gel phase separated by grain borders populated by 
lipids with relatively short chain lengths in the lipid crystalline 
state (adapted from Ref. [57]). 
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1.4 Factors influencing percutaneous absorption 
1.4.1 Physiological factors 
Integrity of the barrier 
As discussed above, the stratum corneum (SC) is the primary barrier 
to drug absorption across the skin, with the intercellular lipids 
constituting the main milieu through which transport must occur. It is 
thus clear that transdermal bioavailability depends upon the barrier 
function of the SC and that strategies to change the composition or the 
organization of the intercellular lipids must be considered to improve 
delivery. Such enhancing technologies are feasible, but not without 
problems and limitations [14,58,59].  
The integrity of this barrier may also be altered by skin diseases that 
generally result either from variation of the lipid/protein composition of 
the SC or from abnormal epidermal differentiation. In psoriasis, for 
example, hyperproliferation of the epidermis leads to a stratum corneum 
that has a modified lipid composition, a lower resistance to transepidermal 
water loss, and an anticipated higher permeability to topically applied 
drugs [60]. 
As far as transdermal bioavailability is concerned, however, patches 
intended for systemic therapy are labeled for application only at “normal” 
skin sites, free from dermatological pathology. In the same way, skin areas 
which are excessively dry, or which have been subjected to an abrasive 
trauma, should be avoided. 
Anatomic site 
Although not extensively studied, there is a belief that skin 
absorption varies widely from site to site on the body depending on the 
thickness and nature of the stratum corneum, and – to a degree 
overemphasized in some publications – on the density of skin appendages 
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[61]. More accurately, it can be said that there is variability, but that over 
most of the surface this does not exceed by much the normal 
inter-individual variability observed at a specific site. It is true that 
certain regions are significantly more permeable – the genitalia (especially 
the scrotum), axilla, face, scalp, and post-auricular skin. In some cases, 
these high-permeability sites have been used to optimize transdermal 
delivery of particular drugs: e.g. the first testosterone patch was designed 
to be worn on the scrotum; and scopolamine is delivered behind the ear. 
However, most transdermal systems will function comparably at many 
different sites, and the recommended location will most likely depend 
primarily upon convenience (e.g., choosing a discreet site for an estradiol 
system) and/or psychological factors (e.g., placing a nitroglycerin patch 
over the heart). 
Age 
Skin age is another factor believed to impact upon percutaneous 
absorption and transdermal bioavailability. The evidence behind this 
conclusion, though, is not particularly extensive. It is known that from 
soon after birth until early “old-age”, there is little change in the rate of 
transepidermal water loss across normal, intact skin [62,63]. At the older 
extreme of the age scale, there are data pointing to changes in barrier 
function, but these are not dramatic when viewed in the context of typical 
variability across the entire population. A more important information is 
that as the skin ages, it becomes progressively more fragile and requires a 
longer period of time for recovery after injury. Thus the chronic 
application of transdermal systems to elderly patients should be carefully 
monitored. 
At the opposite end of the age spectrum, as mentioned above, 
neonates born normally at 40 weeks gestational age possess an essentially 
complete stratum corneum barrier. Premature neonates, on the other 
hand, particularly those born at less than 30 weeks gestational age have 
poorly developed barriers and must face various risks including 
  
17
percutaneous intoxication due to inadvertent chemical absorption. 
However, this negative feature also offers a potentially beneficial 
application of transdermal delivery. As drug administration to very 
premature neonates is fraught with difficulties (e.g., finding a vein for 
injection can require considerable time and cause much discomfort to the 
infant), the skin offers a route of entry that is easily accessible. This 
possibility has already been exploited for theophylline [64]. The challenge 
now is to ascertain whether the approach is feasible and manageable 
during the early weeks following premature birth, when the skin barrier 
function is maturing and changing. 
Skin metabolism 
Presystemic metabolism in the skin can obviously modify 
transdermal drug bioavailability. The cutaneous first-pass effect for 
nitroglycerin, for example, has been estimated at 15-20% [65]. The viable 
epidermis is a biochemically active tissue with metabolic capability 
[66,67]. Indeed, a multitude of enzymes have been identified in the skin, 
including a cytochrome P450 system [68]. However, the capacity of the 
viable epidermis below a transdermal patch to metabolize a delivered drug 
is limited (it must be remembered that nitroglycerin is an exceptionally 
sensitive compound, with a systemic half-life of only a few minutes), and 
the role of biodegradation is likely to be minor. Indeed, one of the 
advantages of transdermal delivery is avoidance of presystemic 
metabolism and an excellent illustration of this attribute is found with 
estradiol. 
Ultimately, the importance of metabolism in the skin depends upon 
the capacity of the enzyme system(s) involved and the relative rates of 
diffusion and bioconversion. As the metabolizing capacity is typically 
small, biodegradation is likely to be most significant only when transport 
fluxes are low. The use of enhancing technologies, therefore, with the 
specific aim to increase flux, will probably reduce any problems associated 
with metabolism.  
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1.4.2 Extrinsic factors 
Occlusion 
Of the numerous methods to enhance the percutaneous absorption of 
drugs, occlusion is the simplest and most common one. It is defined as the 
complete impairment of passive transepidermal water loss at the 
application site. The predominant effect of occlusion is increased hydration 
of the stratum corneum (SC), swelling of the corneocytes, and uptake of 
water into intercellular lipid domains. The normal water content of the SC 
is 5-15%; this figure can be increased up to 50% by occlusion. Moreover, 
skin temperature generally increases from 32°C to 37°C with occlusion 
and also contributes to penetration enhancement [69]. In some cases, 
however, raised hydration may not always increase drug permeation [70]. 
Nature of the vehicle 
The flux J of a drug through the stratum corneum can be described 
most simply by Fick's first law [71]: 
M Ms, v
s,v
D c cJ = 
L c
⋅ ⋅   Eq. 1.2 
where DM is the diffusion coefficient of the drug in the membrane, cs,M its 
solubility in the membrane, L the diffusion path length across the 
membrane, cv the concentration of the drug dissolved in the vehicle, and 
cs,v the solubility of the drug in the vehicle. Three strategies of permeation 
enhancement may be postulated based on Eq. 1.2: (i) increased DM, (ii) 
increased cs,M, i.e. increased drug partitioning into the membrane, and 
(iii) increased cv/cs,v, i.e. the degree of saturation of the drug in the vehicle 
(the supersaturation approach). The latter strategy is based on 
interactions between the drug and the vehicle, the first two approaches 
imply an effect of the vehicle on the barrier function of the stratum 
corneum. This can be exemplified by chemical penetration enhancers 
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diffusing into the stratum corneum and subsequently disordering the 
intercellular stratum corneum lipids, or by the extraction of such lipids by 
a solvating component in the formulation [14,72]. 
Microbial metabolism 
A topically applied compound will also encounter the 
micro-organisms found on both healthy and diseased skin. These 
organisms have been shown to be capable of metabolizing drugs such as 
glucocorticoid esters (bethamethasone-17-valerate) and glyceryl trinitrate. 
Although microbial degradation may act on compounds applied to the skin 
surface, this effect is limited and may become of more importance with the 
proliferation of transdermal delivery systems. Such devices may be left on 
the skin surface for periods of up to one week and could provide an 
environment in which the micro-organisms can flourish [73]. 
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2 Biological and artificial models to study skin 
permeation 
The prediction of chemical transport across the skin is important for 
both the optimisation of topical and transdermal drug delivery, and the 
assessment of risk following dermal exposure to chemicals [1,2]. To 
facilitate the estimation of percutaneous absorption, a number of in vivo, 
in vitro and cell-culture models have been developed (Table 2.1) [3-6]. The 
predictive capacity of the different approaches as well as their relative 
utility will be discussed here in order of decreasing complexity; those most 
worthy of further study will be highlighted. 
2.1 In vivo models 
2.1.1 A pharmacokinetic approach to in vivo studies 
A general approach to model skin absorption has been to build 
“pharmacokinetic” models in which various compartments represent the 
delivery device, the stratum corneum, the viable tissue and the blood. 
Normal elimination kinetics are assumed from the blood compartment 
(Fig. 2.1). The first-order rate constants connecting the compartments can 
be ascribed physical significance [7], e.g. the slowest step k1 equals 
transfer across the stratum corneum equals 2sc scD / h  where sch  is the 
diffusional path length and scD  the diffusional coefficient of the drug in 
the stratum corneum. The rate constant k2 describes the diffusion of the 
penetrant through the viable epidermis. Thus, as for k1, it may be 
evaluated from the relationship 22 epid epidk  = D  / h  where epidD  is the 
diffusion coefficient of the drug through the viable epidermis of diffusional 
path length epidh . The rate constant k3 is related to back diffusion from 
the viable epidermis to the stratum corneum and thus reflects the affinity 
of a drug for the stratum corneum.  
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The ratio k3/k2 is related to the partition coefficient between the 
lipophilic stratum corneum and the aqueous viable epidermis, and  has 
been shown to be linearly correlated with the octanol/water partition 
coefficient [8]. The model has been used successfully to predict the 
transdermal delivery of a number of drugs [9-14]. 
Skin 
surface
Viable 
epidermis
Stratum
corneum
k1
k2
k3
Dermal 
capillaries
urine
k4
C1 , V1 C2 , V2 C3 , V3 C4 , V4
k1 k4k2
k3
 
Fig. 2.1. Schematic representation of the pharmacokinetic model. 
2.1.2 Skin permeation in humans 
Percutaneous penetration studies performed in humans provide the 
most relevant information. These studies are considered as the “gold 
standard” against which all methods for measuring skin absorption should 
be evaluated [3,15]. However, such experiments are not always easy to 
carry out, they may be expensive, and they can involve unacceptable risks 
to the volunteers. Among the advantages, in addition to the relevance and 
realism provided by a human in vivo experiment, it is at least theorically 
possible to obtain important pharmacokinetic information pertaining to 
skin absorption. On the other hand, however, there are certain 
disadvantages, not the least of which is the variability associated with 
human percutaneous absorption [16] and the fact that not all experiments 
are conducted in the same homogenous population of volunteers under 
identical conditions, nor on the same anatomic site, and so on. 
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Table 2.1. Different biological and artificial models to assess 
percutaneous absorption. 
 Advantages Limitations 
In vivo models 
Human Gold standard of relevance 
Pharmacokinetic 
information is obtainable 
Ethical considerations 
Time-consuming 
experiments 
Inter-individual variability 
Animal Good alternative for 
toxicological studies 
Good correlation with 
in vivo human data 
Skin barrier may be more 
permeable than in man 
Large interspecies 
variability 
“Hybrid” models Experiments performed 
with intact tissues 
Low throughput 
Complicated model 
In vitro models 
Skin fragments Good intermediate level of 
complexity 
Tissue source does not need 
to be human  
High variability within 
treatments 
Time-limited experiments 
due to short viability 
Cell cultures  Used to investigate both 
cutaneous metabolism and 
dermal irritation 
Poor prediction of skin 
permeation in man 
Time-consuming and 
expensive methodology 
Artificial membranes Fast screening possible 
Experiments at low cost 
Difficult in vivo 
extrapolation 
Poorly characterized 
systems 
 
Historically, human experiments were performed using small 
amounts of radiolabelled permeant applied to the skin in a small volume 
of organic solvent which quickly evaporated [17,18]. Thereafter, the 
elimination of the administrated radioactivity in the urine and/or feces 
was determined and, from this information, the percentage dose absorbed 
was deduced. While this experiment is of interest from a practical 
standpoint in that it is conducted in man, it has certain limitations in that 
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the measurement compartment, i.e. the excreta, is far-removed from the 
application site on the skin. Any conclusion about the percutaneous 
absorption phenomenon, beyond the cumulative amount absorbed, is 
therefore difficult to reach. One also has to question the ethics of applying 
radioactive substances to human skin in vivo ⎯ a practice that is accepted 
in some countries, but absolutely forbidden elsewhere.  
Beside the extremely rigorous methods (e.g. full pharmacokinetic 
evaluation) used to assess skin absorption, a range of different studies 
have been performed and the information obtained therefrom varies in 
both quality and quantity [19,20]. More recently, an alternative in vivo 
experiment has replaced the evaluation of drugs in a compartment distant 
from the application site with, instead, determination of the permeant in 
the compartment to which it is being administrated, i.e. in the stratum 
corneum [21]. In its simplest form, post-application of a drug-containing 
formulation, this method involves removal of the stratum corneum by 
repeated adhesive-tape-stripping and quantification of the amount of 
substance absorbed by extraction and analysis of the individual tapes. 
This technique holds much promise for the comparison of different 
formulations containing the same drug and the determination of 
bioequivalence, for example, and as a rather tedious way to screen 
formulations. 
It should be noted that this current method was somewhat 
anticipated in a series of studies published several years ago [22]. In that 
work, the stratum corneum was also removed after a short period 
(30 minutes) of contact between the applied vehicle and the skin, and the 
amount taken up into the barrier layer was determined. It was shown that 
this amount was highly correlated with the percentage dose applied which 
would have ultimately permeated into the body (measured by urinary 
excretion over 4 days) following an identical exposure. While this 
relationship is hardly surprising given the brief period of skin exposure 
involved, the methodology provided an extremely simple approach to 
evaluate the body burden of a chemical following its brief contact with the 
skin. This is an invaluable aid, therefore, when assessing the potential for 
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toxicity after dermal exposure to cosmetic or personal-care products which 
typically remain on the skin for only relatively short periods of time. 
2.1.3 Animal skin permeation 
The use of in vivo animal models to study skin permeation represents 
another considerable body of work [4]. Many different species have been 
examined, not the least of which include the rhesus monkey, the pig (mini- 
and weanling pigs), the rabbit, and many different species of rodents (rats, 
mice, guinea pigs, both hairy and hairless). The advantage of using an 
animal model as opposed to man is that animals are generally more 
accessible, and the procedures used can be more invasive than those 
possible in human volunteers. The disadvantages of using animals, on the 
other hand, are mainly due to the relevance of such models to represent 
and predict permeation in man. Furthermore, animal experiments may be 
quite expensive (especially if one uses a rhesus monkey, for example), may 
be as time-consuming as human studies since the animals need to be 
acclimated, and may require specialized equipment. 
Looking at the animal models used to date, some observations can be 
made. First of all, it is clear that there exist animal models which 
correlate well with human models. The most notable examples are the 
rhesus monkey and the pig, including the minipig and wealing pig [23]. 
Unfortunately, these animals are neither the easiest nor the most 
economic to use. With respect to the more classical laboratory animals 
such as the hairy rat, mouse, rabbit or guinea pig, the literature shows 
that percutaneous absorption in these models is much higher than in man. 
To understand why these models overestimate human skin permeation, 
one has to take into account the possibility of a significant role in skin 
uptake via follicular pathways, which are much more developed than in 
the generally “bald” human skin. Moreover, these rodents typically have a 
thinner stratum corneum than man [24]. These physiological 
characteristics could partially explain the use of rat as the standard 
animal of choice for toxicological testing. This argument, however, is far 
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from convincing given that the differences in percutaneous absorption 
between rat and man can be as great as 10-fold.  
Similarly, for the hairless rodent species, the permeation of chemicals 
is again higher than through human skin. Again, this is presumably due 
to the thinner barrier layer and to a different lipid composition compared 
to humans. Differences range from 2-3 fold up to nearly one order of 
magnitude. Nevertheless, hairless species are qualitatively reasonable 
predictors of trends in absorption. There is, however, an important 
problem with hairless species when one examines the influence of 
formulation components such as penetration enhancers on drug transport 
across the skin. It has been demonstrated that the more fragile stratum 
corneum of a hairless animal exaggerates the effects of these excipients 
and may significantly over-predict their effects in man. 
2.1.4 “Hybrid” models 
There have been other in vivo models developed which are more 
sophisticated, more complicated and, in consequence, less practical to use. 
For example, it was shown several years ago that it was possible to graft 
human skin onto the backs of athymic mice [25]. The viability of the skin 
after the graft had taken was good, and the existence of a functional 
cutaneous microcirculation could be demonstrated. Rejection could be 
reduced by treating the animals with immunosuppressive agents. An 
in vivo model was therefore available which allowed permeation across 
human skin to be investigated in an easy to handle rodent. Furthermore 
and importantly the human skin retained its permeability characteristics. 
Nevertheless, this is a time-restricted and labor-intensive model.  
Another similar model involves the so-called skin sandwich flap [26]. 
Following a complex surgical procedure, an external skin “sandwich” 
consisting of the host athymic rat skin on one side and grafted human skin 
on the other, was grown on the animal and perfused via single afferent 
and efferent blood vessels, much like an isolated perfused organ 
preparation. Quite detailed pharmacokinetic analyses of the absorption 
and distribution of topically applied drugs could be undertaken, at least 
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within the constraints of the period available for experimentation 
(necessarily short because anesthesia of the animal was required). Neither 
of these models has been much used, primarily because of their technical 
complexity and expense. While useful perhaps as research tools, these 
approaches are not practical for routine use, and literature citations 
describing their use are now very rare. 
2.2 In vitro models 
An in vitro experiment to measure the percutaneous absorption of a 
drug is a much simpler approach than an in vivo measurement [27]. 
However, with this simplicity comes a number of limitations, and the 
question of relevance to predict in vivo permeation must always be raised. 
The literature is replete with papers describing in vitro 
percutaneous-absorption studies. The range of compounds studied and the 
variety of skin membranes used is quite staggering. As for in vivo 
methods, the range of animal species (in addition to man) which have 
given their skin for such permeation experiments is very broad. 
2.2.1 Diffusion cells for measuring in vitro permeation 
The most frequently used in vitro method is a simulated membrane 
permeation experiment. Its design involves various rate-limiting 
membranes (e.g., excised animal or human skin, artificial membranes), 
adjustable environments, numerous protocols and the use of diffusion 
cells, i.e. systems containing a donor and a receptor compartment [28]. 
The donor compartment can be closed or open, depending on the type of 
administration protocol. As for the receptor compartment, it can be either 
closed (static design) or open (flow-through design) [29-33]. An appropriate 
analytical method (UV-spectrophotometry, liquid-scintillation counting, 
etc.) is used to quantify and monitor the appearance of drug in the 
receptor solution and/or the decline from the donor compartment as a 
function of time [34]. 
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The major advantage of in vitro investigations is that the 
experimental conditions can be controlled precisely, such that the only 
variables are the membrane and the test material. A potential 
disadvantage, however, is that little information on the metabolism, 
distribution, and effects of blood flow on permeation can be obtained. 
2.2.2 Skin models 
Isolated perfused tissues 
Perfused tissue models use excised regions of skin, complete with 
their associated microvasculature, immediately after sacrifice and with 
continuous perfusion (e.g., with Krebs-Ringer buffer, glucose and 
albumine aerated with oxygen and carbon dioxide). Several variations 
involve both different species and different areas of skin. Isolated perfused 
porcine skin flaps [35], bovine udders [36], and rabbit ears [37,38] have 
also been used. The perfused pig ear model uses an isolated ear perfused 
with oxygenated blood from the same pig [39]. These techniques allow the 
investigation of the effect of local blood circulation on the accumulation 
and removal of topically applied materials. In addition, one of the major 
disadvantages of the usual in vitro method, namely the lack of a perfused 
network of skin capillaries, is nearly overcome. Nevertheless, these 
preparations are complex for routine use and animal skin is not spared. 
Human skin 
Among the range of models available for in vitro experiments, human 
skin has been described as the material of choice [3]. The principal sources 
of human skin are cosmetic-surgical procedures, cadavers, and tissue 
banks. Not surprisingly, tissue obtained immediately following plastic 
surgery is preferred since the skin can be maintained metabolically active 
for some time, and the source and condition of the tissue can be 
ascertained during surgery. On the other hand, with skin obtained from a 
cadaver or from a tissue bank, one does not always know the origin of the 
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tissue, nor what may have happened to the tissue between the time that it 
is harvested and the moment that it is used in an in vitro experiment. 
Equally, it is very unlikely that such tissue would retain much in the way 
of metabolic activity, and it cannot be used, therefore, in experiments 
which require full skin viability [40].  
The preparation of skin tissue for an in vitro experiment depends, of 
course, on the investigation envisaged. Every conceivable slice of skin has 
probably been examined: full-thickness skin, skin dermatomed to a 
particular depth (from a few to several hundred µm), heat- or otherwise 
separated epidermis, dermis, skin from which the barrier has been 
removed (e.g., by tape-stripping) and, most simply, stratum corneum 
isolated by enzymatic treatment (trypsinization). 
Based on the assumption that the stratum corneum represents the 
main barrier in skin penetration, solute permeability across the skin can 
thus be determined by using a diffusion cell where the isolated stratum 
corneum is embedded as a membrane [41]. Although permeability 
experiments through this horny layer have been carried out in vitro, they 
do not differ markedly from an in vivo situation since this dead layer is 
also present in the living organism. However, such studies are carried out 
in water, resulting in an artifactual hydration which promotes solute 
penetration [42]. Therefore, any deduction one can make will not pertain 
directly to an in vivo situation, but to an extensively hydrated skin. This 
drawback may be tolerable, given that under normal in vivo conditions the 
skin is easily hydrated, particularly when a drug is applied is an aqueous 
gel or under occlusion [43]. 
Animal skin 
Like biological membranes, isolated skin fragments from animals 
(e.g., rat, mouse, rabbit, squirrel, guinea pig, snake and pig) are frequently 
used [44-49]. Depending on the number of hair follicles seen in such skins 
preparations, three different phenotypic hair densities have been defined 
as hairy, fuzzy and hairless [50]. 
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Among the many animal skins used, those from snakes and domestic 
pigs have been proposed as relevant models. Thus, the response of shed 
snake skin to lipophilicity and molecular weight mimics that of the human 
stratum corneum more closely than that of hairless mouse skin [51]. In 
addition, the rate of water evaporation of shed snake skin is comparable to 
that of human skin. Nevertheless, the lack of an optimum correlation 
between snake and human skin is likely due to the differences of their 
lipids in structure and proportions [52]. A particular advantage of this 
model, however, is that snakes shed their skins on a regular basis, thereby 
providing a renewable source of tissue without the need to kill the animal. 
Otherwise, the domestic pig is perhaps the best skin model, as it has been 
demonstrated to have histological and physiological properties similar to 
those of human skin. The epidermal lipid biochemistry of the pig has also 
been shown to be similar to that of humans [53]. Although animal skin is 
more readily available than human skin, care must be taken when 
selecting a type of skin, because the method remains time-consuming and 
may show poor reproducibility [5]. There is no question, however, that 
in vitro skin-permeation experiments have yielded a wealth of information 
about the percutaneous penetration process, in particular with respect to 
the key structure-penetration relationships involved [54]. 
As described by the European Centre for the Validation of 
Alternative Methods (ECVAM), the commonly used methods for 
measuring percutaneous absorption can be ranked in a hierarchy 
(Fig. 2.2). Although the ranking of animal skin types represented here is 
generally appropriate, one must take exception to the ranking of 
methodologies on the left side of the diagram. The choice of different 
in vivo and in vitro methodologies depends on the compounds being 
studied, and on the questions being asked. Thus, in predicting human 
dermal absorption, an in vivo study may not be preferable to an 
appropriately designed in vitro experiment. 
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Fig. 2.2. Hierarchy of physiological levels (on the left side) and skin 
types (on the right side) for measuring percutaneous 
absorption, as recommended by the European Centre for the 
Validation of Alternative Methods (ECVAM) [3]. 
2.2.3 Cell-culture techniques 
In recent years, attention has been focused on the development of 
skin substitutes to provide biological materials for the treatment of acute 
and chronic wounds [55,56], and to provide models permitting toxicological 
and pharmacological studies in vitro [57-59]. The skin equivalents used for 
permeation testing are typically the epidermis or full-thickness skin. The 
full-thickness equivalents are composed of both dermal and epidermal 
tissues, with the dermis being constituted from a collagen matrix 
populated or not by living fibroblasts. The epidermal substitutes are 
composed of normal human keratinocytes that have been cultured at the 
air-liquid interface to insure proper development and terminal 
differentiation [60,61]. These skin equivalents have many advantages, 
including the ability to eliminate animal experimentation. Also, they use 
human skin cells which exhibit morphological and biochemical features 
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similar to native skin. Beside such analogies, the barrier function of these 
substitutes is significantly deficient in comparison to human skin, and the 
epidermal lipids show abnormalities in composition [62]. Such cell 
cultures are more permeable than intact skin and their lower content in 
ceramide, the most important lipid class for the barrier function, may be 
the cause for this quantitative difference [63-65].  
More recent comparisons of permeability have shown that these 
cutaneous models are discriminative in terms of absorption rates and yield 
the same ranking of permeants as normal human skin [66]. 
2.2.4 Artificial membranes 
Several synthetic membranes can be used to model the transport of 
drugs across the skin [5,67]. They are exemplified by cellulose acetate 
membranes, which have been used in various diffusion studies [68-70]. 
Like all dialysis membranes, those made of cellulose acetate are porous 
barriers which model the skin seen as a passive diffusion barrier, with 
very little involvement of drug partitioning into the intercellular lipid 
pools. Consequently, in these experimental models, the rate of diffusion is 
determined by solute concentration and the length of the diffusion 
pathway. Although this mechanism is not representative of diffusion 
through intact skin, it may be relevant as a model for damaged skin, 
where the relatively aqueous dermis is the only remaining barrier[5]. 
In addition to hydrophilic acetate membranes, an array of synthetic 
polymer membranes containing hydrophobic groups have been evaluated 
as potential models for penetration of compounds through the skin. The 
hydrophobic groups are intended to provide functional mimics for drug 
partitioning into lipids. Among these mixed-polarity membranes, foils of 
dimethylpolysiloxane (silicone rubber or Silastic®) have been most 
extensively used [45,71-74]. These models, however, do not incorporate all 
of the structural features needed to evaluate interactions occurring during 
transport across lipoidal intercellular channels. 
Besides such solid membranes, organic liquid-supported membranes 
containing hydrocarbons, long-chain alcohols or isopropyl myristate have 
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been investigated [75-78]. Also, skin lipids (ceramides, fatty acids, 
cholesterol, etc.) or liposomes composed of various skin lipids, have been 
tested [79,80]. Several synthetic (mixed cellulose ester, polyethylene-
vinylacetate, polypropylene, etc) or natural materials (e.g. eggshell 
membrane) have been used to prepare artificial membranes. Such systems 
have been proposed as reasonable models for the epidermal barrier[81]. 
Other devices combine two or more different membranes into 
laminate or composite systems to mimic the hydrophilic and hydrophobic 
domains of the skin [5]. Such models, however, are not relevant because 
the desorption of solutes out of the stratum corneum is linear with the 
square root of time, whereas linear relationships have been obtained with 
laminates. More recent experiments have used synthetic graft copolymers 
to model the heterogeneity of skin domains [82-84]. These latter 
membranes have proved useful as relevant models for the quantitative 
evaluation of transdermal penetration. 
Although skin-imitating membranes will continue to play a role in 
the future, artificial membranes should provide the most useful forecast of 
in vivo transdermal delivery processes when: (1) the passive diffusion 
barrier imposed by the stratum corneum is the major resistance to 
transport; (2) the drug of interest is known to be metabolically inert and 
not specifically bound in viable skin; (3) the formulation does not contain a 
permeability enhancer which can interact with the skin but not the 
membrane; and (4) in vivo experiments of similar design have been or can 
be performed and correlated with in vitro results. 
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2.3 Aims of the thesis 
The aims of this thesis are to highlight the relevant physicochemical 
properties responsible for permeation across biological membranes, 
namely human skin and bacterial cells. This thesis is divided into three 
parts. 
Part I is devoted to a critical review on skin permeation. First the 
predictive capacity of the different in vivo and in vitro models used to 
estimate skin permeation is examined in chapter 2. Then, quantitative 
structure-permeation relationships (QSPeRs) to predict percutaneous 
absorption are reviewed in chapter 3, and their statistical reliability is 
also discussed. 
Part II illustrates the application of experimental and computational 
models in predicting skin permeation. In this context, chapter 5 is based 
on the use of silicone membranes, as artificial models for the barrier 
function of skin. A set of phenolic derivates in addition to heterogeneous 
compounds are investigated in terms of physicochemical parameters 
relevant in permeation. The application of a computational tool, the 
VolSurf procedure, to predict human skin permeation is shown in 
chapter 6. Specific considerations on the nature of molecular interaction 
fields used in this method are also discussed. 
Part III attempts to correlate the antibacterial activity, measured in 
terms of minimal inhibitory concentration (MIC), of a set of sulfonamides 
with their physicochemical properties. 
Finally, a general conclusion and perspectives for future work is 
presented in chapter 8. 
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3 Quantitative structure-permeation 
relationships (QSPeRs) to predict skin 
permeation: a critical review 
3.1 Introduction 
Because the determination of absorption of chemicals into and 
through the skin involves ethical difficulties with experiments on animals 
and human skin [1], the quantification of transdermal penetration raises 
great interest in industrial, governmental and academic circles. 
Quantitative structure-permeation relationships (QSPeRs) relate 
variations in the permeation of series of compounds with variations in 
their physicochemical and/or structural properties. QSPeRs provide 
insights into permeation mechanisms, prediction of the permeation of 
novel compounds (even before their synthesis) and allow to limit in vivo 
experiments. In transdermal studies, QSPeR models are often based on 
multivariate regression analysis to encode an experimental index of 
permeation such as the permeability coefficient, Kp. A key feature in the 
development of QSPeRs is that all available data must be consistent and 
reliable. Variations caused by heterogeneous experimental conditions will 
decrease the statistical validity of models. Furthermore, the 
physicochemical parameter space should be broadly explored to provide 
relevant information on the factors governing skin permeation. 
The ability of a compound to diffuse passively across the skin can be 
variously assessed. Commonly, parameters from Fick's first law (Eq. 3.1), 
including flux and permeability coefficient, are used [2]: 
M  M Mp
D PJ = C = K C
h
⋅ ⋅ ∆ ⋅ ∆  Eq. 3.1 
where J is the flux, DM the diffusion coefficient into the membrane, P the 
partition coefficient of the solute between the membrane and solvent, h 
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the diffusional path length, ∆CM the difference in concentrations between 
both sides of the membrane, and Kp the permeability coefficient. Typically 
such assessment is made following in vitro exposure of skin fragments to 
the permeant. Other assessments may include the amount, or percentage, 
of an exogenous chemical being absorbed in vivo. 
The purpose of this review is to give an overview of some important 
models to evaluate skin permeation. Physicochemical determinants in 
passive drug absorption and the relevance of the various approaches are 
also discussed. A summary of the chemical classes and ranges covered in 
terms of molecular weight, lipophilicity and permeability is presented in 
Table 3.1. 
3.2 Statistical analysis 
Most published QSPeR models appeared without complete statistics 
and were recalculated here using a stepwise multiple regression procedure 
in Tsar 3.3 (Oxford Molecular) running on Windows 2000 PC. All 
calculations were performed in an identical manner, the statistical 
parameters highlighted being the number of compounds included in the 
analysis (n), the square correlation coefficient (r2), the standard deviation 
(s), Fischer's test (F), and the predictive correlation coefficient (q2). This 
latter parameter is obtained by cross-validation using a “leave-one-out” 
deletion pattern (see section 6.5.4) [3-5]. Moreover, 95% confidence limits 
are given in parentheses and the relative contributions of each variable to 
the model is calculated using Mager’s standardization procedure [6]. 
3.3 Common molecular parameters used in QSPeRs 
3.3.1 Molecular weight and size 
Molecular size is believed to play a distinct role in permeation 
processes [7,8]. Drug diffusivity, in general, is size-dependent, i.e., large 
molecules diffuse more slowly than small ones.  
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Table 3.1. Summary of the chemical classes and range of molecular 
weight (MW), lipophilicity (log Poct) and permeability (log Kp) 
upon which each model was developed. 
Equation Reference Chemical class Ranges a) 
Eq. 3.9 Potts & Guy 1992 [9] 
Flynn’s database  
(n = 93) 
18 < MW < 765 
-2.3 < log Poct < 5.5
-6.1 < log Kp < 0.1 
Eq. 3.12 Lien & Gao 1995 [10] 
Alkanols, phenols, steroids 
(n = 22) 
18 < MW < 362 
-1.4 < log Poct < 3.9
-5.5 < log Kp < -1.2 
Eq. 3.13 Barratt 1995 [11] 
Alkanols, phenols, steroids, 
barbiturates, other drugs  
(n = 60) 
18 < MW < 362 
-2.3 < log Poct < 5.5
-5.5 < log Kp < 0.1 
Eq. 3.15 Potts & Guy 1995 [12] 
Alkanols, phenols,  
miscellaneous compounds 
(n = 37) 
18 < MW < 158 
-1.4 < log Poct < 3.2
-3.5 < log Kp < 0.1 
Eq. 3.17 Abraham et 
al. 1995 [13] 
Alkanols, phenols, steroids 
(n = 46) 
32 < MW < 362 
-0.8 < log Poct < 3.7
-5.5 < log Kp < -1.2 
Eq. 3.20 Abraham et 
al. 1997 [14] 
Alkanols, phenols, steroids,
miscellaneous compounds 
(n = 53) 
32 < MW < 392 
-0.8 < log Poct < 4.0
-4.2 < log Kp < 0.1 
Eq. 3.21 Pugh et al. 1996 [15] 
Alkanols, phenols, drugs 
(n = 52) 
32 < MW < 303 
-0.8 < log Poct < 4.0
-4.3 < log Kp < -1.1 
Eq. 3.22 Dearden et al. 2000 [16] 
Flynn’s database 
(n = 91) 
18 < MW < 765 
-2.3 < log Poct < 5.5
-6.1 < log Kp < 0.1 
Eq. 3.23 Cronin et al. 1999 [17] 
Flynn’s database, 
miscellaneous compounds 
(n = 107) 
30 < MW < 391 
-1.5 < log Poct < 7.5
-5.5 < log Kp < -0.2 
a) Permeability coefficients (Kp) are expressed in [cm/s] (Eqs 3.9, 3.15, 3.17, 3.20, 
3.21) and in [cm/h] (Eqs 3.12, 3.13, 3.22 and 3.23). 
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In simple liquids, this dependence is often expressed by the 
Stokes-Einstein equation [18]: 
R TD = 
6 r N
⋅
⋅ π ⋅ η ⋅ ⋅   Eq. 3.2 
where D is the diffusion coefficient obtained from Fick's law (Eq. 3.1), R 
the molar gas constant, T the absolute temperature, η the viscosity of the 
solvent, r the solvated radius of the diffusing solute, and N Avogadro's 
number. Assuming spherical molecules, Eq. 3.2 means that D is inversely 
proportional to the cube-root of the molecular volume (V).  
In more organized media such as polymers and the stratum corneum, 
the dependence on size is more severe and has been empirically described 
by an exponential relationship [9]: 
−β⋅⋅0 (V)D = D e   Eq. 3.3 
where D0 is the diffusivity of a hypothetical molecule having zero 
molecular volume, and β is a constant. This means that drug diffusivity 
across the stratum corneum decreases as molecular weight (MW) 
increases since V and MW are interdependent. 
In terms of permeability coefficient (Kp), the diffusion parameter (D) 
plays an important role in addition to lipophilicity (P), as described in the 
following equation:  
⋅
p
D Plog K  = log  = log D + log P - log h  
h
 Eq. 3.4 
The partition coefficient (P) of a solute between the skin and water 
has been frequently described in terms of octanol/water partition 
coefficient (Poct) [19,20] which depends on molecular volume and polar 
interactions (see section 3.3.2). The combination of diffusion and partition 
coefficient in a single equation (Eq. 3.4) shows that the solute’s volume 
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contributes both positively and negatively to its permeation, as illustrated 
later by Eqs 3.9 and 3.17. A practical result of this observation is that 
small polar compounds often have better permeabilities than expected 
from their lipophilicity alone, due to compensation by a higher diffusivity. 
3.3.2 Solvatochromic parameters 
Linear solvation free-energy relationships (LSERs) are based on the 
solvatochromic parameters developed by Taft, Kamlet, Abraham and 
co-workers [21-25]. LSER analyses serve to factorize some given molecular 
property (Sp) of neutral organic solutes, e.g. partitioning, retention or 
permeation [19,26-29], in terms of structural parameters such as the 
calculated van der Waals volume (Vw) and the so-called solvatochromic 
parameters (dipolarity/polarizability π*, hydrogen-bond donor acidity α, 
and hydrogen-bond acceptor basicity β). The linear equation 3.5 reflects a 
differential solvation model constructed with an endergonic factor (i.e. the 
volume term accounting for solvophobic/hydrophobic and dispersive forces) 
and an exergonic factor (i.e. the polar interactions represented by π*, 
α and β terms). 
p wlog S = v V  + p *  + a  + b  + c⋅ ⋅ π ⋅ α ⋅β  Eq. 3.5 
where v, p, a, and b are the regression coefficients which reflect the 
relative contribution of each solute parameter to Sp. The constant term c 
includes information on the analyzed system. 
3.3.3 Lipophilicity and related parameters 
Lipophilicity is classically recognized as a meaningful parameter in 
structure-activity relationships (QSARs). It is also the single most 
informative and successful physicochemical property in medicinal 
chemistry [30,31]. Not only has lipophilicity found innumerable 
applications in QSARs, but its study has revealed a wealth of information 
on intermolecular forces, intramolecular interactions, and molecular 
structure in the broadest sense [32-34]. 
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Lipophilicity is determined experimentally as partition coefficients 
(log P, valid only for a single ionic state) or as distribution coefficients 
(log D, referring to a pH-dependent mixture of ionic forms, see chapter 4) 
[35]. As a ratio of two concentrations at equilibrium, the partition 
coefficient is the net result of all intermolecular forces linking a solute and 
the two phases between which it partitions. When a given type of 
interaction elicited by the solute is of similar energy in the two solvents, 
the two contributions compensate each other and log P will contain no 
information about this type of interaction. 
It is now common to factorize lipophilicity into two sets of terms 
(Eq. 3.6), namely a cavity term positively related to lipophilicity, and a 
negatively related polarity term [36]: 
log P = a V - ⋅ Λ   Eq. 3.6 
where V is the molar volume and Λ the global polarity of a given solute in 
a given solvent system. The slope a depends on the solvent system and on 
the method used to calculate molecular volumes, whereas the Λ term is 
mostly related to the solute's H-bonding capacity. This latter parameter, 
however, also contains information on dipolarity/polarizability. 
The contributions of the volume term in octanol and alkanes are 
known to be similar [27,37] so that the difference log Poct minus log Phep 
(noted ∆log Poct-hep) is a function of the polar terms only, and in fact 
mostly of the H-bonding donor acidity (α) (Eqs 3.7 and 3.8), as 
demonstrated by a factorization into the solvatochromic parameters: 
∆ ⋅ π ⋅β
⋅ α
oct-hep
2
log P  = 0.12 (±0.30) * + 1.96 (±0.42)
                     + 3.40 (±0.25)  - 0.43 (±0.27)
n = 75;  r  = 0.92;  s = 0.31;  F = 288
 Eq. 3.7 
∆ ± ⋅ α ±oct-hep
2
log  P  = 3.54 ( 0.36)  - 0.37 ( 0.15)
n = 75;  r  = 0.84;   s = 0.45;  F = 325
 Eq. 3.8 
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The ∆log P parameter has found valuable applications in QSPeR 
studies, e.g. in percutaneous absorption or crossing of the blood-brain 
barrier [19,38-40]. 
Lipophilicity is also markedly influenced by intramolecular 
interactions which can been classified into three main classes [34]: 
electronic conjugations; interactions involving polar groups; and steric and 
hydrophobic effects. Several structural factors have been found to be 
responsible for intramolecular interactions, rendering them too complex to 
be factorized into simple molecular descriptors such as log P and log D.  
Two experimental methods have been proposed to deal with 
intramolecular forces affecting lipophilicity. The first method is the 
calculation and application of a number of diff parameters, deduced from 
lipophilicity descriptors obtained in the same solvent system for two states 
(e.g. ionic) of a given solute. Recently, the various diff parameters and 
their significance has been reviewed [37]. The second method refers to a 
pair of solvent systems and is based on the graph obtained by plotting 
log Poct vs log Pxxx (being xxx a second system solvent) for a balanced 
training set of compounds [27]. The addition to this graph of the solutes 
under study can reveal the existence of intramolecular effects rendering 
these solutes deviant. Alternatively, the same information can be obtained 
by calculating and analyzing ∆log P parameters, but the results may not 
be as clear-cut as those obtained with the graphical approach. 
3.4 Quantitative structure-permeation relationships: 
pre-1990 period 
Over the last thirty years, there have been significant attempts to 
relate the skin permeability of compounds to their physicochemical 
properties. Quantitative models (i.e. QSPeRs) were seldom presented, 
particularly in the earlier studies. Most of these were based on the 
analysis of homologous or closely related series comprising relatively few 
compounds. Many of these studies revealed a linear relationship with 
lipophilicity, i.e. increasing lipophilicity was associated with increasing 
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skin permeation [41,42]. Some studies also reported a parabolic 
relationship with lipophilicity, particularly when highly lipophilic 
compounds were included [42]. Whilst these studies showed that it was 
possible to derive QSPeR models for skin penetration, each model was 
valid only for a particular chemical class or a series of compounds. A 
further problem of analyzing homologous or closely related series is that 
there is little physicochemical variety in the data. This results in 
co-linearity between descriptors, especially for congeneric series, so that it 
is not possible to separate the effects of lipophilicity and molecular size. A 
number of excellent reviews dealing with the modeling of skin 
permeability of homologous or closely related series of compounds have 
been published [43-45]. 
3.5 Analyses based on Flynn’s dataset  
Attempts to develop a more global approach to the QSPeR prediction 
of skin permeability were greatly facilitated by the large database 
published by Flynn in 1990 [46]. A collection of 97 permeability 
coefficients (Kp) for 94 compounds (3 triplicates) with a relatively broad 
range of properties (18 < MW < 765 and -2.3 < log Poct < 5.5) were 
gathered in this publication. Until recently, this provided the largest 
heterogeneous database of in vitro skin permeabilities through human 
skin. It should be noted, however, that these data were a compilation from 
15 different literature sources and that they necessarily contain a high 
degree of experimental error due to inter-laboratory variability. The 
predictive models presented below will be based on Flynn's database and 
on related studies, published during the last decade. 
In his original paper, Flynn proposed a number of algorithms to 
predict skin permeability. His results showed that lipophilicity 
(octanol/water partition coefficient) and molecular size were relevant 
parameters. A simple approach with algorithms for low and high 
molecular weight compounds has been described, which can be presented 
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as a decision tree (Fig. 3.1). No statistical measure of fit was provided at 
this time. 
MW
log Poct
log Poct
< 0.5
< 0.5≥ 0.5≤ 3.0
≥ 0.5
≤ 3.5
> 3.0
> 3.5
< 150 Da > 150 Da
log Kp = - 3
log Kp = log Poct - 3.5
log Kp = - 0.5
log Kp = log Poct - 5.5
log Kp = - 1.5log Kp = - 5
 
Fig. 3.1. Decision tree for predicting approximate skin permeability 
coefficients (Kp), based on Flynn’s algorithm [46]. 
The data published by Flynn were subsequently analyzed by many 
workers. Potts and Guy [9] demonstrated the use of log Poct in 
combination with either molecular weight (MW) or molecular volume to 
predict the permeability coefficients collected by Flynn. For 93 of the 
compounds they reported the following relationship: 
⋅ ⋅p oct
2 2
oct
log K  [cm/s] = 0.72 (±0.13) log P  - 0.0059 (±0.0014) MW
                    - 6.36 (±0.28)
n = 93;  r  = 0.67;  q  = 0.65;  s = 0.74;  F = 92
relative contributions: log P (53%);  MW (47%)
 Eq. 3.9 
It should be noted that this equation is used for predicting the 
permeability coefficient from an aqueous solution of the diffusant. The 
physical significance of this empirical equation is clear. As the permeants 
become more lipophilic, their permeability increases due to better 
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partitioning into the skin but as they become larger, their diffusion into 
the skin is reduced. Our statistical analysis shows that the model is 
significant in terms of the descriptors used. Although the statistical fit to 
Eq. 3.9 is comparatively poor, the authors did observe that up to 30% 
variability in the experimental data was to be expected [47], so that an r2 
of approximatively 70% was considered to be significant. Moreover, the 
authors did not discuss the problem of outliers. 
In a recent study, five algorithms based on log Poct and molecular 
weight were compared in terms of predictive reliability for skin 
permeation [48-52]. A large database of 99 solutes was used, and two 
particular algorithms stood out as better predictors of the skin permeation 
of highly hydrophilic and highly lipophilic chemicals compared to the 
model of Potts and Guy. 
At a similar time, El Tayar and co-workers [19] examined various 
subsets from Flynn’s dataset. They confirmed the role of lipophilicity in 
controlling skin permeability for a variety of these subsets. They also 
described a correlation with the parameter ∆log Poct-alk (the partition 
coefficient in octanol/water minus the partition coefficient in 
alkane/water).  
⋅ ∆p oct-alk
2 2
log K [cm/s] = - 1.36 (±0.40) log P  - 3.39 (±0.99)
n = 21;  r  = 0.81;  q  = 0.76;  s = 0.50;  F = 80
 Eq. 3.10 
This latter parameter is considered to be a measure of the hydrogen 
bond donor acidity of solutes. El Tayar et al. further suggested that 
molecular size was not relevant in the data set analyzed. Statistical bias 
due to two clustered congeneric series and/or differences in partition 
coefficient measurement are responsible for this erroneous conclusion. 
Whilst the fact that hydrogen bonding is important in controlling skin 
permeability has been taken up by many other workers, the induction that 
molecular weight was not important was strongly and rightly refuted by 
Potts and Guy [9], as underlined by the improved equation.  
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⋅ ⋅p oct
2 2
oct
log K [cm/s] = 0.80 (±0.16) log P  - 0.0108 (±0.0015) MW
             - 5.91 (±0.28)
n = 21;  r  = 0.89;  q  = 0.86;  S = 0.40;  F = 70
relative contributions: log P  (42%); MW (58%)
 Eq. 3.11 
This fact suggests that the complex mechanism of skin permeation 
cannot be described by a single physicochemical parameter. In addition to 
hydrogen bond donor acidity implicitly contained in lipophilicity, an 
additional term (MW) is necessary to better predict the dataset. 
The Flynn dataset was also analyzed by Pugh and Hadgraft using a 
novel approach [53], namely a so-called ab initio approach based on 
indicator variables for various molecular sub-structures and features. The 
results using a 17- or 11-descriptor model were comparable, but not 
significantly better, than those of Potts and Guy [9]. This was a 
fundamentally empirical approach to the prediction of skin permeability, 
but lacked the uniform approach and mechanistic simplicity of methods 
based on physicochemical properties. Using this approach, however, Pugh 
and Hadgraft did identify a number of compounds as significant outliers 
(notably atropine, estriol, naproxen, nicotine, nitroglycerine, sucrose, and 
toluene). There is considerable agreement between these outliers and 
those identified in later studies.  
Lien and Gao [10] analyzed a subset from Flynn’s dataset which 
included non-electrolytes and steroids. They demonstrated that the 
number of hydrogen bonds formed by a compound (Hb), plus molecular 
weight and a biphasic response to lipophilicity, could model skin 
permeability in a satisfactory manner: 
( )⋅
⋅ ⋅
⋅
2
p oct
oct b
2 2
2
oct
log K  [cm/h] = - 0.08 (±0.13) log P  
+ 0.84 (±0.59) log P  - 0.25 (±0.12) H
- 1.8 (±2.0) log MW + 4.2 (±3.3)
n = 22;  r  = 0.95;  q  = 0.91;  s = 0.30;  F = 88  
relative contributions: log P  oct b(12%); log P (43%);H (26%);  
                                    log MW (19%)
Eq. 3.12 
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This model is clearly at the limit of statistical validity in terms of the 
number of variables included to the observations, although it emphasizes 
the possible importance of hydrogen bonding. The authors, however, did 
not pinpoint the strong correlation between the squared log Poct value and 
log Poct (r2 = 0.77) and between log Poct and log MW (r2 = 0.53) for the set 
of compounds. Moreover, two parameters ((log Poct)2 and log MW) are non 
significant due to large confidence intervals. Such statistical anomalies 
due to an insufficient number of compounds leads to an 
over-interpretation of the data. 
Barratt [11] subsequently analyzed the complete Flynn’s dataset and 
developed a QSPeR model after subdividing the original set into three 
distinct groups (steroids, other pharmacologically active compounds and 
small compounds). He noted that a subset of hydrocortisone derivates 
within the steroid group were very poorly predicted. To model the data, 
Barratt extended Potts and Guy’s approach [9] by using molecular volume 
as a measure of molecular size and adding melting point (mpt). The 
usefulness of this latter descriptor has never been fully addressed. The 
author proposed that, combined with log Poct, it offers a measure of 
aqueous solubility. From the dataset, it is not possible to prove or disprove 
this suggestion. However, it should be noted that melting point is a 
physicochemical property highly dependent on hydrogen bonding, hence 
this descriptor may emphasize the importance of hydrogen bonding to 
model skin permeability. After removing the hydrocortisone derivates, the 
most significant equation reported for a subset of 60 “small molecules and 
steroids” was: 
⋅ ⋅
⋅
p oct
2 2
oct
log K  [cm/h] = 0.820 (±0.091) log P  - 0.0093 (±0.0021) MV
             - 0.004 (±0.032) mpt - 2.36 (±0.22)
n = 60;  r  = 0.90;  q  = 0.89;  s = 0.39;  F = 176
relative contributions: log P  (49%);  MV (38%); mpt (13%)
 Eq. 3.13 
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The statistical results clearly indicate that the melting point 
parameter is non significant. Indeed, its removal does not decrease the 
predictivity of the model as described by Eq. 3.14: 
⋅ ⋅oct
2
oct
p
2
±0.085) log P - 0.0119 (±0.0015) MV
-2.31 (±0.22)
n = 60;  r  = 0.89;  q  = 0.87;  s = 0.42;  F = 219
relative cont
log K
ributions: log P  (51%); MV (
 [c
49%
m/h] = 0.830
)
 (   
              
 Eq. 14 
The role of hydrogen bonding was further investigated by Potts and 
Guy [12]. A QSPeR model based on 37 “non-electrolyte” compounds 
selected from Flynn’s compilation was developed. The algorithm did not 
contain a lipophilic term, but included molecular volume and descriptors 
for hydrogen bond donor (Hd) and acceptor (Ha) capacity:  
⋅ ⋅
⋅
p d
a
2 2
d a
log K  [cm/s] = 2.56 (±0.50) MV/100 - 1.74 (±0.46) H  
             - 3.85 (±2.44) H  - 4.89 (±0.50)
n = 37;  r  = 0.94;  q  = 0.92;  s = 0.24;  F = 169
relative contributions: MV/100 (38%); H  (30%); H (32%)
 Eq. 3.15 
Whilst Eq. 3.15 has some utility in shedding mechanistic light onto 
the prediction of skin permeability (i.e. in that hydrogen bonding capacity 
is inversely related to skin permeability, and hydrogen bond acceptor 
ability is more important than hydrogen bond donor capacity) the reduced 
size of the dataset limits its predictability, especially for large compounds 
(see range in Table 3.1). In order to compare the relevance of H-bonding to 
lipophilicity, a new model (Eq. 3.16) has been calculated using only two 
parameters. The high correlation between molecular volume (MV) and 
molecular weight (MW) for the set of compounds (r2 = 0.81) allows one 
parameter to be replaced by the other. 
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⋅ ⋅p oct
2 2
oct
log K  [cm/s] = 0.93 (±0.37) log P  - 0.013 (±0.013) MW
             - 5.67 (±0.80)
n = 37;  r  = 0.78;  q  = 0.72;  s = 0.44;  F = 61
relative contributions: log P  (71%); MW (29%)
 Eq. 3.16 
It must be noted that Eq. 3.16 is very similar to Eq. 3.9. The 
difference in intercepts is related to the specific set of compounds. Due to 
the smaller dataset, however, molecular weight appears statistically non 
significant. 
Other similar results indicating the importance of molecular size and 
hydrogen bonding, were also published by Abraham et al. [13]. For a set of 
46 compounds (mainly the “non-electrolytes” selected by Potts and Guy 
[12]) in Flynn’s dataset, it was demonstrated that:  
⋅ π ⋅ Σα
⋅ Σβ ⋅
π Σα
H H  2 2
H  2
H H   2 2
p
x
2 2
log K  [cm/s] = - 0.59 (±0.23) - 0.62 (±0.43)
- 3.43 (±0.41) + 1.80 (±0.30) V  
- 5.07 (±0.21)
n = 46;  r = 0.96;   q  = 0.95;  s = 0.25;  F = 242
relative contributions: (17%); (4
ΣβH  2 x
%); 
(43%); V  (36%)
 Eq. 3.17 
where H2π  is dipolarity/polarisability, H2Σα  hydrogen-bond donor acidity, 
H
2Σβ  hydrogen-bond acceptor basicity and Vx McGowan volume [54]. 
The positive coefficient associated with molecular size (Vx) reflects an 
unbalance between the opposite influences of molecular size on 
lipophilicity (Eq. 3.18) and diffusion (Eq. 3.3).  
⋅ π ⋅ Σα
⋅ Σβ ⋅
π Σα Σ
H H
2 2
H  2
H H  2 2
oct
x
2 2
log P  = - 0.98 (±0.25)  + 0.68 (±0.47)  
- 3.72 (±0.44) + 4.12 (±0.33) V  
- 0.08 (±0.27)
n = 46;  r  = 0.96;  q  = 0.94;  s = 0.25;  F = 222
relative contributions: (18%); (3%); βH  2
x
(29%); 
V  (50%)
 Eq. 3.18 
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Based on the relationship described by Potts and Guy [9], Eq 3.17 is 
rewritten as follows: 
⋅ ⋅p oct x
2 2
oct x
log K  [cm/s] = 0.788 (±0.096) log P - 1.44 (±0.18) V
             - 5.64 (±0.26)
n = 46;  r  = 0.90;  q  = 0.89;  s = 0.37;  F = 196 
relative contributions: log P  (43%); V  (57%)
 Eq. 3.19 
A clearly negative influence of molecular size is highlighted, 
reflecting the effect of size on the diffusion component of permeation 
(Eqs 3.3 and 3.4). 
Abraham et al. [14,55] later considered the issue of outliers and the 
possible erroneous values of some steroids. In their review based on the 
prediction of transport properties of solutes [55], a slightly expanded 
equation was proposed:  
⋅ ⋅ π
⋅ Σα ⋅ Σβ
⋅
H  2
H H
2 2
p 2
x
2 2
2
log K  [cm/s] = 0.45 (±0.24) R  - 0.49 (±0.23)
- 1.49 (±0.27) - 3.43 (±0.31)
+ 1.93 (±0.25) V  - 5.13 (±0.21)
n = 53;  r  = 0.96;  q  = 0.95;  s = 0.21;  F = 216
relative contributions: R  π Σα
Σβ
H H  2 2
H  2 x
(7%); (12%); (11%); 
(38%); V  (32%)
 Eq. 20 
where R2 represents the excess molar refraction. The work of Abraham 
and co-workers confirms that there may be problems with the 
permeability coefficients of some of the compounds, especially steroids. It 
also confirms the importance of hydrogen bonding when an explicit 
lipophilicity descriptor is absent from the QSPeR equation.  
Pugh et al. [15] also addressed the issue of hydrogen bonding and 
molecular size in skin permeation. Their findings demonstrated that 
hydrogen bond donor acidity is dominant over acceptor basicity. The 
relative effect of the donor versus acceptor capacity was quantified as 
being 0.6:0.4. A later study by Pugh et al. [56] demonstrated the 
usefulness of calculated molecular charges (i.e. the sum of partial charges 
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on atoms) as descriptors of hydrogen bonding, as opposed to the 
solvatochromic parameters. The relationship obtained for a set of 52 
values was: 
⋅ ⋅
2 2
log (D/h) = - 2.69 (±0.13) - 0.00268 (±0.00032) MW charge 
n = 52;  r  = 0.83;  q  = 0.82;  s = 0.33;  F = 242
 Eq. 3.21 
where D [cm2/s] is the diffusion coefficient and h [cm] is the diffusional 
path length through the skin. 
The complexity in modeling the Flynn’s dataset was exemplified by 
Magee [57]. In order to test the hypothesis that drug absorption changes 
with its lipophilicity, the dataset was factorized into three overlapping 
regions of log Poct (-1.38 to 1.96; 1.53 to 2.97; 2.50 to 5.49). A difference in 
the QSPeRs based on log Poct and molecular weight was reported, and an 
increased importance of hydrogen bonding for the most lipophilic group of 
chemicals was highlighted. Individual chemical classes were also analyzed 
within the heterogeneous dataset. Predictably, correlations for individual 
chemical classes (probably measured in the same laboratory) were better 
than for the complete dataset. These results are not necessarily relevant 
in terms of being predictive models, but they do highlight the mechanistic 
possibilities of QSPeR analysis.  
The complete Flynn’s dataset was also analyzed by Dearden et al. 
[16] who utilized a total of 81 physicochemical descriptors including those 
for hydrophobicity, molecular size and hydrogen bonding. A highly 
predictive but mechanistically complex QSPeR model was reported based 
on six parameters:  
⋅ Σ ⋅ Σ α
⋅ ⋅ ⋅
⋅
B
R
p
2
log  K  [cm/h] = 0.834 - 0.626 Ca - 23.8 (Q+)/  
- 0.289 SsssCH - 0.0357 SsOH - 0.482 I  
+ 0.405 B
n = 91;  r  = 0.83;   s = 0.56;  F = 69
 Eq. 3.22 
where ΣCa is the HYBOT-PLUS H-bond acceptor free energy factor, 
Σ(Q+)/α the HYBOT-PLUS positive charge per unit volume, SsssCH and 
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SsOH are electrotopological atom-type indices for single bonded CH and 
OH, IB is the Balaban index, and BR the number of rotatable bonds. 
Although atropine, naproxen and nicotine were poorly predicted, the 
results clearly indicate that H-bond acceptor capacity and polarity lower 
skin permeability. Moreover, SsssCH and IB, both reflecting molecular 
size, are better descriptors than molecular weight itself. The inclusion of 
the BR term (a measure of conformational flexibility) is most interesting, 
and suggests that this property enhances permeability. However, due to 
the lack of data in the publication it is difficult to evaluate the pertinence 
of all these terms and/or their possible intercorrelation. 
3.6 Other recent QSPeR analyses 
A larger database of 114 skin permeability values established by 
Kirchner et al. [58] incorporates many data from the Flynn’s dataset, with 
considerable additional data from regulatory reports from Health Canada. 
In an attempt to model these data, Kirchner et al. subdivided the dataset 
into 5 groups according to calculated molar volume. Correlations for each 
group were obtained with log Poct, indicating the dependence on 
lipophilicity. The dependence of the complete dataset on lipophilicity was, 
however, rather poor (r2 = 0.32).  
All these data were subsequently reanalyzed by Cronin et al. [17], 
who demonstrated that seven significant outliers occurred in the set. 
These included compounds that had more than ten sites to accept or 
donate a hydrogen bond (i.e., sucrose and digitoxin), and well as large 
compounds such as estriol, atropine, hydrocortisone and etorphine. 
Propylene chloride was also excluded from the list as having a spurious 
permeation value. Removal of these outliers and reanalysis against a wide 
variety of QSPeR parameters, including those for hydrogen bonding and 
other molecular properties, revealed the following, highly significant, 
equation:  
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⋅
⋅
p oct
2 2
oct
log  K  [cm/h] = 0.773 (±0.082) log  P  
- 0.0103 (±0.0014) MW - 2.33 (±0.15)
n = 107;  r  = 0.86;   q  = 0.85;  s = 0.39;  F = 317
relative contributions: log P  (57%); MW (43%)
 Eq. 3.23 
It was noted that despite the larger data set, Eq. 3.23 is very similar 
to Eq. 3.9 proposed by Potts and Guy [9] (the difference in intercepts is 
due to the difference in units in the permeability coefficients). The 
statistical improvement over the original Potts and Guy model (r2 = 0.86 
vs r2 = 0.67) was closer investigated in the recent study of Frasch et al. 
[59]. The results indicated that of the 107 compounds studied, 63 were 
taken from the Occupational Safety and Health Association (OSHA) and 
had calculated log Kp values based on a method which is a trivial 
modification of the original Potts and Guy equation. Thus, the apparent 
statistical improvement reported by Cronin et al. [17] is an artifact 
because the permeation values are not experimentally determined. 
Therefore, continued use of these data would lead to a biased selection of 
the statistical models, an underestimation of the experimental variability, 
and an overestimation of the predictivity of the models. 
The problem of identifying and dealing with outliers is a 
controversial issue that has seldom been addressed sufficiently in QSPeR 
analyses. The reasons for the removal of outliers, and the consequence of 
so-doing (or indeed not doing) are poorly understood. It is clear from a 
number of studies described above [11,17,53] that some compounds are 
consistently found to be outliers. To shed some light on these outliers, it is 
pertinent to consider observations by Johnson et al. [60] and Degim et al. 
[61]. Johnson et al. [60] reinvestigated the steroid permeability values 
taken from Scheuplein et al. [62] and recorded in Flynn’s dataset. Large 
discrepancies were found between the values from Scheuplein et al. [62] 
and other, more recently, published data. Degim et al. [61] re-measured a 
number of permeability coefficients, including three compounds (naproxen, 
atropine and nicotine) that had been found to be outliers. For these later 
compounds, measured values were found to be significantly different from 
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those compiled by Flynn. Thus, there is considerable evidence that some of 
the permeability coefficients in Flynn’s dataset may have considerable 
error associated with them. The removal of such outliers was thus justified 
to produce a statistically valid model. For future predictions of skin 
permeability based on Flynn’s dataset, the reported values should be 
treated with caution to avoid affecting the validity of resulting models.  
Whilst a number of QSPeR approaches have been attempted, few 
have considered the possible effect of differences in skin conditions. An 
exception to this was the work of Hostynek and Magee [63]. These authors 
indicated that for the human in vivo absorption of miscellaneous 
chemicals both the vehicle in which the material was delivered and the 
degree of occlusion of the device were important. For the former property, 
a significant relationship was developed for the in vivo absorption data 
(penetration constant at the point of maximum flux (KpMax)) of 20 
miscellaneous compounds with an indicator variable (VEH) for the 
different vehicles used (i.e. a value of 1 for acetone and 2 for ethanol): 
⋅ ⋅ ⋅
⋅
pMax
2
log  K  [cm/h] = - 0.60 VEH - 0.014 MR - 0.16 HBA
                     - 0.29 HBD + 2.1
n = 20;  r  = 0.80;   s = 0.35;  F = 15
 Eq. 3.24 
where MR is the molar refraction, HBA is the number of hydrogen bond 
acceptors, and HBD is the number of hydrogen bond donors. This model 
appears very limited due to the large number of parameters with respect 
to the number of compounds. Moreover, no data was available to assess 
statistical pertinence. 
A larger dataset was available to assess the effect of the degree of 
occlusion on the maximum flux of compounds through human skin in vivo. 
Here, an indicator variable (OCCL) for occlusion was used (i.e. a value of 1 
for open, 2 for protected, 3 for occluded):  
µ ⋅ ⋅ ⋅
⋅
 Max
2
oct
2
log  J [( g/cm )/h] = 0.15 log  P  - 0.013 MR - 0.29 HBD
               + 0.28 OCCL + 0.11
n = 48;  r  = 0.66;   s = 0.40;  F = 21
 Eq. 3.25 
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As well as the importance of such features as the vehicle and degree of 
occlusion, the same parameters for molecular size, lipophilicity and 
hydrogen bonding were seen to be important. The relatively low 
correlation coefficient is another indication of the errors in the dataset, 
undoubtedly due to their compilation from a variety of different sources.  
Other more recent studies have again illustrated the importance of 
partitioning in the structure-based prediction of abdominal skin 
permeability coefficients [64]. Also, Ghafourian and Fooladi [65] 
demonstrated the use of theoretical parameters derived from structural 
chemistry to replace solvatochromic descriptors in QSPeRs.  
3.7 Conclusion 
The aim of this review was to survey the most significant models for 
the prediction of skin permeation. The large number of models that have 
been developed highlights their usefulness as predictive tools in both the 
drug delivery and toxicology fields. Such quantitative 
structure-permeation relationships do not resort to expensive and 
time-consuming human studies or animal models. Moreover, they are 
most accurate for compounds within similar classes and useful for 
predicting drug absorption at the conceptual stage, i.e., prior to their 
synthesis and further development or formulation spending. Certain 
limitations of these models, however, are to be pinpointed. An inherent 
problem lies in the fact that their applicability is restricted by the limited 
range of polarity and size of the permeants on which they are based. In 
addition, most of the models use large compilations of data from various 
investigators and laboratories employing different experimental protocols. 
Thus, these models show fair explanation of variance in the lower 
molecular size and the middle range of lipophilicity, while the divergences 
for both very hydrophilic and very lipophilic compounds become 
conspicuous. Furthermore, rigorous statistics show that some models are 
based on non-significant descriptors. As such, they do not afford 
mechanistic insights and may lead to an over-interpretation of the data. 
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4 Quantification of lipophilicity 
4.1 Experimental measurements of lipophilicity 
4.1.1 Introduction 
Lipophilicity is a molecular property influencing the pharmacokinetic 
behavior and pharmacodynamic properties of many compounds [1]. Since 
most drugs are partly or largely ionized at physiological pH, an 
understanding of the lipophilicity of both their neutral and ionic form is 
important. 
Conventionally, lipophilicity is expressed as the logarithm of the 
partition coefficient (P) of a solute present in a single electrical state and 
is given by Eq. 4.1: 
o
w
Clog P log
C
⎛ ⎞= ⎜ ⎟⎝ ⎠
  Eq. 4.1 
where Co and Cw are the concentrations at equilibrium of the solute in the 
organic and aqueous phase, respectively. Log P depends on the 
temperature and the solvent system used [2].  
When more than one electrical species are present in solution, as can 
be the case with ionizable solutes, the observed ratio of concentrations is 
the distribution coefficient (D), which takes into account the intrinsic 
lipophilicity of the different electrical species present and their relative 
concentrations. At a given pH, the lipophilicity of an ionizable solute is 
thus described by Eq. 4.2:  
pH N I
N Ilog D  log f P (f P )[ ]= ⋅ + Σ ⋅  Eq. 4.2 
where fN and fI are the molar fractions of the neutral and ionized form(s) 
and PN and PI are the partition coefficients of the neutral and ionized 
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species, respectively. Sigmoidal curves called lipophilicity profiles are 
obtained when plotting the log D values against pH. At pH values where 
the neutral form predominates, the log D values are identical to log PN 
values, whereas with increasing ionization the log D values decrease 
linearly, until again a constant log D value is reached and equals the 
log PI value. 
4.1.2 The shake-flask method 
Probably the most widely used technique to measure partition 
coefficient is the so-called “shake-flask method”, which involves shaking 
the two solvents together until the partition equilibrium of the solute is 
reached, and then measuring the concentration in each phase. By 
controlling the pH in the aqueous phase, the log P of neutral solutes can 
be measured by this method. Because of its simplicity and clear 
relationship to the partitioning phenomenon, the shake-flask technique is 
regarded as a benchmark method against which other methods are 
validated. However, it is tedious and suffers from a number of practical 
limitations, such as the precision of phase volume ratio, solute stability or 
volatility, solute impurities, formation of microemulsions and time 
consumption [3]. 
A lipophilicity profile can be obtained by measuring log D at several 
different pH values, but it has to be highlighted that the log P values 
measured for ionized solutes are apparent values (see Eq. 4.13) and thus 
strongly depend on experimental conditions such as phase volume, nature 
of the buffer and ionic strength [4]. 
4.1.3 The potentiometric method 
The potentiometric technique allows measurement of the ionization 
constants and the log P values of ionizable solutes exclusively [5-8]. This 
method is based on the observation that when an ionizable compound in 
aqueous solution is titrated in the presence of an organic phase, the 
titration curve shifts to the right for acids and to the left for bases. This 
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shift is related to the phase ratio and to the lipophilicity of both electrical 
species of the solute [9-11]. In the simple case of a monobasic drug B, the 
apparent pKa ( appapK ) of the substance measured in the presence of the 
organic phase is given by Eq. 4.3: 
+
Bapp
a a BH
r P  + 1pK pK  - log 
r P + 1
⎛ ⎞⋅⎜ ⎟= ⎜ ⎟⎝ ⋅ ⎠
 Eq. 4.3 
where PB and 
+BHP are the partition coefficients of the neutral and 
protonated drug, respectively, and r is the phase volume ratio. Thus the 
determination of the log P values of a monobasic (or monoacid) compound 
requires knowledge of its pKa and a minimum of two titrations in the 
presence of two different phase volume ratios, yielding two appapK  values. 
By assuming that 
+BHlog P is a constant, the resolution of the system 
given by Eq. 4.4 (2 equations, 2 unknown parameters) then yields log PB 
and 
+BHlog P values. 
B
BH
B
BH
app1  1a a
 1
app2  2a a
 2
r P + 1pK pK  - log 
r P + 1
r P  + 1pK pK  - log 
r P + 1
+
+
⎡ ⎛ ⎞⋅⎢ ⎜ ⎟=⎢ ⎜ ⎟⋅⎝ ⎠⎢⎢⎢⎢ ⎛ ⎞⋅⎢ ⎜ ⎟=⎢ ⎜ ⎟⋅⎢ ⎝ ⎠⎣
 Eq. 4.4 
The advantage of the potentiometry method is the possibility to use a 
large set of solvents and to measure a large range of log P values [12]. 
Nevertheless its main limitation comes from the assumption that 
+BHlog P is a constant since Eq. 4.12 (see later) shows clearly the 
dependence of 
+BHlog P on experimental conditions, and particularly 
phase volumes. Some general considerations have thus to be taken into 
account when analyzing the results: 
  
78 
• When PB >> +BHP , pKa shifts obtained by Eq. 4.3 do not depend 
on 
+BHlog P and the potentiometric method yields reliable log PB 
values. 
• When +BHP  cannot be neglected relative to PB, the results given 
by potentiometric titrations must be considered with caution. 
4.1.4 Cyclic voltammetry at the interface between two 
immiscible electrolyte solutions (ITIES) 
Cyclic voltammetry is an electrochemical method to determine the 
lipophilicity of ions and to study their mechanism of transfer at the 
liquid-liquid interface [4,13,14]. This technique requires the use of a 
polarizable interface which is available with a solvent system such as 
1,2-dicloroethane/water [15,16]. The main advantage of cyclic voltammetry 
is to provide standard log P values for ions, independent on the 
experimental conditions (except on temperature and solvents) [17]. At this 
stage, some general thermodynamic aspects of the partitioning of ions and 
ionizable compounds need to be shortly recalled. 
The partition of salts can be described by a system consisting of two 
immiscible liquid phases α and β (for example water and 1,2-dichloro-
ethane) and containing n ions Xi: 
 phase 
  (V )α
α
 phase 
  (V )β
β
n
i
i=1
Xα∑
n
i
i=1
Xβ∑
 
where Vα and Vβ are the volumes of phases α and β. 
At equilibrium, the electrochemical potential of each ion Xi is the 
same in both phases α and β:  
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i i
βαµ = µ    Eq. 4.5 
The electrochemical potential of the ion Xi is the sum of a chemical 
and an electrical term: 
i i i =  + z Fα α α⋅µ µ ⋅ φ   Eq. 4.6 
where αµi  is the chemical potential of ion Xi in phase α, zi is the charge of 
ion Xi, F is the Faraday constant (9.65·104 C·mol-1) and αφ  the Galvani 
potential of phase α in Volt (i.e. the bulk potential of phase α). 
The chemical potential is defined by: 
0,
i ii =  + R T lna
α α αµ µ ⋅ ⋅   Eq. 4.7 
where αµ ,0i  and αia  are respectively the standard chemical potential and 
the activity of Xi in phase α, R is the gas constant (8.31 J·K-1·mol-1) and T 
is the temperature in Kelvin. 
From Eq. 4.5, we obtain: 
0, 0,
i i i 
i i i
 - aR T=  -  =  + ln
z F z F a
β βαα α βφβ α
⎛ ⎞µ µ ⎛ ⎞⋅ ⎜ ⎟∆ φ φ ⋅⎜ ⎟ ⎜ ⎟⋅ ⋅⎝ ⎠ ⎝ ⎠
 Eq. 4.8 
where αβ∆ φ  is the Galvani potential difference between phases α and β and 
represents the potential difference across the interface between two 
immiscible electrolyte solutions (noted ITIES) α / β. 
Eq. 4.8 can be written as: 
0 i
i
i i
aR T=  + ln
z F a
βα αβ β α
⎛ ⎞⎛ ⎞⋅ ⎜ ⎟∆ φ ∆ φ ⋅⎜ ⎟ ⎜ ⎟⋅⎝ ⎠ ⎝ ⎠
 Eq. 4.9 
where 0iαβ∆ φ  is the standard transfer potential of ion Xi between phases α 
and β. Supposing that the ion transfers without formation of any ion-pair 
and without any chemical or redox reaction, 0iαβ∆ φ  can be expressed by: 
  
80 
tr, 
00, 0,
i0 i ii
i i
G - 
 = =
z F z F
,α ββ ααβ
∆µ µ∆ φ ⋅ ⋅
→
 Eq. 4.10 
where tr,i
0,G  α→β∆  is the standard Gibbs energy of transfer of ion Xi from 
α to β. 
The 1,2-dichloroethane/water partition coefficient of ion Xi (noted 
i
dcelog  P ) between phases α and β is potential-dependent and is given by 
Eq. 4.11: 
i 0i ii  idce
i
a z F z Flog P = log  = - + 
R T ln10 R T ln10a
β ⋅α αβ βα
⎛ ⎞ ⋅⎜ ⎟ ⋅ ∆ φ ⋅ ∆ φ⎜ ⎟ ⋅ ⋅ ⋅ ⋅⎝ ⎠
 Eq. 4.11 
0,i
dceLog P  represents the partition coefficient of Xi when the interface 
is not polarized and depends only on the chemical structure of Xi and on 
the temperature. The standard partition coefficient is given by: 
0,i 0i idce
z Flog P = - 
R T  ln10
αβ
⋅ ⋅ ∆ φ⋅ ⋅  Eq. 4.12 
Thus Eq. 4.11 can be rewritten as:  
i 0,i i  dce dce
z Flog P = log P + 
R T ln 10
⋅ αβ⋅ ∆ φ⋅ ⋅  Eq. 4.13 
Cyclic voltammetry at the ITIES is a potential-controlled 
electrochemical method so that the standard partition coefficient obtained 
by this method is independent on the Galvani potential difference between 
the two phases ( αβ∆ φ ) and corresponds to i ,0dcePlog . At the opposite, the 
shake-flask method is not a potential-controlled method. Each experiment 
corresponds to a particular value of αβ∆ φ , according to particular 
experimental conditions (nature and concentration of all ions, phase 
volumes). The partition coefficient measured by the shake-flask method is 
thus an apparent partition coefficient (noted idcelog P ).  
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The experimental set-up used on cyclic voltammetry experiments is 
illustrated in Fig. 4.1. The ITIES are polarized by using a 4-electrode 
potentiostat with two reference electrodes to control the Galvani potential 
difference and two counter-electrodes allowing the passage of the current. 
2 31
6
4
5
 
Fig. 4.1. Schematic representation of the electrochemical cell used for 
cyclic voltammetry measurements. (1) reference electrode 
(Ag/AgCl or Ag/Ag2SO4); (2) counter-electrodes (platinum wire 
sealed in glass); (3) reference electrode (Ag/AgCl); (4) aqueous 
phase (LiCl or Li2SO4); (5) organic phase (BTPPATPBCl); (6) 
aqueous reference (BTPPACl + LiCl). 
The Galvani potential difference ( )αβ∆ φ  is varied from an initial 
value, where the ion of interest is in one phase only, to a final value at 
which the ion has migrated into the other phase, and vice versa. This 
migration of ions results in a current which increases as the flux of ions 
across the interface increases [4]. 
Analysis of the current response can give information about the 
thermodynamics, kinetics and mechanisms of ion transfer reactions across 
the liquid-liquid interface [18]. The current response is visualized in a 
voltammogram (Fig. 4.2), from which the half-wave potential of the 
transferring ion Xi can be measured 1/2i( )αβ∆ φ . Using this half-wave 
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potential, the standard transfer potential of ion Xi 0i( )αβ∆ φ  can be 
calculated by Eq. 4.14: 
1/2 0 1/2 0
i i ref ref -  =  - 
α α α αβ β β β∆ φ ∆ φ ∆ φ ∆ φ  Eq. 4.14 
where 1/2ref
αβ∆ φ  and 0refαβ∆ φ  are the half-wave potential and the standard 
transfer potential of a reference ion, respectively.  
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Fig. 4.2. Typical cyclic voltammogram obtained at the 
water/1,2-dichloro-ethane interface for the transfer of the 
cation tetramethyl-ammonium. The potential scan rate ν is 20, 
40, 60, 80 and 100 mV/s; the forward scan (FWD) is from left to 
right and the reverse scan (REV) from right to left. The 
half-wave potential of the cation ( 1/2i
w
o∆ φ ) is localized between 
the two pics of current. 
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It is important to note that the applied potential difference between 
two reference electrodes depends on the nature of the electrodes used, and 
it is thus necessary to convert the scale of applied potential to the Galvani 
potential scale. This can be achieved by internally referencing each 
measurement with a transferring ion for which the standard transfer 
potential is already known in most solvent systems.  
Using Eqs 4.10 and 4.12, the standard Gibbs energy of transfer of the 
ion Xi tr,i
0,( G )α→β∆  and its standard partition coefficient 0i(log P )  can be 
calculated. 
4.2 Computational estimation of lipophilicity 
The computational methods to calculate log P values have been 
reviewed [19,20]. They are based on a one-, two-, three- or 
four-dimensional description of molecular structure [21]. 
The two-dimensional approach of Rekker [22,23] is based on the 
concepts of fragments and correction factors. The main advantage of this 
method is its simplicity, which makes it well-suited to identify the 
discrepancies between experimental and calculated log P values. Moreover 
in contrast with most computational methods, Rekker's fragmental 
method allows the calculation of log P not only in n-octanol/water system 
but also in alkane/water. 
Among two-dimensional approaches, the method of Leo and Hansch 
(CLOGP) is probably the most frequently used [19,20,24]. The CLOGP 
algorithm is based on the additivity of molecular fragments and the use of 
correction factors. Whereas the large and increasing number of correction 
factors continues to improve the accuracy and usefulness of CLOGP for 
calculating partition coefficient of complex compounds, the large number 
of factor makes it difficult to unravel the origin of discrepancies between 
experimental and calculated log P values. 
The main disadvantage of two-dimensional methods remains the loss 
of information induced by a two-dimensional consideration of molecular 
structure. The introduction of tri-dimensional methods such as the 
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Molecular Lipophilicity Potential (MLP) [25,26] to calculate a log P value 
(obtained by back-calculation from the solvent-accessible surface area) 
allows to take into account the influence of conformational changes. This 
computational method and its application to the prediction of skin 
permeation will be detailed in chapter 6. 
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5 Silicone membrane: a model for the barrier 
function of skin  
5.1 Introduction 
Transdermal drug delivery is an important area of pharmaceutical 
and toxicological research. The skin acts as a highly efficient barrier 
preventing the ingress of xenobiotics and reducing water loss from the 
body. Notwithstanding this barrier property, the topical application of 
drugs is a promising route of administration whose potential advantages 
are well documented [1].  
Understanding the physicochemical factors that control passive 
percutaneous absorption is a topic of current interest [2-4]. Knowledge of 
these factors may allow one to predict the absorption characteristics of 
candidates for transdermal delivery. In this respect, many in vivo and 
in vitro experimental techniques have been used to elucidate the 
underlying diffusion mechanisms [5]. However, the ultimate outcome of 
any model system is obviously its ability to yield observations in 
agreement with the more complex process it is meant to mimic. For 
percutaneous penetration, this means in vivo experiments in humans, 
which are often ethically unacceptable (e.g., during early-stage drug 
development), expensive and time-consuming. Among the various models 
used to mimic in vivo experiments in humans, a wide variety of synthetic 
membranes may be identified [6].  
The skin is a heterogeneous membrane, and it is recognized that the 
superficial stratum corneum most frequently controls percutaneous 
absorption, i.e. this layer represents the rate-determining step for 
diffusion [7]. The lipoidal nature of the stratum corneum diffusion 
pathway suggests that artificial lipophilic membranes may provide useful 
in vitro models for permeation studies [8]. Silicone membranes are of 
particular interest in this context [3,9,10]. 
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The purpose of the present study was to characterize the mechanisms 
of permeation across silicone (polydimethylsiloxane) membranes by 
emphasizing the most distinctive structural parameters in a series of 
permeants. As previously described, the hydrogen-bonding capacity of 
compounds restricts their skin permeation [11]. An initial set of 
substituted phenols was therefore chosen to evaluate how H-bonding 
influences permeation across such membranes, since in such compounds 
simple substitutions produce significant variations in H-bonding 
properties with only little change in other molecular parameters such as 
size and shape. In addition to these phenols, a small additional set of four 
drugs was also examined. 
Experimental and computational parameters were used to quantify 
the H-bonding capacity. The experimental parameter was the difference 
between solute partition coefficients measured in two solvent systems 
(∆log Poct-dce) [12]. The computational parameter was calculated by the 
Molecular Hydrogen-Bonding Potentials (MHBPs) recently developed in 
our laboratory [13]. Permeation experiments were performed in a simple 
diffusion cell, and a mathematical model of pseudosteady-state diffusion 
was developed to determine the permeability coefficients. 
5.2 Mathematical model 
The most commonly used method to analyze in vitro permeation data 
obtained by an infinite dose technique is the lag time method of the 
steady-state results [14]. Whereas this approach is readily applicable, it is 
often difficult to determine when steady-state is achieved, a serious 
shortcoming since a misleading interpretation at this stage can lead to 
large errors in permeation values [15]. Furthermore, for this analysis to 
apply, concentrations in the receptor solution must be kept constant 
(usually at nearly zero) throughout the experiment. The 
pseudosteady-state method described here bypasses such a problem. 
Taking into account drug concentration buildup in the receiving chamber, 
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the mathematical model removes the experimental constraint of 
maintaining sink conditions.  
The experimental permeation method (Fig. 5.1) involved placing a 
dilute solution of the test compound in the donor chamber (D) and 
monitoring the accumulation of that compound in the initially solute-free 
solution of the receiving chamber (R). A membrane of thickness L and area 
A separated the two well-stirred compartments (of volumes VD and VR, 
respectively) containing the same solvent. Assuming a one-directional 
flux, the solute diffused from the donor chamber (CD), shown on the 
left-hand side of the membrane, into the less concentrated solution (CR), 
shown on the right.  
X=0
L
CD CR
CM(x=0) = PM/D ·CD CM(x=L) = PM/R ·CR
∞∞
D RM
X=L
 
Fig. 5.1. Schematic diagram of the in vitro permeation experiment. 
M = membrane, D = donor chamber, R = receptor chamber. 
This in vitro permeation system is described mathematically with a 
pseudosteady-state model as outlined in the Appendix [16] with the result: 
⎛ ⎞⎜ ⎟⎜ ⎟⎝ ⎠
γ ⋅R0
D
 D  - C - Cln = t
C
  Eq. 5.1 
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in which 
( )D R
D R
p  
A K = V + VV V
⋅γ ⋅⋅  Eq. 5.2 
and Kp, the permeability coefficient, is defined as: 
M p = 
D PK L
⋅   Eq. 5.3 
where DM is the diffusion coefficient in the membrane and P is the 
partition coefficient of the solute between the membrane and solvent. 
Plotting the negative natural logarithm of the concentration ratio against 
time, a straight line with a slope equal to γ is observed from which Kp can 
be determined as 
D p
VK = 2 A
γ ⋅
⋅   Eq. 5.4 
in which it was assumed that VD = VR. 
5.3 Materials and methods 
5.3.1 Materials 
2,6-Difluorophenol, 2,6-dichlorophenol, 2,6-dibromophenol, 
2,5-dinitrophenol and orphenadrine were purchased from Aldrich (Buchs, 
Switzerland). Phenol, 2-bromophenol, 4-bromophenol, 2-nitrophenol, 
3-nitrophenol, 4-nitrophenol, 2,4-dinitrophenol and nitrobenzene were 
obtained from Fluka (Buchs, Switzerland). Lidocaine and (S)-nicotine were 
provided by Sigma (Buchs, Switzerland) and diazepam by Lipomed 
(Arlesheim, Switzerland). The Silatos™ silicone sheeting (150 x 200 x 0.12 
mm, d = 1.33 g/cm3), a medical grade dimethylsiloxane polymer, was 
purchased from Atos Medical (Hörby, Sweden). Analytical grade 
1,2-dichloroethane (DCE) and n-octanol were obtained from Fluka (Buchs, 
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Switzerland). All other reagents were of analytical grade and were 
employed as received. Distilled water was used throughout. 
5.3.2 pKa measurements 
The protonation constants were determined by potentiometric 
titrations using the GLpKa apparatus (Sirius Analytical Instruments Ltd, 
Forrest Row, East Sussex, UK) as previously described [17]. The low 
aqueous solubility of compounds 3, 4, 5, 6 and 13 (Table 5.1) required pKa 
measurements in the presence of methanol as co-solvent. For acidic 
compounds, at least five separate 20-mL semi-aqueous solutions of 
ca. 1 mM, in 20-40% (w/w) methanol, were initially alkalinized to an 
appropriately high pH with standardized KOH. The solutions were then 
titrated with HCl 0.5 M to low pH (minimum 2.0). The same procedure 
was applied for basic compounds but the analysis ran from low to high pH 
(maximum 12.0) with standardized KOH. The titrations were conducted 
under an inert gas atmosphere (Ar) at 25.0 ± 0.1°C. The initial estimates 
of psKa values (the apparent ionization constants in the H2O/co-solvent 
mixture) were obtained from Bjerrum plots. These values were refined by 
a weighted non-linear least-squares procedure. The refined values were 
then extrapolated to zero percent of co-solvent by the Yasuda-Shedlovsky 
procedure [18]. 
5.3.3 Partition coefficients measurements 
The partition coefficients in octanol/H2O and DCE/H2O were 
determined by the pH-metric method with the GLpKa apparatus. The 
principle of the pH-metric method for pKa and log P measurements has 
been explained in detail elsewhere [17,18]. At least three separate 
titrations of compounds 1-15 (ca. 1 mM) were carried out in the pH range 
1.8 to 12.2, using various volumes of octanol or DCE (volume ratios of 
organic solvent/H2O ranging from 0.3 to 0.8). All experiments were 
performed under Ar at 25.0 ± 0.1°C. 
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5.3.4 Assessment of hydrogen-bonding capacity 
∆log Poct-alk has been shown to express essentially the capacity of 
solutes to donate hydrogen bonds [19]. However, the determination of 
partition coefficients in alkane/water systems is often difficult because of 
the low solubility of many compounds. The DCE/water system appears to 
be a promising alternative by which to overcome these experimental 
constraints [12]. Hence, the H-bond donor acidity of each drug was 
assessed by the difference (log Poct-log Pdce). 
In addition to experimental approaches to quantify a molecule’s 
capacity to form hydrogen bonds, a computational tool ⎯ Molecular 
Hydrogen-Bonding Potentials (MHBPs) ⎯ has been recently described 
[13] comprising a H-bonding donor potential (MHBPdo) and a H-bonding 
acceptor potential (MHBPac), which are calculated in a stepwise 
procedure. First, a H-bonding fragmental system containing literature 
donor (α) and acceptor (β) values [20,21] was developed, as well as 
geometric functions relating the variations in potential with distance and 
angle. The fragmental system and the geometric functions were then 
combined to generate the H-bonding potentials. These are calculated at 
each point of the molecular surface and the sums of the donor and acceptor 
potentials are the two parameters which characterize the molecular 
H-bonding capacity (ΣMHBP). 
5.3.5 Permeation experiments 
A wide variety of diffusion cell systems have been developed for use 
with rate-limiting membranes, but many show relatively poor mixing 
hydrodynamics and lack the possibility of automation [22]. In this study, 
all in vitro experiments were performed with a specially designed diffusion 
cell consisting of two half-compartments of 9 mL volume and an effective 
diffusion area of 2.0 cm2 (Fig 5.2). Silicone membranes were cut into 
round pieces of 24 mm diameter and clamped between the two glass 
chambers using a Teflon joint. The membranes were immersed in distilled 
water for 1h before use. The donor chamber was filled with a dilute drug 
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solution (ca. 1 mM), buffered to pH 4.0 (50 mM citrate-phosphate salts) for 
phenols or pH 7.4 (50 mM phosphate salts) for basic compounds. All 
buffers contained 5% EtOH [23,24] although the presence of the solvent 
was necessary only for the less soluble compounds. Both compartments 
were stirred with Teflon-coated magnetic bars at 150 rpm; two other 
stirrers, connected to a motor, were positioned below the cell system to 
produce synchronous stirring in both cells. This entire device was fastened 
in a Plexiglas cage and temperature-controlled by immersion in a water 
bath at 37°C. Finally, the solution in each compartment was separately 
circulated through a flow-through cell (Hellma, type 176.700-QS, 
Müllheim, Germany) mounted in a spectrophotometer (Perkin Elmer, 
Lambda 11, Ueberlingen, Germany) using Teflon tubing (1/30 in. internal 
diameter, Zeus Industrial Products, Raritan, N.J., USA). A peristaltic 
pump set at 9 mL/min (Ismatec, Reglo FMI 005, Glattbrugg, Switzerland) 
allowed on-line measurements in the chambers and data collection by a 
computer connected to the spectrophotometer.  
water bath (37°C)
magnetic bar
silicone membrane (∅ 2.0 cm)
UV 
spectrophotometer recorder
pumppump 
receptor
(9.0 ml)
donor
(9.0 ml)
 
Fig. 5.2. System used for permeation studies allowing on-line 
measurements, see details in text. 
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It must be noted, however, that the low permeation of relatively 
hydrophilic solutes (log Poct < 1) precluded the accurate determination of 
their Kp. 
5.3.6 Adjustment for ionization 
Permeability coefficients were measured for chemicals with different 
ionization behavior. Some of the analyzed compounds were essentially 
neutral at the experimental pH, whereas others were partly or mostly 
ionized. As a first approximation, penetration can be attributed to the 
neutral species alone, particularly when the fraction unionized is not too 
low (i.e., fui > 0.1). Consequently, the permeation coefficients of unionized 
species were calculated by dividing the observed permeability coefficient, 
based on the total concentration, by the unionized fraction (fui). For 
compounds with a single acid-base reaction, this parameter is correlated 
to the dissociation constant (pKa) and the pH of the donor chamber by the 
following equation:  
 ui g
1f = 
(1 10 )+
  Eq. 5.5 
where the exponent g = (pH - pKa) for acids and (pKa - pH) for bases. 
5.4 Results and discussion 
The experimental and computational physicochemical parameters for 
the two sets of compounds are summarized in Table 5.1. All experiments 
were performed at a fixed pH value of 4.0 or 7.4 for the initial or 
additional set, respectively, and the calculated permeation coefficients 
were adjusted for ionization according to Eq. 5.5.  
 
 
 Table 5.1.  Experimental and computational physicochemical parameters for the compounds studied. 
 Compound Permeation Physicochemical properties 
  Kp a) 
[cm/h] 
log Kp pKa b) MW 
[g/mol] 
log Poct c) log Pdced) ∆log P e) MHBPac f) MHBPdo f) Σfac g) Σfdo g)
1 phenol 0.129 -0.889 9.99 94.11 1.49 0.26 1.23 37.7 74.4 0.30 0.60 
2 2,6-difluorophenol 0.333 -0.478 7.09 130.10 2.05 0.93 1.12 38.8 71.6 0.31 0.60 
3 2,6-dichlorophenol 0.912 -0.040 6.91 163.0 2.75 2.12 0.63 39.3 40.3 0.31 0.36 
4 2,6-dibromophenol 1.521 0.182 6.53 251.92 3.36 2.94 0.41 39.7 40.3 0.31 0.36 
5 2-bromophenol 0.701 -0.154 8.32 173.02 2.35 1.78 0.57 38.7 45.3 0.31 0.36 
6 4-bromophenol 0.360 -0.444 9.13 173.02 2.59 1.51 1.08 24.8 83.7 0.20 0.67 
7 2-nitrophenol 1.233 0.091 6.92 139.11 1.79 2.81 -1.02 44.9 6.4 0.37 0.05 
8 4-nitrophenol 0.030 -1.527 6.90 139.11 1.91 0.72 1.19 28.9 101.1 0.26 0.82 
9 3-nitrophenol 0.045 -1.347 8.10 139.11 2.00 0.92 1.08 25.4 97.3 0.23 0.79 
10 2,4-dinitrophenol 0.300 -0.523 3.96 184.11 1.52 2.46 -0.94 56.5 6.1 0.49 0.05 
11 2,5-dinitrophenol 0.505 -0.297 4.97 184.11 1.75 2.49 -0.74 56.2 6.1 0.49 0.05 
12 nitrobenzene 2.009 0.303 − 123.11 1.85 3.13* -1.28 27.5 0.0 0.28 0.00 
13 diazepam 0.450 -0.347 3.45 284.75 2.92 3.10 -0.18 70.9 0.0 0.71 0.00 
14 lidocaine 0.322 -0.493 7.94 234.40 2.33 3.16 -0.83 166.7 64.7 1.40 0.50 
15 nicotine 0.184 -0.735 8.08/3.21 162.24 1.23 1.21 0.02 131.8 0.0 1.25 0.00 
16 orphenadrine 22.289 1.348 9.10 269.39 3.84 4.52 -0.68 132.3 0.0 1.18 0.00 
95 
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Footnotes for Table 5.1: 
a) Calculated permeation coefficient using the non-steady-state diffusion model and 
adjustment for ionization (see Eq. 5.5); n = 3; SD < 0.02. 
b) Determinated by potentiometry; n = 3; SD < 0.1. 
c) Logarithm of n-octanol/water partition coefficient determined by potentiometry; 
n = 3; SD < 0.02. 
d) Logarithm of 1,2-dichloroethane/water partition coefficient determined by 
potentiometry; n = 3; SD < 0.02. 
e) Difference between the log Poct and log Pdce of a solute. 
f) Molecular Hydrogen-Bonding Potential, calculated on the molecular surface for an 
acceptor (ac) or a donor (do) solute. 
g) Sum of the fragmental values of polar atoms (ac) or polar hydrogen atoms (do) in a 
solute. 
* Measured by centrifugal partition chromatography, with pH 4.6 buffer as the 
stationary phase [12]. 
 
5.4.1 Permeability of phenolic compounds across silicone 
membranes 
Effect of lipophilicity 
The actual partition coefficient between a membrane and the bathing 
solution is a key determinant of permeability. In this study, the 
amphiprotic n-octanol and the inert 1,2-dichloroethane (DCE) were chosen 
as surrogate models. As revealed by Fig. 5.3A and 5.3B, log Pdce describes 
solute permeation across silicone membranes better than log Poct. The 
reason may be that the polydimethylsiloxane membrane, like DCE but 
unlike octanol, has little ability to form hydrogen bonds (see below). 
Moreover, although there is a general trend of increasing permeability 
with lipophilicity in 1,2-dichloroethane as depicted in Fig. 5.3B, two 
distinct groups of compound are apparent in the graph. The first 
represents the halophenols, the second the nitro-derivates.  
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Fig. 5.3. Permeability of the initial set of compounds across silicone 
membranes as a function of lipophilicity measured in terms of 
n-octanol/water partitioning (A), 1,2-dichloroethane/water 
distribution (B), and by the difference between these two 
solvent systems (C). z halophenols, dihalophenols and phenol, 
{ nitrophenols, * di-nitrophenols,  nitrobenzene. Compound 
numbering follows that in Table 5.1. 
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As is readily appreciated, lipophilicity is strongly influenced by the 
nature of the substituents and by their position around the aromatic ring. 
Effect of hydrogen-bonding capacity 
This property has often been used in structure-permeation 
relationships and is related to skin permeation [11,25]. Different 
experimental approaches can be used to assess H-bonding capacity; e.g., 
the solvatochromic parameters α (H-bond donor acidity) and β (H-bond 
acceptor basicity) [26-28]. The ∆log Poct-dce (log Poct - log Pdce) parameter 
expresses mainly the hydrogen-bond donor acidity of a solute [12]. Indeed, 
log Poct contains no contribution from the solute H-bond donor capacity, 
unlike log Pdce of which it is a major component. 
The separation between the two groups of compounds seen in 
Fig. 5.3B (the halophenols and the nitro-derivates) is clearer in Fig. 5.3C. 
For the halophenols, the ∆log Poct-dce parameter decreases when the 
substituent is located close to the hydroxy group; compare, for example, 
2-bromophenol (5) and 4-bromophenol (6). The presence of a halo-atom in 
the ortho- rather than para-position weakens the H-bond donor acidity of 
the -OH moiety due to proximity effects, and facilitates permeability 
across the polymer membrane (see Table 5.1).  
For the nitrophenols, the influence of the substitution pattern on 
membrane permeability can be summarized as follows. First, the presence 
of a single phenolic group produces a positive ∆log P value relative to 
non-H-bond forming solutes. The lower log Pdce relative to log Poct is 
consistent with the fact that 1,2-DCE does not form H-bonds with solutes. 
The presence of nitro substituents in the para- or meta-position means 
that the phenolic group predominates over the nitro group in terms of 
∆log Poct-dce value. The hydrogen-bond donor acidity of para-nitrophenol 
is slightly reinforced compared to meta-nitrophenol due to an inductive 
effect, thereby decreasing its permeability. Finally, the ∆log Poct-dce 
values of ortho-substituted phenols are significantly reduced due to their 
high log Pdce values, indicating that this H-bond donor capacity is not 
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expressed in the DCE/water system. A strong intramolecular hydrogen 
bond between the nitro group and the phenolic function accounts for this 
behavior. 
The strong stabilization of this intramolecular H-bond in non-polar 
solvents [29] renders these compounds much more lipophilic than other 
nitrophenols in the DCE/water system. In the octanol/water system, the 
large amount of water in the organic phase offers additional possibilities 
for the formation of intermolecular H-bonds which compete with 
intramolecular H-bonds and affect the lipophilicity ranking of these 
compounds (Table 5.1).  
In addition to experimental approaches to quantify a molecule’s 
capacity to form hydrogen bonds, a computational tool ⎯ Molecular 
Hydrogen-Bonding Potentials (MHBPs) ⎯ has been developed [13]. 
Examples of such calculated potentials are illustrated in Fig. 5.5 for ortho 
and para-nitrophenol. The H-bonding acceptor potential on the molecular 
surface of 4-nitrophenol (A) and 2-nitrophenol (C) are similar, in stark 
contrast to their H-bonding donor potential (B) and (D), respectively. 
Indeed, the presence of an intramolecular interaction greatly decreases or 
abolishes the H-bonding donor capacity of a solute. As depicted in 
Fig. 5.4B and the corresponding parameters of the linear regression 
(n = 12, r2 = 0.60, q2 = 0.40), a major determinant of diffusion across 
silicone membranes is clearly the H-bond donor acidity but not the H-bond 
acceptor basicity (Fig. 5.4A). This observation agrees with the permeation 
results from human skin experiments [3]. Moreover, Fig. 5.4B illustrates 
the influence of an ortho-nitro group on the MHBPs. As can be seen, the 
dinitrophenols (10, 11) deviate from the linear relationships between 
H-bonding capacity and permeation through silicone membranes, 
suggesting that other factors beside H-bonding influence permeation. 
Several studies based on silicone membrane permeation support this 
observation [30,31]. 
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Fig. 5.4. Permeability of the initial set of compounds across silicone 
membranes as a function of their molecular H-bonding acceptor 
(A) and donor (B) potential. z halophenols, dihalophenols and 
phenol, { nitrophenols, * di-nitrophenols,  nitrobenzene. 
5.4.2 Permeability of selected drugs across silicone membranes 
A set of four additional drugs was investigated to assess the 
generality of the previous observations. The influence of physicochemical 
and structural variability was therefore analyzed over an extended range 
of lipophilicity and molecular weight compared to the initial set. 
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Fig. 5.5. Calculated molecular H-bonding acceptor and H-bonding donor 
potentials of 4-nitrophenol (A and B, respectively) and 
2-nitrophenol (C and D, respectively). 
As seen in Fig. 5.6, log Pdce is a significant parameter for the 
prediction of solute permeability across silicone membranes. As mentioned 
above, the major contributions to log Pdce are hydrophobicity and H-bond 
donor acidity [12]. Eq. 5.6 illustrates the linear relationship between 
permeability coefficient and partition coefficient in DCE/water; that is, a 
single parameter allows a fair prediction of permeability:  
p dce
2 2
log K  = 0.49 (±0.26) log P  - 1.36 (±0.55)
n = 16;  r  = 0.70;  q  = 0.56;  s = 0.38;  F = 32
⋅
 Eq. 5.6 
In this and the following equations, 95% confidence limits are given in 
parentheses; n is the number of compounds, r2 the square correlation 
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coefficient, q2 the cross-validated correlation coefficient, s the standard 
deviation, and F the Fischer's test. 
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Fig. 5.6. Permeability of the initial set (z) and additional set of 
compounds ({) through silicone membranes as a function of 
lipophilicity measured in terms of 1,2-dichloroethane/water 
partitioning (Eq. 5.6). 
The hydrogen-bonding donor acidity is a relevant parameter which 
greatly influences permeation across polydimethylsiloxane membranes. 
Adding the four drugs to the linear regression between log Kp and 
MHBPdo yields a poorer correlation (n = 16, r2 = 0.42, q2 = 0.22) since 
diazepam, nicotine and orphenadrine have no H-bond donor capacity. 
However, a better relationship is recovered by adding log Poct in the 
multilinear equation 5.7. 
 p oct do
2 2
log K  = 0.56 (±0.37) log P - 0.0108 (±0.0064) MHBP
             - 1.16 (±0.72)
n = 16;  r  = 0.77;  q  = 0.61;  s = 0.35;  F = 21
⋅ ⋅ Σ
Eq. 5.7 
Statistically, Eq. 5.7 is comparable to Eq. 5.6. This shows that 
predictions of silicone membrane permeation can be based on the single 
log Pdce parameter (Eq. 5.6) which expresses the same intermolecular 
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forces as the combined log Poct and a H-bond donor parameter (e.g. 
ΣMHBPdo in Eq. 5.7, or ∆log P) [12,28].  
5.4.3 Comparison with human skin permeation  
As silicone membranes are artificial barriers used to model skin 
lipids [3,6], the membrane permeability coefficients (Kp(sil)) of seven 
compounds were compared to their corresponding in vitro values across 
human epidermis (Kp(epid)) (Fig. 5.7). The correlation was good (Eq. 5.8): 
 p(sil) p(epid)
2 2
log K = 1.15 (±0.36) log K  + 1.29 (±0.58)
n = 7;  r  = 0.90;  q  = 0.83;  s = 0.19;  F = 46
⋅
 Eq. 5.8 
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Fig. 5.7. Correlation of solute permeabilities through human epidermis 
and silicone membranes. See Table 5.2 for data and Eq. 5.8. 
As indicated by the positive intercept in Eq 5.8, the permeability 
through silicone membrane is about ten times higher than that through 
excised human skin (Table 5.2). The relationship indicates that silicone 
membranes may be a useful trend-predictive model for skin permeation. 
 
  
104
Table 5.2. Experimental permeability coefficients of selected compounds 
through silicone membranes and across human epidermis. 
 Compound Silicone membrane Human epidermisa) 
  Kp 
[cm/h] 
 log Kp 
 
Kp 
[cm/h] 
 log Kp 
 
1 phenol 0.129 -0.889 0.008 -2.090 
6 4-bromophenol 0.360 -0.444 0.036 -1.440 
7 2-nitrophenol 1.233 0.091 0.100 -1.000 
8 4-nitrophenol 0.030 -1.527 0.006 -2.250 
9 3-nitrophenol 0.045 -1.347 0.006 -2.250 
14 lidocaine 0.322 -0.493 0.017  -1.770b) 
15 nicotine 0.184 -0.735 0.019 -1.710 
a) Data from Flynn et al. [32]. 
b) Data from Johnson et al. [33]. 
5.5 Conclusion 
This study demonstrates that the permeation of xenobiotics across 
polydimethylsiloxane membranes is controlled primarily by their H-bond 
donor capacity, in turn strongly influenced by intramolecular interactions. 
Lipophilicity also plays a role. Thus, a single H-bond donor parameter is 
shown to correlate with silicone membrane permeability for a congeneric 
set of phenols, whereas a lipophilicity term must be added when 
heterogeneous drugs are included in the regression (Eq. 5.8). 
Interestingly, the permeation of the extended set is also well described by 
lipophilicity in the 1,2-dichloroethane/water system (log Pdce, Eq. 5.6), 
which encodes a strong contribution from H-bond donor capacity [12], in 
contrast to log Poct which does not. 
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5.6 Appendix: Development of the mathematical model 
The key assumptions are: (i) depletion of the donor chamber; (ii) 
accumulation in the receiving chamber; (iii) instantaneous equilibrium at 
the skin-solution interfaces; (iv) a homogeneous membrane as the barrier 
to diffusion; (v) a constant diffusion coefficient; (vi) no binding or 
metabolism within the membrane; (vii) no solvent diffusion. 
To determine the solute concentration profile and the flux across the 
membrane, it is necessary to write three unsteady-state solute mass 
balances:  
membrane M: 
2
M M
M 2 
C C= Dt x
∂ ∂⋅∂ ∂  Eq. A1 
donor chamber D: D D MM
x 0
 V dC C= DA dt x =
∂⋅ ⋅ ∂  Eq. A2 
receptor chamber R: R R MM x L
 V dC C= - DA dt x =
∂⋅ ⋅ ∂  Eq. A3 
where C is the concentration of the permeant expressed in g/cm3, V is the 
volume in cm3 of each chamber, DM is the diffusion coefficient in the 
membrane in cm2/sec, A is the area of the membrane in cm2, and x is the 
depth in membrane M. 
These differential equations are subject to specific conditions: 
at t = 0,  0D D C = C  , R  C = 0  ,  MC = 0  Eq. A4 
at x = 0,  M M/D DC P C= ⋅  Eq. A5 
at x = L,  M M/R RC P C= ⋅  Eq. A6 
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If the two compartments contain the same solvent conditions, the 
following simplification is allowed: PM/D = PM/R = P. Described as the 
partition coefficient of the solute between the membrane and solvent, this 
latter parameter is assumed not to vary with solute concentration. 
Moreover, if P • L • A << V, the amount of solute in the membrane will 
be always negligible compared to the amount of solute in the two 
compartments. As a result, the variation in concentration in the donor and 
receptor solutions will be slow compared to the diffusion rate across the 
membrane. In other words, the concentration profile across the membrane 
will always be close to its steady-state value, even though the 
compartment concentrations are time-dependent. This suggests that a 
pseudosteady-state solution strategy is appropriate. 
Assuming pseudosteady-state, where the rate of change of 
concentration, MC / t∂ ∂ , will be zero, Eq. A1 is first integrated twice and 
combined with Eqs A5 and A6, to obtain the following expression for the 
concentration profile 
 M D D R  
PC = P C - x (C - C )L⋅ ⋅ ⋅  Eq. A7 
Eq. A7 is differentiated and evaluated at x = 0 and x = L to obtain:  
M M
D R
x 0 x L
 C C P  - (C - C )
x x L= =
∂ ∂= =∂ ∂  Eq. A8 
It has been shown that it is experimentally more robust to analyze the 
data as the difference [CD(t) - CR(t)] rather than either CD(t) or CR(t) 
individually (14). Subtracting Eq. A3 from Eq. A2 and substituting for 
Eq. A8 yields: 
( ) ( )D R D R d C  Cdt - C = - Cγ ⋅ −  Eq. A9 
in which γ is defined by Eq. 5.2. 
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Eq. A9 is solved subject to the initial condition Eq. A4 to give:  
⎛ ⎞ γ⎜ ⎟⎜ ⎟⎝ ⎠
⋅D R0
D
  C - Cln = t
C
-   Eq. A10 
This pseudosteady-state analysis holds as long as P • L • A / VD < ~0.1, 
assuming that VD = VR [34]. 
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6 Molecular fields in quantitative structure-
permeation relationships: 
the VolSurf approach 
6.1 Introduction 
In traditional 2D-QSARs (Quantitative Structure-Activity 
Relationships), also known as the Hansch approach, descriptors for 
hydrophobic, steric, and electronic effects are generally used to correlate 
and predict biological activities [1-3]. These descriptors are taken as 
substituent constants assumed to be transferable from one series of 
compounds to another. They do not involve 3D molecular properties and 
one often encounters the problem of missing parameter values. However, 
numerous successful applications are described in the literature [4,5] 
despite the fact that the biological activities and physicochemical 
properties of a compound are strongly dependent on its 3D shape. By 
limiting the analysis to the 2D aspects of molecular structure, 2D-QSAR 
models can usually be applied only to congeneric datasets. By taking into 
account tri-dimensional aspects of molecular structure, 3D-QSARs and 
related approaches can directly address the fundamental principles of 
intermolecular recognition which determine many biological properties [6]. 
3D-QSARs often apply to a more diverse set of compounds than 
traditional 2D-QSARs, since molecules are described by properties 
calculated directly from their tri-dimensional structures. 3D-QSAR 
methods define molecular properties in terms of 3D molecular interaction 
fields (MIFs). 
6.2 TLSER: a 2D-QSAR theoretical tool 
As described in chapter 3, linear solvation free-energy relationships 
(LSERs) are used to factorize some given molecular properties (Sp) of 
neutral organic compounds, e.g. partitioning, retention or permeation  
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[7-9], in terms of structural parameters such as the calculated van der 
Waals volume (Vw) and the so-called solvatochromic parameters 
(dipolarity/polarizability π*, hydrogen-bond donor acidity α, and 
hydrogen-bond acceptor basicity β) [10]. The coefficients of the descriptors 
in these multivariate equations reflect the nature of solute-solvent 
interactions.  
Although there are tables of LSER parameters and predictive 
relations to help estimate them, LSER values of complex molecules are not 
easy to determine. Thus, other alternative methods to LSERs called 
Theoretical Linear Solvation Energy Relationships (TLSERs) have been 
developed [11-13].  
In this study, the theoretical parameters were estimated as follows. 
The molecular volume was easily calculated by a standard computational 
software, and the hydrogen-bond capacity parameters were available from 
the Molecular Hydrogen-Bonding Potentials (MHBPs, see section 6.3.3). 
As for the  π* parameter, a new fragmental system called Pistal 1.0 was 
used [14]. This latter is associated with a research algorithm to compute 
automatically the π* values for any compound. Pistal 1.0 is available on 
the Web: 
http://www-ict.unil.ch/ict/pistal/ 
The TLSER models so established can be used in a predictive way for new 
compounds whose descriptors can be easily calculated. 
6.3 Molecular fields: 3D-QSAR theoretical tools 
One method to investigate interactions between a molecule and its 
environment is the generation of Molecular Interaction Fields (MIFs). 
These fields describe the variation of interaction energy between a target 
molecule and a chemical probe moved in a 3D grid constructed around the 
target (see Figs 6.1A and 6.1B). The total interaction energy is calculated 
at each point of the 3D grid. The regions of interest around the target 
molecule are highlighted by color coding (see Figs 6.1C and 6.1D). Regions 
of large positive energies indicate the zones from which the probe would be 
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repelled, while those of large negative energies correspond to energetically 
favorable binding regions [15]. 
Since the information contained in 3D molecular fields is related to 
the interacting partners, the amount of information in MIFs is clearly 
greater than that in one- or two-dimensional computed molecular 
descriptors. 
6.3.1 The GRID force field 
The GRID force field [16-18] is one of the most widely used 
computational tools to map the molecular surfaces of molecules and 
macromolecules. It uses a potential based on the total energy of 
interaction (Etot) between a target molecule and a probe. The GRID 
energy function is given by Eq. 6.1: 
∑ ∑ ∑tot LJ el HbE  = E  + E  + E  Eq. 6.1 
where ELJ (Lennard-Jones potential) measures the induction and 
dispersion interactions, Eel (electrostatic potential) measures the charged 
interactions and EHb the hydrogen-bond (acceptor and donor capacity) 
interactions.  
A probe is a small molecule or chemical fragment, e.g. a water 
molecule, a methyl group, a carboxylate group or a carbonyl oxygen atom. 
By moving the probe over all nodes of the grid, GRID yields the 
distribution of attractive and repulsive forces between the probe and the 
target. 
The water probe is used to simulate the enthalpy part of the 
solvation-desolvation processes. The hydrogen-bonding carbonyl and 
amide probes and the hydrophobic probe (called DRY in the GRID force 
field) are used to simulate interactions with the polar headgroups and the 
hydrophobic core of biological membranes, respectively, or with polar or 
hydrophobic regions in proteins. As GRID probes are selective, their use 
allows to collect data on molecular property fields which can be used in 
QSAR, 3D-QSAR and selectivity studies [19-22]. 
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Fig. 6.1. Graphical definition of a typical molecular interaction field 
(MIF), using indomethacin. A. 3D grid surrounding the 
compound. B. Interaction between the probe (e.g. a water 
molecule) and the target compound. C. The MIF represented by 
colored dots. D. The MIF represented by volumes. 
6.3.2 The Molecular Lipophilicity Potential (MLP) 
The Molecular Lipophilicity Potential (MLP) is a transformation of 
log Poct values (conceptually one-dimensional representations) into 
three-dimensional representations [23,24]. The MLP describes the 
combined lipophilic influence of all fragments in a molecule on its 
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environment and can be calculated at any given point in space around a 
molecule. Two components are needed to calculate a lipophilicity potential: 
a fragmental system of lipophilicity and a distance function, as expressed 
by the following general equation: 
N
k i ik
i=1
MLP  = f fct(d )⋅∑   Eq. 6.2 
where k indicates a given point in space (a node in the grid), i indicates a 
given molecular fragment, N is the total number of fragments in the 
molecule, fi the lipophilic increment of fragment i, fct a distance function 
(e-d/2 in the present MLP), and dik the distance between fragment i and 
point k.  
In sharp contrast to the GRID force field, the MLP is not obtained by 
calculating the interactions between a probe and the molecule. Rather, all 
interactions with the molecular environment are implicitly contained in 
the lipophilic atomic fragmental values. The system of Broto et al. [25] 
with new fragments and adapted values was used as fragmental system. 
The MLP can spread out the molecular lipophilicity on the 
Solvent-Accessible Surface (SAS) of a molecule, allowing a quantitative 
visualization by color-coding (see Fig. 6.2) of the hydrophilic (polar) 
regions (MLPhi) and the hydrophobic ones (MLPho). 
The MLP can be used for the back-calculation of log P values [26], to 
explore conformational effects on lipophilicity, as a docking tool, and as an 
additional field in 3D-QSARs [27,28]. 
6.3.3 The Molecular Hydrogen-Bonding Potential (MHBP) 
Hydrogen bonds are major forces of recognition in biochemistry and 
molecular pharmacology, and as such they are an essential component of 
intermolecular interactions. The conformational stabilization of proteins 
by internal H-bonds and the influence of H-bonds in oral and percutaneous 
absorption are telling examples [29-33]. 
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Fig. 6.2. MLP 3D molecular fields of ibuprofen calculated at three 
potential levels (no unit). Hydrophilic (polar) regions (MLPhi) 
are represented in magenta and hydrophobic regions (MLPho) 
in yellow. 
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To explore three-dimensional H-bonding properties, a computational 
tool ⎯ the Molecular Hydrogen-Bonding Potentials (MHBPs) ⎯ has 
recently been created [34], comprising a H-bonding donor potential 
(MHBPdo) and a H-bonding acceptor potential (MHBPac). The 
development of this tool is based on a stepwise procedure similar to the 
one used to generate the MLP. First, a H-bonding fragmental system, 
called Systahl 1.0, was developed starting from published, solvatochromic 
parameters [35,36]. An atomic H-bonding donor fragmental value (α) was 
associated to each hydrogen atom in a polar moiety. Similarly, an atomic 
H-bonding acceptor fragmental value (β) was associated to each polar 
atom. An angular function taking into account the directionality of 
H-bonds, and a distance function, were defined to calculate variations of 
the MHBPs in space. The fragmental system and the geometric functions 
were then combined to generate the MHBPs. These are calculated for each 
point k on a molecular surface (located 1.8 Å away from the center of each 
atom in the molecule) or at each node of a grid (to be imported into 
VolSurf) according to Eq. 6.3: 
N n
k ij jk jk
i=1 j=1
MHBP  = f f(d ) g(U )⋅ ⋅∑ ∑  Eq. 6.3 
where k is a given point in space, N the number of molecular fragments 
identified in the compound, n the number of polar atoms in the molecular 
fragment i, fij the α and/or β value of atom j in the fragment i, djk the 
distance between the polar atom j and the point k, f(djk) the distance 
function, Ujk the angle defined by the point k, the polar atom j and the 
polar hydrogen or the lone pair belonging to the polar atom j, and g(Ujk) 
the angular function. Fig. 6.3 shows the MHBPs regions (MHBPac and 
MHBPdo) of ibuprofen computed at different potential levels. 
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Fig. 6.3. MHBP 3D molecular fields of ibuprofen calculated at three 
potential levels (no unit). Acceptor H-bonds (MHBPac) regions 
are represented in red and donor H-bonds (MHBPdo) regions in 
blue. 
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The distance function f(djk) is given by Eq. 6.4: 
2- (d - a)
jkf(d ) = e π⋅   Eq. 6.4 
where a is the optimal distance between the polar hydrogen or polar atom 
and the calculated point, set at 1.8 Å. A cutoff of 2.6 Å was added to the 
distance function to avoid unrealistic long-distance effects. 
The angular function used to describe how the potential decreases 
when moving away from the axis of the H-bond is given by Eq. 6.5: 
jk jk
90g(U ) = cos(U )
max
⋅  Eq. 6.5 
where max is set at 30° for a donor H-bond and 60° for an acceptor 
H-bond. Moreover, the procedure allows major intramolecular H-bonds to 
be taken into account [37]. 
The MHBPs are specifically devoted to the computation of donor and 
acceptor hydrogen-bond capacity of solutes and can be used as additional 
fields in 3D-QSARs. 
6.4 The VolSurf procedure 
Molecular interaction fields (MIFs) contain a large amount of data 
some of which are redundant or not relevant for a given problem. Recently 
a new method called VolSurf has been developed [38] in order to transform 
the information present in 3D molecular interactions fields into a limited 
number of quantitative 1D numerical descriptors. It is important to note 
that VolSurf descriptors can be obtained for small, medium, and large 
molecules, as well as for biopolymers such as DNA sequences and proteins. 
Initially the standard procedure of VolSurf involves the calculation of 
GRID force field energies with the water and the DRY probes (see below). 
Specific 1D descriptors were developed to extract a maximum of 
information from the standard GRID probes. However, other MIFs 
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produced by different methods (e.g. molecular mechanics or 
semi-empirical) can also be used.  
In our laboratory the MHBPs and the MLP (symbolized as MxPs) 
have been interfaced with VolSurf, and new descriptors taking into 
account the specificity of both fields have been developed. 
6.4.1 The water probe of GRID 
The molecular envelope produced by the water probe of GRID defines 
hydrophilic regions which are accessible to and attract water molecules. 
This probe is used to simulate solvation-desolvation processes and the 
overall energy of interaction is computed at each grid node by Eq. 6.1. 
Fig. 6.4 shows an example of calculation where the hydrophilic 
regions (GRIDwater) of ibuprofen are computed at three energy levels. 
6.4.2 The amide and carbonyl probe of GRID 
The amide NH group and the carbonyl oxygen atom are two GRID 
probes more specific than the water probe. Although the total interaction 
energy is the sum of the Lennard-Jones, electrostatic and hydrogen-bond 
terms, they allow the donor and acceptor hydrogen-bond capacity of a 
target molecule to be distinguished. The amide probe can donate one 
hydrogen-bond, while the carbonyl probe can accept two hydrogen-bonds. 
6.4.3 The DRY probe of GRID  
When a hydrophobic probe (e.g. a methyl or phenyl group) interacts 
with a target molecule, hydrophobic interactions are generated and 
reported in 3D molecular fields. The GRID force field uses a special probe 
called DRY to generate a 3D lipophilic field (see Fig. 6.4).  
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Fig 6.4. GRID 3D molecular fields of ibuprofen calculated at three 
energy levels (expressed in kcal/mol) with a water probe 
(GRIDwater) and a DRY probe (GRIDDRY). Hydrophilic 
regions are represented in magenta and hydrophobic regions in 
yellow. 
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The DRY probe specifically generates a “hydrophobic” interaction 
energy, which is computed at each grid point as: 
tot entropy LJ HbE  = E  + E  - E  Eq. 6.6 
where Eentropy is the ideal entropic component of the hydrophobic effect in 
an aqueous environment, ELJ measures the induction and dispersion 
interactions occurring between any pair of molecules, and EHb measures 
the hydrogen-bond interactions between water molecules and polar groups 
on the target surface.  
6.4.4 VolSurf and the 1D descriptors 
From points in the MIFs containing the same information, VolSurf 
builds a framework (a volume or a surface) related to specific molecular 
properties. Different images can be obtained for the regions by contouring 
the MIFs points at different energies or potential levels. Afterwards a 
simple summation over the selected points yields back the overall volume 
for the considered properties at the defined level of energy or potential 
defining a 1D descriptor. Consequently a change of energy level or 
potential modifies the size and shape of the related volume, and the 
information content is altered. In order to take into account this effect, 
VolSurf uses several ranges of energy or potential levels to compute 
molecular volumes and surfaces (see Table 6.1). So each level becomes a 
1D descriptor. 
As VolSurf was initially developed to process energy quantities, i.e. 
negative values, positive potential values produced by the MxPs fields are 
multiplied by a negative factor of -1.0.  
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Table 6.1. Definition of eight VolSurf levels for the GRID force field and 
the MxPs fields. 
  GRID probes MHBPs b) MLP b) 
Level Water a) DRY Donor Acceptor Hydrophilic Hydrophobic
1 -0.20 -0.20 -0.05 -0.02 -0.05 -0.15 
2 -0.50 -0.40 -0.15 -0.04 -0.10 -0.30 
3 -1.00 -0.60 -0.25 -0.11 -0.25 -0.70 
4 -2.00 -0.80 -0.35 -0.18 -0.50 -1.00 
5 -3.00 -1.00 -0.45 -0.26 -0.75 -1.40 
6 -4.00 -1.20 -0.55 -0.34 -1.00 -1.70 
7 -5.00 -1.40 -0.65 -0.40 -1.25 -2.10 
8 -6.00 -1.60 -0.75 -0.50 -1.50 -2.50 
a) Identical for GRID polar probes (e.g. amide or carbonyl). 
b) The choice of levels is explained in the thesis of S. Rey [14]. 
 
Standard VolSurf descriptors are classified into three categories: 
• The size and shape of the molecule, e.g. molecular volume or 
weight. 
• The size and shape of the contoured regions of the MIFs. 
• The calculation from existing 1D descriptors, e.g. the ratio 
between the total molecular volume and the total molecular 
surface. 
Size and shape descriptors 
The study of molecular surfaces and volumes has predictive value in 
various areas of chemistry. The concept of molecular shape is of 
fundamental importance to assess similarities, regularities and 
correlations in drug design and optimization, and in toxicity analysis. 
Moreover, the characterization of macromolecular surfaces is one of the 
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most important problems in molecular biophysics. VolSurf produces four 
descriptors of size and shape. 
• Molecular volume (Vtot): This descriptor is represented by the water-
excluded volume (in Å3), or the volume enclosed by the repulsive 
interaction between the water probe and the target molecule computed 
at +0.25 kcal/mol. 
• Molecular surface (Stot): This descriptor represents the surface (in Å2) 
traced out by a water probe interacting at +0.25 kcal/mol. 
The following descriptors are directly calculated from the molecular 
volume and surface: 
• Molecular rugosity (Rmol): defined by the ratio volume/surface 
(Vtot/Stot). This is a measure of molecular wrinkled surface (rugosity). 
For a sphere, the rugosity is the radius of the sphere divided by 3. The 
greater the difference from a sphere, the smaller the ratio and the 
smaller the rugosity. 
• Molecular globularity (Gmol): This is defined as S/Sequiv, in which 
Sequiv is the surface area of a sphere of equal volume to that one of the 
considered molecule (Vtot). Globularity is 1.0 for perfect spherical 
molecules. It assumes values greater than 1.0 when the shape of the 
molecule differs from a sphere. The greater the difference from a 
sphere, the greater the globularity. 
Descriptors of hydrophilic regions 
Hydrophilic regions are defined as the molecular envelope accessible 
by solvent water molecules. The volume of this envelope varies with the 
level of interaction energies between water and the solute molecule. In 
general, hydrophilic descriptors computed from molecular fields of -0.2 to 
-1.0 kcal/mol account for polarisability and dispersion forces, whereas 
descriptors computed from molecular fields of -1.0 to -6.0 kcal/mol account 
for polar and H-bond donor-acceptor regions (see Table 6.1). 
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Descriptors of hydrophobic regions 
In analogy with the hydrophilic regions, “hydrophobic” regions are 
defined as the molecular envelope generating attractive “hydrophobic” 
interactions. VolSurf computes “hydrophobic” descriptors from the DRY 
probe at eight different energy levels adapted to the usual range of 
hydrophobic interactions (i.e. from 0.0 to -2.0 kcal/mol). 
INTeraction EnerGY (Integy) moments 
The spatial distribution of molecular interactions can be 
characterized by additional descriptors, namely the integy moments. 
Integy moments are vectors pointing from the centre of mass to the centre 
of the hydrophilic, respectively hydrophobic regions. When the integy 
moment is high, there is a clear concentration of interaction regions in 
only one part of the space. If the integy moment is small, the interaction 
areas are well-distributed around the molecule. All the integy moments 
can be visualised in the real 3D molecular space. 
Integy moments are defined for each type of MIFs at eight different 
energy or potential levels used to generate the corresponding regions (see 
Table 6.2). 
Capacity factors 
Capacity factors are defined as the ratio of the considered hydrophilic 
surface (Spol) over the total molecular surface (Spol/Stot), i.e. the polar 
interactions per surface unit. Capacity factors are calculated at eight 
different energy or potential levels (see Table 6.2), the same levels used to 
compute the corresponding hydrophilic descriptors (see Table 6.1).  
Hydrogen-bonding parameters 
These variables are obtained as the differences between the 
hydrophilic volumes between the water and another polar probe (e.g. 
amide or carbonyl) calculated for each energy level considered. They 
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encode the hydrogen-bonding capabilities of target molecules, which can 
be different depending upon the nature of the polar probe used. 
Hydrophilic-Lipophilic Balance (HLB) 
This is the ratio between the hydrophilic regions measured at 
-4 kcal/mol and the “hydrophobic” regions measured at -0.8 kcal/mol. The 
balance, namely HLB, describes which effect dominates in the molecule, or 
if they are roughly balanced. If the interactions energy of a probe with a 
target molecule is smaller than the reported levels, -3 and -0.6 kcal/mol 
levels are used respectively. 
Amphiphilic moment 
It is defined as a vector, noted A, pointing from the center of the 
“hydrophobic” domain to the center of the hydrophilic domain, its length is 
proportional to the strength of the amphiphilic moment. 
Critical packing parameters 
These descriptors define a ratio between the hydrophilic and 
“hydrophobic” part of a molecule. In contrast to the hydrophilic-lipophilic 
balance (HLB), critical packing refers just to molecular shape and is 
defined by Eq. 6.7: 
⋅
3
5 3
Volume D  (water probe)CP = 
Surface of W  (DRY probe)  Length of D
 Eq. 6.7 
The “hydrophobic” and hydrophilic calculations are performed at -0.6 and 
-3.0 kcal/mol, respectively. Critical packing (CP) is a good parameter to 
predict molecular packing such as in micelle formation, and may be 
relevant in solubility studies. 
The development of similar descriptors using the MxPs fields is 
currently in progress. 
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Table 6.2. Summary of 1D descriptors of VolSurf for the GRID probes and 
MxPs fields (MHBPs and MLP). n varies from 1 to 8, and m 
from 1 to 3. 
 GRID probes MHBP MLP 
 Water DRY Polar b) Ac Do Hi  Ho 
Interaction regions Wn Dn PWn Ahn Dhn Hin Hon 
Integy moments IWn IDn – IAhn IDhn IHin IHon 
Capacity factors CWn – – CAhn CDhn CHin CHon 
Local interaction 
energy or potential 
minima 
Em – – PAm PDm PHim PHom 
Local interaction  
minima distances 
Dm – – DAm DDm DHim DHom 
Hydrophilic- 
lipophilic balance 
– HLB a) –  –  –  – IHLB c) 
Amphiphilic 
moment 
– A a) –  –  –  – IA c) 
Critical packing – CP a) –  –  –  – ICP c) 
Hydrogen bonding 
descriptors 
– – HBn  –  –  –  – 
a) Variables computed only when the water probe (GRIDwater) is present. 
b) Polar probe (e.g. amide or carbonyl). 
c) Descriptors under progress. 
Local interaction energy or potential minima 
These represent the energy of interaction (in kcal/mol) of the highest 
three local energy minima (E1 to E3) between the water probe and the 
target molecule. Alternatively, the minima refers to the three deepest local 
minima of the MxPs fields (PAn for MHBPac, PDn for MHBPdo, PHon for 
MLPho and PHin for MLPhi regions). 
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Energy or potential minima distances 
These descriptors represent the distances between the highest three 
local energy or potential minima (Dn refers to the GRID water probe, DAn 
to MHBPac, DDn to MHBPdo, DHon to MLPho and DHin to MLPhi 
regions). 
Hydrogen-bonding descriptors 
These descriptors (HB1 to HB8) are obtained as the differences 
between the hydrophilic negative volumes (W1 to W8) calculated with the 
water and any other polar probe (e.g. amide or carbonyl). 
6.5 Chemometrics tools 
As mentioned above the information contained in 3D molecular fields 
is very large. Moreover, when various compounds are studied at the same 
time, a simple graphic analysis and visualization of the fields generated by 
each single compound is no longer sufficient to highlight the useful 
information. In this case, appropriate chemometric methods are needed to 
condense and extract the desired information. Chemometrics comprises 
the application of multivariate statistics, mathematics, and computational 
methods to chemical results. Principal component analysis (PCA), 
principal component regression (PCR) and partial least squares (PLS) are 
very useful techniques allowing to summarize the information provided by 
the numerous variables (PCA) and to correlate them with a biological 
activity (PCR and PLS) [39]. 
6.5.1 Principal Component Analysis (PCA) 
PCA is a statistical multivariate technique very useful to handle a 
data matrix (X-matrix) with n objects and p variables (X(n,p)). Even if the 
objects are less than one hundred and the variables are several thousands, 
PCA is a powerful tool to decompose the data and to unravel the hidden 
information. 
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The PCA works by decomposing the data matrix as the product of two 
smaller matrices (Eq. 6.8): 
• The loading matrix (P(p,a) with a < p), which contains 
information about the variables. It consists of a few vectors called 
Principal Components (PCs), obtained as linear combinations of 
the original X-variables. 
• The score matrix (T(n,a)), which contains information about the 
objects. Each object is described in terms of its projection onto the 
PCs, instead of the original variables. The score of an object is its 
coordinates in the PC space. 
 X(n,p) = T(n,a) · P'(a,p) + E(n,p)   Eq. 6.8 
where n is the number of objects, p is the number of variables, a is the 
number of principal components, and the prime signifies a transposed 
matrix. 
The information not encoded in the P and T matrices remains in the 
residual matrix (E(n,p)), which contains the unexplained part of the 
X-variance.  
The principal components (PCs) have two fundamental properties. 
First, they are extracted by linear combinations of the original X-variables 
in decreasing order of importance. The first PC always lies along the 
direction of maximum variance and therefore contains the maximal 
information, followed by the second PC and so on. Usually the first four or 
five PCs explain more than 90% of the X-variance. Second, the PCs are 
orthogonal to each other, thus containing no correlated information. 
Score plots (plots of the objects in the PC’s space) are used to reveal 
the presence of clusters of objects, thus indicating the structural 
uniformity of a set of molecules, or to highlight the peculiar behavior of 
outliers. Loading plots (plots of variables in the PC’s space) are useful to 
discover the relation between the original variables and the PCs, i.e. the 
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loading of a single variable indicates how much this variable participates 
in defining the PC. 
6.5.2 Principal Component Regression (PCR) 
Principal components extracted from a X-matrix of variables can be 
used as independent variables (X’s) in a regression model, the Y-matrix 
containing the dependent variables (e.g. biological properties). PCR is a 
distinct two-step process: first a PCA is carried out on the X-matrix and 
then a Multiple Linear Regression (MLR) is performed on the T-matrix 
produced by the PCA. The goal is to explain a dependent variable (Y) in 
terms of a number of explanatory variables. In PCR, however, the 
information extracted comes only from the X-matrix without taking into 
account the target property [40]. To deal with two different blocks of 
variables (X’s and Y’s), use of the PLS procedure (see next section) is 
strongly recommended. 
6.5.3 Partial Least Squares (PLS) 
The classical regression technique (Multiple Linear Regression, 
MLR) is inadequate in 3D-QSAR studies because it assumes that the 
X-variables are uncorrelated and because it can be used only with a small 
number of descriptors relative to the number of compounds. The needed 
ratio of 5 between the number of compounds and the number of variables 
is totally overwhelmed in 3D-QSAR data matrices (large number of 
variables). 
The X-variables derived from an interaction field do not fulfill these 
requirements. For example, in VolSurf the variables generated are 
numerous (VolSurf descriptors) in comparison to the number of objects 
(compounds). Moreover, these variables are highly correlated due to the 
continuity properties of the interaction field. 
PLS is the method of choice to handle the kind of matrices present in 
3D-QSAR studies because it relates structural descriptors (stored in the 
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X-matrix) to activities or properties (stored in the Y-matrix) by using the 
target properties along with the decomposition of the X-matrix [41]. 
PLS works by decomposing the X-matrix as the product of two 
smaller matrices (Eq. 6.9), like in the PCA procedure: 
• The loading matrix (P), which contains information about the 
variables. It contains a few vectors called Latent Variables (LVs) 
obtained as linear combinations of the original X-variables. 
• The score matrix (T), which contains information about the 
objects. Each object is described in terms of its projection onto the 
LVs. 
The PLS model has to satisfy the following conditions: 
 X(n,p) = T(n,a) · W'(a,p) + E(n,p)   Eq. 6.9 
 X is decomposed in X-scores (T) and X-weights (W) 
 Y(n,k) = U(n,a) · C'(a,k) + F(n,k)   Eq. 6.10 
 Y is decomposed in Y-scores (U) and Y-weights (C) 
 U(n,a) = T(n,a) · B(a,a) + H(n,a)   Eq. 6.11 
 X-scores (T) correlates Y-scores (U) (inner relation) 
where n is the number of objects , p is the number of X-variables, k is the 
number of Y-descriptors (target properties), a is the number of LVs, (B) is 
the diagonal matrix, (E) is the X-residual matrix, (F) is the Y-residual 
matrix, and (H) is the residual matrix. The weights (W) represent the 
coefficients that multiply the X-variables to best fit the Y-variables. 
Therefore, the loadings represent better the first constraint used to built 
the PLS model (the representation of the X-matrix) while the weights 
represent better the second constraint (the fitting of the Y-matrix). 
The LVs have at least three fundamental properties. First, they must 
correlate as well as possible with the Y-variables. Second, they are 
extracted in decreasing order of importance. Third, they are orthogonal to 
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each other. Thus PLS uses the structure of the Y-data directly as a guide 
to decompose the X-matrix, so that the outcome constitutes an optimal 
regression. The statistical significance for each model dimension is 
determined by cross-validation methods (see next section). 
6.5.4 Cross-validation 
Cross-validation is an approach for selecting which model gives the 
best result in predictivity. It is particularly useful to determine the best 
level of complexity (number of principal components or latent variables) 
for a model in order to distinguish between information and noise. In this 
method, many models are derived each with one or several compounds 
excluded from the dataset and predicted by the corresponding model. This 
approach is very valuable because it performs an internal validation of the 
model. In the most common “leave-one-out” cross-validation, every 
compound is once eliminated. Thus N models (N = number of compounds) 
are derived and the N predictions are compared with the experimental 
values. The predictivity of the model is evaluated by q2, the predictive 
correlation coefficient, which is defined as follows: 
N
2
2 i=1
N
2
i=1
(Y - Y')
q  = 1 - 
(Y - Y)
∑
∑
  Eq. 6.12 
where Y is the experimental value, Y' is the predicted value, Y  is the 
average of all predicted values, and N is the number of objects. The SDEP 
(Standard Deviation of Errors of Prediction) is calculated by Eq. 6.13:  
N
2
i=1
(Y - Y')
PRESSSDEP =  = 
N N
∑
 Eq. 6.13 
The PRESS (Predictive Error Sum of Squares) parameter measures 
the predictive power of the model. Actually, q2 and SDEP are calculated 
from PRESS in the same manner as the squared correlation coefficient r2 
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and the standard deviation s are calculated when no cross-validation is 
performed. Most often, the highest q2 or the lowest SDEP is taken as the 
criterion for the optimal number of principal components or latent 
variables [42,43]. For theoretical reasons, q2 cannot be higher than r2 and 
SDEP cannot be smaller than s. A value of q2 equal to 1.0 corresponds to 
perfect predictions, while a negative value means that the predictions by 
the model are worse than taking the average value of all biological data as 
the predictions. A “good” value of q2 (q2 > 0.4) shows that a model is 
statistically significant [44,45]. 
There are other modes than the “leave-one-out” one to perform a 
cross-validation, i.e “leave-two-out”, “fixed groups” and “random groups”. 
For the two latter, the objects are assigned in a fixed or random way to n 
groups, each one containing an equal number of objects. Then models are 
built keeping one of these groups out of the analysis until all objects were 
kept once. A main inconvenient of cross-validation is that there is no 
general agreement on how to built the reduced groups and how many 
objects to keep. Another way to evaluate the predictivity of the model is to 
use an external prediction set, namely a test set. The compounds 
belonging to the test set are included with the training set in the data 
table for the generation of the variables. The training set is used to built 
the model which will help to predict the activities or properties of the 
compounds belonging to the test set. These predicted values are then 
compared with the experimental ones. 
6.6 Application of 2D and 3D-QSAR analysis to skin 
permeation 
Skin permeation is a phenomenon of major significance not only in 
drug research, but also in a cosmetic and toxicological perspective. As 
reviewed in chapter 3, several 2D-QSAR models based on experimental 
solvatochromic parameters have been developed to predict skin 
permeation [33,46-49]. Although these models gave some mechanistic 
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insight onto skin permeation, their predictivity was limited due to the 
small datasets analyzed.  
The use of TLSER parameters, based on the replacement of 
experimental by calculated solvatochromic parameters, allow increase of 
the number of compounds studied for which experimental data are not 
available. However, by considering only the 2D aspects of molecular 
structure, 2D QSARs are inherently empirical and limited. By considering 
the 3D aspects of molecular structure, 3D QSARs and related techniques 
pinpoint that the bioactivities and physicochemical properties of a 
compound are consequences of its 3D size, general 3D shape and precise 
geometry. 
The usefulness of VolSurf descriptors is exemplified in this study by 
correlating molecular properties with pharmacokinetic data taken from 
the literature [50]. Three distinctive molecular interaction fields (GRID, 
MLP and MHBPs) were used to derive 3D quantitative structure-activity 
relationships.  
A series of 86 chemically heterogeneous compounds, including 
alcohols, phenols, steroids, barbiturates and other drugs, was analyzed 
(Table 6.3). Skin permeability coefficients (Kp), expressed in cm/h, cover a 
range of permeation values from -5.52 (hydrocortisone) to 0.16 
(flurbiprofen) log units, where -5.52 represents poor percutaneous 
penetration, and 0.16 a very good percutaneous penetration. All data were 
obtained with human skin either epidermis (71 compounds) or 
full-thickness of skin (15 compounds).  
6.6.1 Data validation criteria 
In order to optimize the prediction of skin permeation, all 
permeability coefficients (Kp) analyzed in this study were taken from a 
validated database [50]. The permeation data of five compounds 
(aldosterone, β-estradiol, corticosterone, progesterone, and testosterone) 
were modified according to recent studies on skin permeation of steroids 
[51] (see chapter 3). Each data point was measured in vitro through 
human skin from aqueous vehicles and had to meet five criteria:  
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 (1) the temperature was known and ranged from 20 to 40°C,  
 (2) more than 10% of the penetrating compound was in the unionized 
form,  
 (3) a valid log Poct (either a log P* value [52] or else a value 
calculated using ClogP 4.41 [53] which was developed from these 
recommended log Poct) was available,  
 (4) the measurement had been determined at steady-state,  
 (5) the donor and receptor fluids did not affect (more than water 
does) the barrier of the skin. Steady-state permeability 
coefficients require a constant vehicle concentration (or 
adjustment to account for changing vehicle concentration). 
Retained temperature range 
The effect of temperature on permeation has been explored 
experimentally by Blank et al. [54] who showed that permeability 
coefficients (Kp), measured for normal alcohols, increased approximately 
2.9 fold when the temperature increased by 10°C. Other examples [55] 
highlight the influence of temperature on permeation so that the range of 
temperature retained was limited to 20-40°C. 
Adjustment for ionization 
The permeability coefficients were measured for chemicals which 
exhibit diverse ionization behavior. While many compounds are essentially 
unionized at the experimental pH, others exist in equilibrium with a 
charged species (frequently protonated amines or dissociated carboxylic 
acids, e.g. ibuprofen and nicotine). Still others coexist as a complex 
mixture of zwitterionic, charged, and unionized species (e.g., 
2-amino-4-nitrophenol). Moreover, it has been found that permeability 
coefficients for unionized compounds are frequently one or two orders of 
magnitude larger than those of their ionized forms [56-59]. The 
relationship depends upon the compounds and in particular on the 
lipophilicity of the unionized species. Consequently, the unionized fraction 
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available for penetration can greatly influence the magnitude of the 
observed permeability coefficient. 
As a first approximation, penetration can be attributed to the neutral 
species alone, particularly when the fraction unionized is not too low (i.e., 
fui > 0.1). Consequently, the permeation coefficients of unionized species 
were calculated by dividing the observed permeability coefficient, based on 
the total concentration, by the unionized fraction (fui). When more than 
90% of the compound is ionized (i.e., fui < 0.1), the rate of penetration of 
the ionized species can not be neglected. Thus, the data in the validated 
database meet the criteria that fui ≥ 0.1). Assuming that unionized 
compounds penetrate two orders of magnitude faster than their ionized 
forms, this limit will ensure that errors in estimating the permeability 
coefficient should not exceed 10%.  
For compounds with a single acid-base reaction, the unionized 
fraction in the vehicle (fui) is correlated to the dissociation constant (pKa) 
and the pH of the donor chamber by the following equation:  
ui g
1f
(1 10 )
=
+
  Eq. 6.14 
where the exponent g = (pH - pKa) for acids and (pKa - pH) for bases. The 
vehicle pH rather than the skin pH (typically about pH = 4-5 at the outer 
surface of the stratum corneum) was used due to the low buffer capacity of 
the skin to balance a vehicle with large volume. 
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Table 6.3. Physicochemical and permeation parameters for the 
compounds of the database. 
N° Compound a) MW log Poct b) log Kp c) T [°C] Ref. 
Epidermis      
 Aliphatic alcohols      
1 [2,3-Butanediol] * 90.1 -0.92 -4.30 30 [54]
2 [n-Butanol] * 74.1 0.88 -2.60 25 [60]
3 [n-Decanol] * 158.3 4.57 -1.10 25 [60]
4 [Ethanol] * 46.1 -0.31 -3.10 25 [60]
5 [n-Heptanol] * 116.2 2.72 -1.49 25 [54]
6 [n-Hexanol] * 102.2 2.03 -1.89 25 [60]
7 Mannitol 182.2 -3.10 -4.17 27 [61]
8 [Methanol] * 32.0 -0.77 -3.30 25 [60]
9 [n-Nonanol] * 144.3 4.26 -1.22 25 [60]
10 [n-Octanol] * 130.2 3.00 -1.28 25 [60]
11 [n-Pentanol] * 88.2 1.56 -2.22 25 [60]
12 [n-Propanol] * 60.1 0.25 -2.92 25 [60]
 Phenols    
13 2-Amino-4-nitrophenol * 154.1 1.53 -3.07 32 [62]
14 4-Amino-2-nitrophenol * 154.1 1.53 -2.55 32 [62]
15 [4-Bromophenol] * 173.0 2.59 -1.44 25 [63]
16 [4-Chlorocresol] * 142.6 3.10 -1.26 25 [63]
17 [2-Chlorophenol] * 128.6 2.15 -1.48 25 [63]
18 [4-Chlorophenol] * 128.6 2.39 -1.44 25 [63]
19 [4-Chloroxylenol] * 156.6 [3.48] -1.23 25 [63]
20 [2-Cresol] * 108.1 1.95 -1.80 25 [63]
21 [3-Cresol] * 108.1 1.96 -1.82 25 [63]
22 [4-Cresol] * 108.1 1.94 -1.76 25 [63]
23 [2,4-Dichlorophenol] * 163.0 3.06 -1.22 25 [63]
24 [4-Ethylphenol] * 122.2 2.58 -1.46 25 [63]
25 [β-Naphthol] * 144.2 2.70 -1.55 25 [63]
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Table 6.3. Continued 
N° Compound a) MW log Poct b) log Kp c) T [°C] Ref. 
26 [3-Nitrophenol] * 139.1 2.00 -2.25 25 [63]
27 [4-Nitrophenol] * 139.1 1.91 -2.25 25 [63]
28 [Phenol] * 94.1 1.46 -2.09 25 [63]
29 [Resorcinol] * 110.1 0.80 -3.62 25 [63]
30 [Thymol] * 150.2 3.30 -1.28 25 [63]
31 [2,4,6-Trichlorophenol] * 197.4 3.69 -1.23 25 [63]
32 [3,4-Xylenol] * 122.2 2.23 -1.44 25 [63]
 Steroids    
33 [Aldosterone] * 360.5 1.08  -4.23 d) 25 [51]
34 [Cortexolone] * 346.5 2.52 -4.12 26 [64]
35 [Cortexone] * 330.5 2.88 -3.35 26 [64]
36 [Corticosterone] * 346.5 1.94  -3.52 d) 25 [65]
37 [Cortisone] * 360.5 1.47 -5.00 26 [64]
38 [β-Estradiol] * 272.4 4.01  -2.39 d) 25 [65]
39 [Estriol] * 288.4 2.45 -4.40 26 [64]
40 [Estrone] * 270.4 3.13 -2.44 26 [64]
41 [Hydrocortisone] * 362.5 1.61 -5.52 26 [64]
42 [17-α-Hydroxy- 
progesterone] * 
330.5 3.17 -3.22 26 [64]
43 [Pregnenolone] * 316.5 4.22 -2.82 26 [64]
44 [Progesterone] * 314.5 3.87  -1.36 d) 25 [65]
45 [Testosterone] * 288.4 3.32  -2.65 d) 25 [65]
 Others    
46 Benzene * 78.1 2.13 -0.95 31 [66]
47 [2-Butanone] * 72.1 0.29 -2.35 30 [54]
48 Caffeine 194.2 -0.07 -2.74 30 [67]
49 4-Chloro-m-phenylene- 
diamine * 
142.6 0.85 -2.68 32 [62]
50 Diclofenac 296.2 4.40 -1.74 37 [59]
51 [Diethylether] * 74.1 0.89 -1.80 30 [54]
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Table 6.3. Continued 
N° Compound a) MW log Poct b) log Kp c) T [°C] Ref. 
52 [2-Ethoxyethanol] * 90.1 -0.32 -3.60 30 [54]
53 [Fentanyl] 336.5 4.05 -1.81 37 [68]
54 Indomethacin 357.8 4.27 -1.83 37 [59]
55 [Methyl-4-hydroxy- 
Benzoate] * 
152.2 1.96 -2.04 25 [63]
56 Naproxen * 230.3 3.34 -1.42 37 [59]
57 Nicotinate, benzyl * 213.2 2.40 -1.79 37 [69]
58 Nicotinate, butyl * 179.2 2.27 -1.78 37 [69]
59 Nicotinate, ethyl * 151.2 1.32 -2.20 37 [69]
60 Nicotinate, hexyl * 207.3 3.59 -1.75 37 [69]
61 Nicotinate, methyl * 137.1 0.87 -2.49 37 [69]
62 Nicotinate,  
propylene glycol * 
181.2 [0.39] -4.47 37 [69]
63 Nicotinate,  
triethylene glycol * 
255.3 [0.21] -5.00 37 [69]
64 Nicotinate, triethylene  
glycol monomethylether * 
269.3 [0.83] -3.75 37 [69]
65 2-Nitro-p-phenylene- 
diamine * 
153.1 0.53 -3.30 32 [62]
66 [N-Nitrosodiethanolamine] 134.1 [-1.58] -5.26 32 [70]
67 2-Phenylenediamine * 108.1 0.15 -3.35 32 [62]
68 4-Phenylenediamine * 108.1 -0.30 -3.62 32 [62]
69 [Salicylic acid] * 138.1 2.26 -1.52 37 [59]
70 [Sufentanil] 386.6 3.95 -1.80 37 [68]
71 Urea 60.1 -2.11 -3.70 27 [61]
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Table 6.3. Continued 
N° Compound a) MW log Poct b) log Kp c) T [°C] Ref. 
Full-thickness skin    
 Barbiturates    
72 [Amobarbital] 226.3 2.07 -2.64 30 [71]
73 [Barbital] 184.2 0.65 -3.96 30 [71]
74 [Butobarbital] 212.3 1.73 -3.72 30 [71]
75 Cyclobarbital 236.3 1.77 -3.09 37 [72]
76 [Phenobarbital] 232.2 1.47 -3.35 30 [71]
 Others    
77 Aminopyrine 231.3 1.00 -2.99 37 [72]
78 Antipyrine 188.2 0.38 -4.18 37 [72]
79 Flurbiprofen 244.3 4.16 0.16 37 [72]
80 Ibuprofen 206.3 3.50 0.01 37 [72]
81 [Isoquinoline] 129.2 2.08 -1.77 30 [71]
82 Isosorbide dinitrate 236.1 1.31 -1.79 37 [72]
83 Ketoprofen 254.3 3.12 -1.15 37 [72]
84 Nicorandil 211.2 [0.65] -3.58 37 [73]
85 Nicotine 162.2 1.17 -1.70 30 [71]
86 Ouabain 584.7 -1.70 -5.40 30 [74]
a) Compounds contained within brackets also appeared in Flynn’s database [75] (see 
chapter 3). Those indicated with an asterisk to the right were used in the TLSER 
analysis. 
b) Reported log Poct are taken from the Starlist [52], within brackets, calculated 
CLOGP values [53]. 
c) Logarithm of permeability coefficients adjusted for ionization. 
d) Data modified with respect to the validated database [50] according to recent 
studies on skin permeation of steroids [51] (see chapter 3). 
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6.6.2 Material and methods 
Hardware and software 
All calculations were performed on Silicon Graphics Indy R4400 
175 MHz, O2 R5000 180 MHz or Origin 2000 4·R10000 195 MHz 
workstations using the SYBYL 6.5 molecular modeling package (Tripos 
Associates, St. Louis, MO, USA), GRID 1.7 (Molecular Discovery Ltd, 
Oxford, UK) [76], Tsar 3.3 (Oxford Molecular Ltd, Oxford, UK) [77] 
including CORINA algorithm [78], VolSurf 2.0.6 and Golpe 4.5.12 
(Multivariate Infometric Analysis, Perugia, Italy). 
TLSER computation 
The TLSER parameters were calculated by SPL (Sybyl program 
language) macro commands in the Sybyl software. Five descriptors were 
generated for each molecule, i.e. the fragmental sums of acceptor 
(respectively donor) MHBPs with and without intramolecular 
hydrogen-bonds, Σfac and Σfac-ihb (respectively Σfdo and Σfdo-ihb), the 
fragmental sum of π* value, Σpi, and the molecular van der Waals volume, 
Vw. 
Generation of molecular descriptors 
The starting geometries were built by the CORINA algorithm and 
energy-optimized using the Merck Molecular Force Field (MMFF94s) 
including MMFF94 partial atomic charges. 
Molecular Interaction Fields (MIFs) produced by the GRID program 
(grid spacing equal to 0.5 Angstrom) and MxPs fields (MHBPs and MLP) 
computed using the Sybyl software were imported into the VolSurf 
program to generate 1D descriptors according to the adequate levels of 
potential (see Table 6.1). 
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Statistical analysis 
The coefficients of the TLSER model were determined by 
multivariate regression using the Tsar 3.3 program. PCA and PLS 
analyses were performed using the Golpe 4.5.12 program. Cross validation 
was based on a “leave-one-out” deletion pattern (see section 6.5.4). 
6.6.3 Results and discussion 
Principal Component Analysis (PCA) 
Fig. 6.5 shows the results of the principal component analysis (PCA) 
on the dataset (Table 6.3) described by 88 VolSurf descriptors (Table 6.2). 
The PCA scores plot is obtained from GRID force field, using four probes 
(water, DRY, carbonyl and amide), and represents the relative position of 
the compounds in the two-dimensional space of the principal components 
(PCs).  
The first PC lies along the direction of maximum variance and 
therefore contains the maximal information (44%), followed by the second 
PC (15%). Moreover, this plot reveals the presence of four clusters of 
compounds, namely aliphatic alcohols, barbiturates, phenols and steroids, 
in addition to heterogeneous drugs. Mannitol (7) and ouabain (86), as 
significant outliers, were removed from the starting dataset of 
86 compounds. These two compounds are very polar and can form many 
more hydrogen bonds (a maximum of 6 and 12, respectively) than the 
other chemicals studied. As described in the next sections, 
hydrogen-bonding capacity is strongly detrimental for skin permeation.  
The analysis of a single class of compounds leads to a limited 
interpretation of the results due to a low molecular diversity in the 
dataset. While such models have a good statistical fit, their predictivity is 
poor beyond the dataset from which they were developed. It is therefore 
necessary to analyze heterogeneous sets of compounds to extract relevant 
information for predicting skin permeation.  
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Fig. 6.5. PCA scores plot for 84 compounds reported in Table 6.3. Four 
clusters of compounds, namely aliphatic alcohols (□), 
barbiturates (), phenols (U) and steroids (Â) are illustrated in 
addition to other compounds (y). See text for interpretation. 
Theoretical solvatochromic analysis (TLSER) 
A set of 63 compounds, measured through human epidermis (see 
compounds with an asterisk in Table 6.3), was used to establish 
theoretical solvatochromic models (Eqs 6.15 and 6.16). Seven compounds 
(48, 50, 53, 54, 66, 70 and 71) were removed from the starting set of 71 
chemicals due to badly parameterized fragmental values (fac). Work is in 
progress to correct these fragments. Mannitol (7) was also removed as a 
significant outlier. The calculated TLSER parameters (Vw, Σpi, Σfac, Σfdo, 
Σfac-ihb and Σfdo-ihb) are given in Table 6.4.  
In this dataset no intramolecular hydrogen-bond was detected by the 
MHBPs, except for seven compounds (1, 14, 34, 37, 41, 65, 69). Moreover, 
as stratum corneum (the outermost and rate-limiting barrier of the skin) 
contains hydrophilic (keratin-filled cells) and hydrophobic regions 
(intercellular lipids), the hydrogen-bonding capacity of the solutes should 
be more important in this skin layer than in non-polar environments. 
Therefore TLSER models were based on the sum of fragmental values of 
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hydrogen-bond capacity (Σfac, Σfdo) without taking intramolecular 
hydrogen-bonds into account. 
⋅ ⋅ ⋅ + ⋅ Σ
⋅ Σ ⋅ Σ
2 -2
p w
do ac
2 2
w
log K  = 0.74 10-  (±0.33 10 ) V  0.072 (±0.40) pi
             - 0.94 (±0.68) f  - 2.11 (±0.42) f  - 1.59 (±0.35)
n = 63;  r  = 0.81;  q  = 0.76;  s = 0.52;  F = 60
relative contributions:V  (27% Σ Σ
Σ
do
ac
); pi (2%); f  (12%);
f  (59%)
 Eq. 6.15 
where n is the number of compounds, r2 is the squared correlation 
coefficient, q2 is the predictive correlation coefficient, s is the standard 
deviation, and F is the Fischer’s test. Moreover, 95% confidence limits are 
given in parentheses and the relative contributions of each variable to the 
model is calculated using Mager’s standardization procedure [79]. 
Removing from Eq. 6.15 the theoretical dipolarity/polarizability 
parameter (Σpi) which is statistically non-significant leads to Eq. 6.16: 
⋅ ⋅ ⋅ ⋅ Σ
⋅ Σ
Σ Σ
-2 -2
p w do
ac
2 2
w do a
log K  = 0.75 10  (±0.33 10 ) V  - 0.92 (±0.62) f
             - 2.07 (±0.36) f  - 1.57 (±0.34)
n = 63;  r  = 0.81;  q  = 0.77;  s = 0.51;  F = 82
relative contributions: V  (28%); f  (12%); f c (60%)
 Eq. 6.16 
As described by the above TLSER model, the hydrogen-bonding 
capacity, and especially the hydrogen-bond acceptor basicity, has a great 
influence on skin permeation. Although Eq. 6.16 is statistically lower than 
those obtained by Abraham et al. [33,47] with experimental 
solvatochromic parameters (see Eqs 3.18 and 3.20 in chapter 3), it 
underlines the value of theoretical solvatochromic parameters. It should 
also be said that the datasets analyzed by Abraham et al. were smaller 
and less diverse. Eq. 6.16 also confirms the relevance of hydrogen-bonding 
capacity in skin permeation. Finally, it is not surprising that mannitol (7) 
has an abnormally low permeability coefficient due to its high polarity and 
the number of external hydrogen bonds it may form (a maximum of 6).  
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Table 6.4. Calculated solvatochromic parameters for the analyzed 
compounds. 
N° Vw Σpi Σfdo Σfac Σfdo-ihb Σfac-ihb 
1 92.8 0.80 0.66 1.12 0.33 0.84 
2 86.7 0.40 0.37 0.48 0.37 0.48 
3 189.4 0.40 0.37 0.48 0.37 0.48 
4 52.8 0.40 0.37 0.48 0.37 0.48 
5 135.7 0.40 0.37 0.48 0.37 0.48 
6 121.0 0.40 0.37 0.48 0.37 0.48 
8 35.8 0.40 0.37 0.48 0.37 0.48 
9 172.5 0.40 0.37 0.48 0.37 0.48 
10 152.9 0.40 0.37 0.48 0.37 0.48 
11 103.9 0.40 0.37 0.48 0.37 0.48 
12 69.3 0.40 0.37 0.48 0.37 0.48 
13 125.1 1.56 0.60 0.63 0.60 0.63 
14 123.9 1.46 0.65 0.70 0.20 0.66 
15 115.5 0.92 0.67 0.20 0.67 0.20 
16 125.4 0.82 0.67 0.20 0.67 0.20 
17 108.1 0.84 0.36 0.31 0.36 0.31 
18 108.3 0.84 0.67 0.20 0.67 0.20 
19 142.1 0.80 0.67 0.20 0.67 0.20 
20 110.1 0.70 0.55 0.35 0.55 0.35 
21 110.6 0.70 0.55 0.35 0.55 0.35 
22 110.9 0.70 0.55 0.35 0.55 0.35 
23 122.6 0.96 0.36 0.31 0.36 0.31 
24 127.5 0.70 0.55 0.37 0.55 0.37 
25 140.3 1.03 0.60 0.40 0.60 0.40 
26 113.5 1.54 0.79 0.23 0.79 0.23 
27 113.5 1.74 0.82 0.26 0.82 0.26 
28 93.7 0.72 0.60 0.30 0.60 0.30 
29 100.6 0.85 1.20 0.58 1.20 0.58 
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Table 6.4. Continued 
N° Vw Σpi Σfdo Σfac Σfdo-ihb Σfac-ihb 
30 161.0 0.70 0.52 0.37 0.52 0.37 
31 137.5 1.08 0.36 0.31 0.36 0.31 
32 128.0 0.68 0.55 0.35 0.55 0.35 
33 336.1 2.81 0.70 2.59 0.70 2.59 
34 333.3 2.16 0.70 2.14 0.33 1.88 
35 326.5 1.76 0.37 1.58 0.37 1.58 
36 334.4 2.16 0.70 2.14 0.70 2.14 
37 334.6 2.16 0.70 2.65 0.33 2.39 
38 270.1 1.05 0.88 0.93 0.88 0.93 
39 277.2 1.45 1.21 1.49 1.21 1.49 
40 264.0 0.65 0.55 0.88 0.55 0.88 
41 342.6 2.56 1.03 2.70 0.66 2.45 
42 328.0 1.78 0.33 1.58 0.33 1.58 
43 323.9 1.21 0.33 1.07 0.33 1.07 
44 319.7 1.38 0.00 1.02 0.00 1.02 
45 294.4 1.09 0.33 1.07 0.33 1.07 
46 87.3 0.59 0.00 0.00 0.00 0.00 
47 80.8 0.69 0.00 0.51 0.00 0.51 
48 124.1 1.41 0.52 0.60 0.52 0.60 
51 87.3 0.27 0.00 0.45 0.00 0.45 
52 94.6 0.67 0.37 0.93 0.37 0.93 
55 137.0 1.08 0.69 0.45 0.69 0.45 
56 217.1 1.64 0.60 0.79 0.60 0.79 
57 200.5 1.80 0.00 0.98 0.00 0.98 
58 176.3 1.23 0.00 0.98 0.00 0.98 
59 142.2 1.23 0.00 0.98 0.00 0.98 
60 210.5 1.23 0.00 0.98 0.00 0.98 
61 125.3 1.23 0.00 0.98 0.00 0.98 
62 166.1 1.63 0.33 1.54 0.33 1.54 
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Table 6.4. Continued 
N° Vw Σpi Σfdo Σfac Σfdo-ihb Σfac-ihb 
63 232.4 2.17 0.37 2.36 0.37 2.36 
64 250.3 1.90 0.00 2.33 0.00 2.33 
65 128.8 1.71 1.00 0.61 0.70 0.56 
67 110.2 1.29 0.52 0.82 0.52 0.82 
68 109.7 1.29 0.52 0.82 0.52 0.82 
69 118.0 0.87 1.14 0.75 0.59 0.62 
 
3D-QSARs: an initial model based on the GRID field 
The GRID force field was chosen to characterize the interaction sites 
around target molecules using four probes (water, DRY, carbonyl and 
amide). The calculation of descriptors from the 3D maps so obtained was 
carried out by the VolSurf procedure. Due to the lack of some 
well-parameterized fragmental values (in Systahl 1.0) at this time, an 
analysis based on MxPs fields was not performed with this initial dataset.  
The dataset of 84 compounds (see Table 6.3) was used. All data were 
obtained with human skin either epidermis (70 compounds) or 
full-thickness of skin (14 compounds). Mannitol (7) and ouabain (86), 
being significant outliers in previous PCA analyses, were removed from 
the starting dataset of 86 compounds.  
Table 6.5. Statistical parameters of the investigated models. 
Model Type of MIFs n LVs r2 q2 SDEP
1 GRID (water, DRY, carbonyl, amide) 84 3 0.72 0.63 0.71 
2 GRID (water, DRY, carbonyl, amide) 63 2 0.80 0.74 0.57 
3 MLPhi, MLPho, MHBPdo and MHBPac 63 2 0.84 0.77 0.53 
4 MLPhi, MLPho, DRY, MHBPdo, and 
MHBPac 
63 2 0.84 0.78 0.53 
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The statistical parameters of the obtained PLS model are 
summarized in Table 6.5 (Model 1). The good predictive correlation 
coefficient (q2), obtained from a large and heterogeneous dataset, speaks 
to the relevance of the model. 
The relationship between experimental and predicted skin 
permeation depicted in Fig. 6.6 shows that a single model can describe the 
permeation for an heterogeneous dataset. As illustrated, flurbiprofen (79) 
and ibuprofen (80) have a permeation value much larger than expected, 
presumably due to a larger random experimental error [67]. 
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Fig. 6.6. Relationships between experimental and predicted skin 
permeation using the three-component PLS model from the 
GRID probes (water, DRY, carbonyl and amide). The dashed 
line stands for ideal prediction. 
The PLS coefficients plot of the model so obtained (Fig. 6.7) shows the 
contribution of all VolSurf descriptors (Table 6.2). The vertical bars 
represent the contribution of each single descriptor, with a short bar being 
an unimportant descriptor and a long bar an important descriptor. The 
last bar on the right refers to the biological response, here to skin 
permeation. 
From this plot, it can be deduced that volume (V) and surface (S) 
descriptors are positively correlated with skin permeation. An increase in 
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molecular and exposed surface is favorable to skin permeation. Rugosity 
(R) and globularity (G) are also favorable to skin permeation. It means 
that a spherical molecular shape and a wrinkled surface are better to cross 
the skin. 
The polarity descriptors (Wn) are inversely correlated with skin 
permeability. When the polar regions in a molecule are increased, log Kp 
values become smaller (they tend towards -5) and percutaneous 
permeation decreases. The capacity factors (CWn), describing the polar 
interactions per surface unit, are correlated to the descriptors of polar 
regions and also decrease skin permeation.  
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Fig. 6.7. PLS coefficients (3LVs) plot for the correlation of VolSurf 
descriptors obtained from GRID probes (water, DRY, carbonyl 
and amide) with skin permeation. See text for interpretation 
and Table 6.2 for the summary of VolSurf descriptors. V S R G 
refers, in order, to volume (V), surface (S), rugosity (R) and 
globularity (G). 
The spatial distribution of molecular interactions can be 
characterized by additional descriptors, namely the integy moments. All 
the integy moments can be visualized in the real 3D molecular space (see 
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Fig. 6.8). The model underlines that a large integy moment for polar 
interactions (IWn) enhances permeation. Although each of these 
descriptors are positively correlated with percutaneous penetration, their 
meaning depends on the energy level considered. The first interaction 
levels encode dipolarity/polarizability while the last levels encode more 
specific interactions like hydrogen bonds. As illustrated in Fig. 6.8, 
interaction regions obtained with the water probe of GRID are 
concentrated on the -OH and -NO2 groups of 4-nitrophenol at low energy 
levels, and on the -OH group only at a higher energy level. Thus, the 
integy moment becomes larger when the interaction is more specific and 
localized. 
The carbonyl and amide probe of GRID were used to distinguish 
specifically the donor and acceptor hydrogen-bond capacity of permeants. 
The polar descriptors (PWn), especially those encoding hydrogen bond 
donor capacity, are inversely correlated with skin permeation. These 
observations agree with the results of Abraham et al., based on 
solvatochromic analysis (see chapter 3). 
The descriptors of “hydrophobic” regions (Dn) are divided into two 
groups. The first fifth levels of interaction energy are positively correlated 
with skin permeation, while the next levels are inversely correlated. As 
previously described with the water probe, here again specific or 
non-specific interactions depend on the interaction level. As illustrated in 
Fig. 6.8, “hydrophobic” regions of 4-nitrophenol are concentrated on the 
aromatic ring and on the π* system of -NO2 group at low interaction 
levels, and on the aromatic stacking specifically at higher interaction 
levels. Integy moments are all inversely correlated with skin permeation. 
3D-QSAR: GRID and MxPs fields  
Besides GRID field others additional fields were tested to describe 
skin permeation. The information coming from the MLP and MHBPs was 
merged. These two molecular properties are relevant for skin permeation 
(see chapter 3). 
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Fig. 6.8. Integy moments (green bars) of 4-nitrophenol calculated at 
three different energy levels using the water probe of GRID 
field (GRIDwater) and the hydrophobic part of MLP (MLPho). 
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Due to badly parameterized fragmental values (see TLSER analysis), 
a reduced dataset of 63 compounds (Table 6.3) was investigated. The 
range of physicochemical properties (see Figs 6.9 and 6.10) was slightly 
reduced in terms of lipophilicity. 
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Fig. 6.9. Distribution of molecular weight in the initial and the reduced 
dataset containing 84 and 63 compounds, respectively. 
0 5 10 15 20 25
Number of compounds
lo
g 
P o
ct
5
4
3
2
1
-1
0
-2
-3
Reduced dataset
Initial dataset
lo
g 
P o
ct
 
Fig. 6.10. Distribution of log Poct in the initial and the reduced dataset 
containing 84 and 63 compounds, respectively. 
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First, a new model based on the GRID field and four probes (water, 
DRY, carbonyl and amide) was established from the reduced dataset. As 
summarized in Table 6.5, the statistical parameters of the PLS model 
(Model 2) are better than those obtained with GRID (Model 1) on a larger 
dataset. This observation is not surprising due to the smaller and 
chemically less heterogeneous dataset analyzed. 
The relationship between experimental and predicted skin 
permeation depicted in Fig. 6.11 shows that a simple, single model can 
describe the permeation of different classes of permeants. The predictivity 
of this model is however limited to the range of physicochemical 
parameters studied. 
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Fig. 6.11. Relationships between experimental and predicted skin 
permeation using the two-component PLS model from the 
GRID probes (water, DRY, carbonyl and amide). The dashed 
line stands for ideal prediction. 
The PLS coefficients plot (Fig. 6.12) shows qualitatively the same 
information that the previous model based on GRID (Fig. 6.7). Small 
discrepancies arise from the descriptors of “hydrophobic” regions (Dn) 
which are here all positively correlated with skin permeation. 
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Fig. 6.12. PLS coefficients (2LVs) plot for the correlation of VolSurf 
descriptors obtained from GRID probes (water, DRY, carbonyl 
and amide) with skin permeation. See text for interpretation 
and Table 6.2 for the summary of VolSurf descriptors. V S R G 
refers, in order, to volume (V), surface (S), rugosity (R) and 
globularity (G). 
Then, two additional fields (MLP and MHBPs) were merged to 
establish a new model based on the reduced dataset (63 compounds). 
As summarized in Table 6.5, the statistical parameters of the PLS 
model (Model 3) are slightly better than those obtained with the previous 
model (Model 2).  
The relationship between experimental and predicted skin 
permeation depicted in Fig. 6.13 shows that a simple model can describe 
the permeation of different classes of permeants. As indicated, salicylic 
acid (69) behaves as an outlier due to a permeability value much larger 
than expected. The influence of conformational effects on skin permeation 
was tested. Salicylic acid was more deviant using a conformation without 
intramolecular hydrogen bond, suggesting that another phenomenon than 
conformation, e.g. its keratolytic property [80], may account for its higher 
permeation value.  
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Fig. 6.13. Relationships between experimental and predicted skin 
permeation using the two-component PLS model from the 
MxPs fields (MLPhi, MLPho, MHBPdo and MHBPac). The 
dashed line stands for ideal prediction. 
The PLS coefficients plot (Fig. 6.14) shows that volume (V) and 
surface descriptors (S) are inversely correlated with skin permeation. An 
increase in molecular and exposed surface is unfavourable to skin 
permeation. These observations do not agree with the model based on 
GRID field. As described in chapter 3, the solute's volume may contribute 
both positively and negatively to skin permeation, depending on the 
unbalance between the opposite influence of molecular size on lipophilicity 
and diffusion. Rugosity (R) and globularity (G) are two descriptors with a 
low statistical weight, as illustrated by very short bars in Fig. 6.14. 
Here, all polarity descriptors (Hin, IHin, CHin, PHim and DHim) 
described by the hydrophilic part of MLP are inversely correlated with 
skin permeation while the hydrophobic descriptors (Hon, IHon, CHon, 
PHom and DHom) are positively correlated. 
Some descriptors of hydrogen-bonding interactions (Dhn, CDhn, Ahn 
and CAhn) are inversely correlated with skin permeation. While the first 
energy levels have a statistical significance, most compounds (70-80%) 
have an interaction energy value equal to zero in the last energy levels so 
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that their statistical weight is non-significant, as illustrated by short bars 
in Fig. 6.14. Work is in progress to re-parameterize these energy levels. 
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Fig. 6.14. PLS coefficients (2LVs) plot for the correlation of VolSurf 
descriptors obtained from MxPs fields (MLPhi, MLPho, 
MHBPdo and MHBPac) with skin permeation. See text for 
interpretation and Table 6.2 for the summary of VolSurf 
descriptors. V S R G refers, in order, to volume (V), surface 
(S), rugosity (R) and globularity (G). 
The comparison with GRID field model (Fig. 6.12) highlights a large 
discrepancy between the integy moments descriptors. Here the model 
underlines that a large integy moment for polar interactions (IHin) is 
detrimental for skin permeation, while a large integy moment for 
hydrophobic interactions (IHon) enhances permeation. To shed light on the 
nature of these differences, polar and hydrophobic interactions were 
analyzed separately. 
As illustrated in Figs. 6.15 and 6.16, the information encoded by the 
water probe of GRID (GRIDwater) and the hydrophilic (polar) part of the 
MLP (MLPhi) is not equivalent. Although the calculations based on 
4-nitrophenol (Fig. 6.15) and hexyl nicotinate (Fig. 6.16) show that the 
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localization of interactions are energy level-dependent, GRIDwater encodes 
mainly polar interactions in terms of hydrogen bonding interactions, while 
MLPhi encodes polarity in terms of π* interactions and essentially 
hydrogen bond acceptor capacity [23]. The lack of any information on the 
donor capacity in MLPhi arises from the fragmental system based on 
partitioning in octanol.  
Since the parametrization of molecular interaction fields is not 
identical, the balance between functional groups may change between 
GRIDwater and MLPhi, leading to large discrepancies in integy moments. 
Thus the size and the direction of their contributions in PLS analysis can 
also change. 
The interactions encoded by the DRY probe of GRID (GRIDDRY) are 
also different from those described by the hydrophobic part of MLP 
(MLPho). While GRIDDRY encodes specifically π* interactions, as 
illustrated in Fig. 6.17 with interaction regions concentrated on the 
aromatic stacking and on the -NO2 group of 4-nitrophenol, MLPho is 
concentrated on the aromatic ring characterizing the hydrophobic part of 
the molecule. Similar observations come from hexyl nicotinate (Fig. 6.18). 
While GRIDDRY interacts with the aliphatic chain of the molecule and 
more specifically with the nicotinate ring  via π* interactions, the MLPho 
surrounds exclusively the aliphatic moiety.  
Although the above observations are based on two telling examples, 
other compounds of the dataset have highlighted similar discrepancies 
between the probes. 
Based on the above observations, the information coming from 
GRIDDRY was merged with MxPs fields (MLP and MHBP) in order to 
build a solvatochromic-type model (see section 6.2). The statistical 
parameters of the PLS model, as summarized in Table 6.5 (Model 4), are 
similar to those obtained with MxPs fields alone (Model 3). The 
relationship between experimental and predicted skin permeation is 
illustrated in Fig. 6.19. 
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Fig. 6.15. Integy moments (green bars) of 4-nitrophenol calculated at 
three different energy levels using the water probe of GRID 
field (GRIDwater) and the hydrophilic (polar) part of MLP 
(MLPhi). 
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Fig. 6.16. Integy moments (green bars) of hexyl nicotinate calculated at 
three different energy levels using the water probe of GRID 
field (GRIDwater) and the hydrophilic (polar) part of MLP 
(MLPhi). 
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Fig. 6.17. Integy moments (green bars) of 4-nitrophenol calculated at 
three different energy levels using the DRY probe of GRID 
field (GRIDDRY) and the hydrophobic part of MLP (MLPho). 
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Fig. 6.18. Integy moments (green bars) of hexyl nicotinate calculated at 
three different energy levels using the DRY probe of GRID 
field (GRIDDRY) and the hydrophobic part of MLP (MLPho). 
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Fig. 6.19. Relationships between experimental and predicted skin 
permeation using the two-component PLS model from 
GRIDDRY and the MxPs fields (MLPhi, MLPho, MHBPdo 
and MHBPac). The dashed line stands for ideal prediction. 
As clearly depicted by the PLS coefficients plot (Fig. 6.20), all polarity 
descriptors (Hin, IHin, CHin, PHim and DHim) obtained from the 
hydrophilic part of MLP are inversely correlated with skin permeation 
while the hydrophobic descriptors (Hon, IHon, CHon, PHom and DHom) 
are positively correlated. As for the integy moments, GRIDDRY descriptors  
(IDn) are inversely correlated with skin permeation, while those described 
by MLPho (IHon) are positively correlated. This discrepancy is due to the 
non-equivalence between the information encoded by GRIDDRY and 
MLPho, as illustrated by two telling examples (see Figs 6.17 and 6.18). 
The descriptors of hydrogen-bonding interactions (Dhn, CDhn, Ahn 
and CAhn), corresponding to the first energy levels, are detrimental for 
skin permeation. As mentioned above, high energy levels were badly 
parameterized and lead to statistically non-significant descriptors. 
The results in Fig. 6.20 mean that polar interactions should be 
decreased and delocalized to improve skin permeation. Although each of 
these descriptors have the same orientation, their meaning depends on the 
energy level considered. The first interaction levels encode 
  
163
dipolarity/polarizability while the last levels encode more specific 
interactions like hydrogen bonds (see Figs 6.15 and 6.16). In contrast, 
localized hydrophobic interactions are favorable to permeation. It is the 
balance of all descriptors, i.e. of molecular properties, and not a single 
property, which is responsible for skin permeation. Such an interpretation 
supports the view of the stratum corneum as a lipophilic barrier [56] and 
highlights the predominance of a pathway rich in lipids (presumably, 
intercellular) for skin permeation. 
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Fig. 6.20. PLS coefficients (2LVs) plot for the correlation of VolSurf 
descriptors obtained from MxPs fields (MLPhi, MLPho, 
MHBPdo and MHBPac) and GRID field (DRY probe) with 
skin permeation. See text for interpretation and Table 6.2 for 
the summary of VolSurf descriptors. V S R G refers, in order, 
to volume (V), surface (S), rugosity (R) and globularity (G). 
6.6.4 Conclusion 
The VolSurf approach is very attractive and useful to correlate 3D 
molecular structures with pharmacokinetic properties. The 
one-dimensional descriptors are easy to calculate and independent of the 
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alignment of the molecules, and they allow new molecular interaction 
fields or MIFs (e.g., MxPs fields) to be implemented. The choice of the 
MIFs is very important and is related to the type of activity (e.g., skin 
permeation) and the molecular specificities of the dataset. 
While the PLS models obtained from both MxPs (Model 2) and GRID 
fields (Model 3) are statistically equivalent, MxPs fields are better in 
terms of mechanistic interpretation for skin permeation. MxPs fields are 
thus well suited to establish PLS models able to discriminate good and 
poor skin permeants and they allow a different approach to 
pharmacokinetic properties. 
This computational method is easy to apply, but the interpretation of 
the results must be made carefully. Conformational effects may influence 
the predictivity of a model and should be taken into account. Although 
various algorithms exist to obtain 3D structures from 2D geometries, they 
are based on specific rules to derive gas phase conformations which are 
sometimes irrelevant for the analysis of pharmacokinetic data.  
The probes are not equivalent and a detailed knowledge of the 
information encoded in molecular interaction fields (MIFs) is needed to 
correctly interpret the models. As exemplified in this chapter, the DRY 
probe mainly describes a part of hydrophobic interactions, namely 
π-stacking interactions. This limitation may lead to incorrect 
interpretation and can be overcome by the simultaneous use of GRIDDRY 
and MLPho in 3D-QSAR models. 
In addition, it must be underlined that rational drug design from 
VolSurf models is a very difficult task. Indeed the large number of 
non-equivalent parameters coming from different MIFs produces very 
complex predictive models and renders nearly impossible the 
back-translation of the subtle balance of all contributions into 3D 
structures. 
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7 Sulfonamides and bacteria permeation 
7.1 Classification and identification of bacteria 
7.1.1 Bacteria: a definition  
Bacteria are very small, relatively simple unicellular organisms 
whose genetic material is not enclosed in a special nuclear membrane. For 
this reason, bacteria are called “prokaryotes”, from Greek words meaning 
prenucleus. Bacterial cells generally range from 0.20 to 2.0 µm in diameter 
and from 2 to 8 µm in length and appear in one of several shapes. Bacillus 
(rodlike), coccus (spherical or ovoid), and spiral (corkscrew or curved) are 
the most common shapes, but some bacteria are star-shaped or square. 
Individual bacteria may form pairs, chains, clusters, or other groupings; 
such formations are usually characteristic of a particular genus or species 
[1]. 
Unlike animal cells, bacterial cells are enclosed in cell walls that are 
largely composed of a polysaccharide called peptidoglycan. These 
microorganisms generally reproduce by dividing into two equal daughter 
cells; this process is called binary fission. For nutrition, most bacteria use 
organic chemicals, which in nature can be derived from either dead or 
living organisms. Some bacteria can manufacture their own food by 
photosynthesis, and some can derive nutrition from inorganic substances. 
Many bacteria can move by using propelling appendages called flagella 
[2]. 
7.1.2 Taxonomy 
The task of diagnostic microbiology involves detecting and identifying 
etiologic agents of disease when they are recovered from clinical specimens 
or from environmental sources. The science of taxonomy includes 
identification, classification, and naming of these microorganisms. 
Bacterial identification and all typing schemes, whether they are based on 
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biochemical, serologic, or other factors, are actually taxonomic 
classifications at or below the species level. Moreover, reproducible 
systems for identifying microorganisms are critical, so that a particular 
strain will be identified correctly and consistently, regardless of the source 
or the laboratory. 
The classification aspects of taxonomy serve to place microorganisms 
into orderly arrangements of groups so that a new isolate can more easily 
be characterized by comparison with known organisms. The choice of 
criteria for assignment into groups is somewhat arbitrary, although there 
is agreement that the best classifications are those that reflect phylogenic 
relationships [3]. This arbitrariness is reflected in the genetic definition of 
a species as strains of bacteria that exhibit 70% DNA relatedness with 5% 
or less divergence within related sequences [4]. 
As for the nomenclature, the choice of a microbial name is largely 
arbitrary, but it must comply with a set of rules contained in the 
International Code of Nomenclature of Bacteria [5]. Scientific names can, 
among other things, describe the organism, honor a researcher, or identify 
the habitat of the species. Thus, the genus of the bacterium Escherichia 
coli is named for a scientist, Theodor Eschrich, whereas its species name, 
coli, reminds us that E. coli live in the colon, or large intestine. 
From the clinical standpoint, identification uses the attributes 
developed for a classification scheme to characterize and identify 
individual bacterial species or strains, to distinguish from all others the 
organisms being sought, to verify the authenticity or special properties of 
a microbial clone, or to recognize the etiologic agent of a disease [6]. One of 
the most useful and cost-effective tests in the clinical microbiology 
laboratory is the Gram stain [6]. First devised by Hans Christian Gram 
late in the 19th century, it has remained basically the same procedure and 
serves to divide bacteria into two main groups: Gram-positive organisms, 
which retain the primary crystal violet dye and appear deep blue or 
purple, and Gram-negative organisms, which can be decolorized by 
alcohol, thereby losing the primary stain and subsequently taking up the 
counterstain safranin and appearing red or pink. The staining spectrum 
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includes almost all bacteria, many fungi, and some parasites. Thus, it is 
not the chemical constituents but the physical structure of the wall that 
confers Gram-positivity. Indeed, Gram-positive bacteria have very thick 
cell walls consisting of several layers of peptidoglycan, while 
Gram-negative bacteria contain an outer wall layer made of 
lipopolysaccharide (LPS) in addition to a thin peptidoglycan layer. 
7.2 Antibacterial sulfonamides 
7.2.1 Historical background 
The story of sulfonamides goes back to the early 20th century when 
workers of I.G. Farbenindustrie found that the introduction of a sulfamyl 
group imparted fastness to acid wool dyes, thus indicating affinity for 
protein molecules. The interest in dyes as possible antimicrobials was 
stimulated by Ehrlich’s studies on the relationship between selective 
staining by dyes and their antiprotozoal activity, which led to the testing 
of azo dyes for antibacterial activity. Investigations at the I.G. 
Farbenindustrie resulted, in 1932, in a German patent covering 
“prontosil” (Fig. 7.1) and several other azo dyes containing a sulfonamide 
group. Domagk carried out the testing of these dyes and he quickly 
observed that “prontosil” protected mice against streptococcal infections 
and rabbits against staphylococcal infections, though it was without action 
in vitro on bacteria [7]. In 1933, the first clinical success with “prontosil” 
in a case of staphylococcal septicemia was reported by Foerster. 
These studies aroused worldwide interest and further developments 
took place at a very fast rate. One of the earliest systematic investigations 
of sulfonamides was by Trefouel and co-workers working at the Pasteur 
Institute in Paris (1935). Their observations pointed to the sulfonamide 
group as the active structural unit and led to the conclusion that metabolic 
cleavage of the azo linkage in “prontosil” generates 
para-aminobenzenesulfonamide (sulfanilamide, Fig. 7.1), which may be 
responsible for the antibacterial activity. 
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Fig. 7.1. Chemical structure of prontosil (a) and sulfanilamide (b). 
Some of the other developments in the field of sulfonamides that had 
effects on future progress of chemotherapy and drug research in general 
may be mentioned. The standardization by Bratton and Marshall [8] of a 
simple method for the assay of sulfonamides in body fluids and tissues 
permitted precise determination of the absorption, distribution, and 
excretion of these drugs, thus providing a rational basis for calculating 
proper dosage requirements. Wood’s observation of the competitive and 
reversal action of sulfonamides by para-aminobenzoic acid (PABA) was the 
first demonstration of metabolite antagonism as a mechanism of drug 
action [9]. 
7.2.2 Chemotherapeutic agents 
Sulfonamides, employed herein as a generic name for derivates of 
para-aminobenzenesulfonamide (sulfanilamide), belong to the class of 
chemotherapeutic agents. The term “chemotherapy” was coined by Ehrlich 
at the beginning of the 20th century to describe the use of synthetic 
chemicals to destroy infective agents. In recent years the definition of the 
term has been broadened to include antibiotics ⎯ substances produced by 
some microorganisms that kill or inhibit the growth of other 
microorganisms. The term chemotherapy is now also applied to the use of 
chemicals (either natural or synthetic) inhibiting the growth of malignant 
or cancerous cells within the body. 
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7.2.3 Mechanism of action 
Sulfonamides are structural analogs and competitive antagonists of 
para-aminobenzoic acid (PABA), and thus prevent normal bacterial 
utilization of PABA for the biosynthesis of dihydrofolate (DHF) and 
thereby of tetrahydrofolate (THF), which is involved in 1-carbon transfer 
processes [10]. More specifically, sulfonamides are competitive inhibitors 
of dihydropteroate synthase (DHPS), the bacterial enzyme responsible for 
the incorporation of PABA into dihydropteroate, the immediate precursor 
of folic acid [11]. This latter is required for the biosynthesis of DNA and 
RNA precursors both in bacteria and man (see Fig. 7.2). Sensitive 
microorganisms are those that must synthesize their own folic acid; 
bacteria that can utilize preformed folate are not affected. By inhibiting 
the metabolism of the bacteria, these drugs inhibit their growth but do not 
kill them, i.e. they are bacteriostatic rather than bactericidal. 
Bacteriostasis induced by sulfonamides is preceded by a lag phase, while 
stored PABA and folic acid are consumed. This bacteriostatic action is 
counteracted competitively by PABA and by the presence of pus and the 
products of tissue breakdown that contain thymidine and purines, used by 
the bacteria to bypass the need for folic acid. Sulfonamides do not affect 
mammalian cells by this mechanism, since these require preformed folic 
acid and cannot synthesize it. Man is, therefore, comparable to 
sulfonamide-insensitive bacteria that utilize preformed folate. 
The mechanism presented above, however, does not explain all the 
known facts concerning the action of sulfonamides on bacteria. Brown 
[12], using cell-free extracts of E. coli, found that sufonamides can also be 
used as alternative substrates by the enzyme system to form products that 
are probably analogs of reduced forms of pteroate.  
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Fig. 7.2. Folate biosynthetic pathway and mechanism of action of 
sulfonamides. The different enzymes are hydroxymethyl 
dihypteridine pyrophosphokinase (HPPK), dihydropteroate 
synthase (DHPS), dihydrofolate synthase (DHFS) and 
dihydrofolate reductase (DHFR). 
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The synthesis of sulfonamide-containing analogs of folate by intact 
bacteria has also been demonstrated [10]. These analogs could then exert 
inhibitory effects. 
7.2.4 Therapeutic use 
The sulfonamides were the first effective chemotherapeutic agents to 
be employed systematically for the prevention and cure of bacterial 
infections in man. Since sulfanilamide first came into use, many different 
derivates have appeared on the market, being chemically modified to 
achieve a better antibacterial activity, a wider spectrum of 
microorganisms affected, and/or a more prolonged action [7]. Due to their 
low cost they are still used in many parts of the world. However, 
resistance to sulfonamides has emerged among many microorganisms, 
especially streptococci, meningococci and shigella, making them less 
effective than formerly [13-15]. Their therapeutic importance has also 
declined somewhat due to the advent first of penicillin (about 1940) and 
subsequently of other antibiotics. 
Sulfonamides are still used to treat some urinary tract infections, 
leprosy, and in combination with other drugs, diseases such as 
toxoplasmosis. Moreover, sulfapyridine was found to have beneficial 
effects on some inflammatory conditions, unrelated to its antibacterial 
activity [7]. Thus, salicylazosulfapyridine (sulfasalazine) has been used in 
the treatment of ulcerative colitis. This drug, which is very poorly 
absorbed from the gastrointestinal tract, is broken down by intestinal 
bacteria to sulfapyrine and 5-aminosalicylate. The finding that the 
anticolitic effect of sulfalazine lies in its 5-aminosalicylic (5-ASA; 
mesalazine) led to the development of new generations of 5-ASA agents 
[16]. While most sulfonamides are administrated orally, some of them 
(sulfacetamide, sulfadiazine and sulfadicramide) are intended for topical 
use. 
In an attempt to synergize the action of sulfonamides and to avoid 
the development of resistance, the most logical approach is to combine 
them with agents that block the same metabolic pathway as that blocked 
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by sulfonamides, but at a different step. The introduction in the mid-1970s 
of the combination of trimethoprim (i.e. an inhibitor of dihydrofolate 
reductase) and sulfamethoxazole has added a new dimension to treatment 
with these agents. 
Furthermore, careful observation of side-effects in pharmacological 
and clinical studies of the early sulfonamides revealed new and 
unanticipated activities; successful exploitation of these leads opened up 
new areas in chemotherapy such as oral antidiabetics, carbonic anhydrase 
inhibitors, diuretics and antithyroid agents. 
7.2.5 Nomenclature and Classification 
The general term “sulfonamides” has been used for derivates of 
para-aminobenzenesulfonamide (sulfanilamide), whereas specific 
compounds are described as N1- or N4-substituted sulfanilamides, 
depending on whether the substitution is on the amido or aromatic amino 
group, respectively (Fig. 7.3). Most of the sulfonamides used currently are 
N1-derivates.  
Sulfonamides have been classified in different ways depending on 
structural and/or pharmacokinetic properties. The classification based on 
rate of absorption and half-life (the time needed for the concentration of 
the drug in the blood to be reduced to one-half) appears to be clinically 
relevant. Thus sulfonamides with a half-life of less than 10h are termed 
short-acting (e.g. sulfamethizole, sulfisoxazole, sulfanilamide), between 10 
and 24h are considered to be medium-acting (e.g. sulfamethoxazole, 
sulfadiazine), and longer than 24h are long-acting (e.g. sulfadimethoxine, 
sulfadoxine). 
H2N SO2NH
14
R
 
Fig. 7.3. General structure of sulfonamides. See text for the various 
R-substituents. 
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Based on a structural classification, N1-sulfonamides of therapeutic 
use can be divided as follows: 
• N1-acyl derivates 
• N1-heterocyclic derivates containing six-membered rings  
(e.g. pyridine, pyrimidines, pyridazines and pyrazines) 
• N1-heterocyclic derivates containing five-membered rings  
(e.g. thiazole, oxazole, isoxazole, 1,3,4-thiadiazole and 
pyrazole) 
7.2.6 Structure and biological activity of sulfonamides 
Qualitative structure-activity relationships  
As sulfanilamide (Fig. 7.1) is a rather small molecule and there are 
not too many variations that can be carried out without changing the basic 
nucleus, the following generalizations regarding structure-activity 
relationships can be made [7]: 
• The amino and sulfonyl radicals on the benzene ring must be in 
1,4 disposition for activity; the amino group must be 
unsubstituted or have a substituent that is removed in vivo. 
• Replacement of the benzene ring by other ring systems, or the 
introduction of additional substituents on it, decreases or 
abolishes activity. 
• Exchange of the -SO2NH2 by -SO2C6H4-p-NH2 retains activity, 
while exchange by -CONH2, -COC6H4-p-NH2 markedly reduces 
it. 
• N1-Monosubstitution results in more active compounds with 
greatly modified pharmacokinetic properties. N1-disubstitution 
in general leads to inactive compounds. 
• The N1-substitution leading to a pKa value close to the value of 
the physiological pH is favorable to activity. 
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Quantitative structure-activity relationships  
Several investigators paid attention quite early to the amino and 
sulfonamido groups in sulfonamides and noted a correlation between the 
bacteriostatic activity and their degree of ionization. Seydel et al. [17] 
analyzed infrared (IR) spectra of sulfonamides and concluded that the 
amount of negative charge on the aromatic amino group is important for 
activity. However, other workers [18] demonstrated that variation in 
activity within a series of sulfonamides cannot be attributed to a change in 
base strength, since all the active compounds have a basic dissociation 
constant (N1) of about 2, which is close to that of PABA. Thus attention 
has been focussed mainly on the acidic dissociation constant (N4), which 
varies widely from about 3 to 11 depending on the R-substituent. 
In an extensive study of the relationship between the pKa of a series 
of sulfonamides and their in vitro antibacterial activity (MIC, see 
section 7.3.3) against E. coli, Bell and Roblin [19] found a parabolic 
relationship with the maximal activity observed in compounds whose pKa 
approximated the physiological pH. These authors corroborated Woods 
and Fildes’s hypothesis [9] regarding the structural similarity of a 
metabolite and its antagonist, and stated that the more negative the 
SO2 group of sulfonamides, so as to resemble as closely as possible the 
para-aminobenzoate ion, the greater their bacteriostatic activity. 
Furthermore they supposed that increasing the acidity of a compound, due 
to a highly electron-withdrawing R-ring, decreased the negativity of the 
SO2 group, thus reducing the bacteriostatic activity. 
Cowles [20] and Brueckner [21], in a study of the effect of pH of the 
medium on the antibacterial activity of sulfonamides, found that activity 
increased with increase in pH of the medium only up to the drug being 
about 50% ionized, then decreased. While Brueckner assumed different 
intra- and extra-cellular pH values to explain these observations, Cowles 
stated that the sulfonamides penetrate the bacterial cell in the unionized 
form, but once inside the cell, the bacteriostatic activity is due to the 
ionized form which inhibits dihydropteroate synthase (see section 7.2.3). 
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Hence for maximal activity, the half-dissociated state appeared to present 
the best compromise between permeation and activity. This provided an 
alternative explanation for the parabolic relationship observed by Bell and 
Roblin between pKa and MIC. 
In subsequent studies on correlation of physichochemical properties 
with activity, additional parameters were included such as Hammett 
sigma values [22] and other electronic data for net charge calculated by 
molecular orbital methods [23,24], spectral characteristics and 
hydrophobic constant [25-29].  
In these studies it was noticed that some of the sulfonamides had 
lower antibacterial activity than expected, possibly due to their poor 
permeation. To define the role of permeability in the antibacterial activity 
of sulfonamides, investigations were carried on cell-free enzyme systems 
[30,31]. The comparison of cell-free systems with whole cell systems 
highlighted that the intracellular ionic concentration of sulfonamides, 
which is limited by the permeation of the unionized form, governs activity. 
Subsequent work in this field has fully supported the views expressed 
quite early in the development of sulfonamides on the predominant role of 
ionization for antibacterial activity. 
However, while much is known on the pKa, protein affinity [17] and 
intrinsic activity of sulfonamides, the intramolecular effects of the 
R-substituent on acidity and lipophilicity are poorly understood and will 
be investigated in this study. 
7.3 Materials and methods 
7.3.1 Chemical compounds and reagents 
Sulfadiazine, sulfameter, sulfamethazine, sulfathiazole, 
sulfisomidine and sulfisoxazole were purchased from Aldrich (Buchs, 
Switzerland). Sulfacetamide, sulfadimethoxine and sulfaguanidine were 
obtained from Fluka (Buchs, Switzerland). Sulfamonomethoxine and 
sulfamethizole were provided by ICN Biomedicals (Aurora, USA). 
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Sulfabenzamide, sulfacarbamide, sulfamerazine, sulfamethoxazole, 
sulfamethoxypyridazine, sulfamoxole, sulfanilamide, sulfapyridine and 
sulfaphenazole were purchased from Sigma (Buchs, Switzerland). 
Sulfaclozine was given by Novartis Animal Health (Basel, Switzerland), 
sulfacytine by Parke-Davis (Ann Arbor, USA), sulfadicramide by 
Ciba Vision (Hettlingen, Switzerland) and sulfadoxine by 
Hoffman-La Roche (Basel, Switzerland). Methanol, n-octanol, KCl, 
KH2PO4, K2HPO4, LiCl, Li2SO4, NaCl, KOH, NaOH and HCl were 
purchased from Fluka (Buchs, Switzerland). Analytical grade 
1,2-dichlorothane (Merck, Darmstadt, Germany) was used without further 
purification and handled with all necessary precautions [32].  
BTPPATPBCl (bis(triphenylphosphoranylidene)ammonium tetrakis 
(4-chlorophenyl)borate) was prepared by metathesis of potassium 
tetrakis(4-chlorophenyl)borate (Fluka, Buchs, Switzerland) and of 
bis(triphenylphosphoranylidene)ammonium chloride (Aldrich, Buchs, 
Switzerland). 
Dehydrated medium for reconstitution with water of Mueller-Hinton 
and broth was purchased from Difco® (Brunschwig, Basel, Switzerland). 
Distilled water was used throughout. 
7.3.2 Bacterial strain 
Escherichia coli (ATCC 25922) was chosen as bacterial strain in this 
study and was obtained from the American Type Culture Collection 
(ATCC, Manassas, USA) [33]. E. coli is the most common bacterium 
isolated in clinical microbiology laboratories, the most prevalent 
microorganism in feces, the most common cause of urinary tract infection, 
and a common cause of both intestinal and extra-intestinal infections [6]. 
E. coli belongs to the Enterobacteriaceae, a family of Gram-negative, 
rod-shaped bacteria (157 species grouped into 29 genera) which can grow 
rapidly by respiratory metabolism in the presence of oxygen and by 
fermentation in its absence. E. coli is classified as mesophile with respect 
to temperature (normal growth between 21 and 37°C), as neutrophile with 
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respect to pH (ideal growth between pH 5.0 and 9.0), and as moderately 
barotolerant with respect to pressure (slow growth above 1 atm) [34,35]. 
7.3.3 Determination of the minimal inhibitory concentration 
(MIC) 
The method used to quantify the antibacterial activity of 
sulfonamides was to determine the minimal concentration needed to 
completely inhibit the growth of a given bacterial strain. This is called the 
minimal inhibitory concentration (MIC) which was determined using a 
broth macrodilution method, as recommended by the National Committee 
for Clinical Laboratory Standards (NCCLS) [33].  
Preparation of Mueller-Hinton broth 
Mueller-Hinton broth (MHB) is a medium for antimicrobial 
susceptibility testing which is internationally recognized in standard 
procedures [33]. Moreover, the low levels of para-aminobenzoic acid 
(PABA) makes this medium suitable for testing sulfonamides. MHB is 
composed of dehydrated infusion from beef, casein hydrolysate and starch. 
The two former ingredients provide amino acids and other useful 
substances for growth, while starch acts as detoxifying agent. MHB was 
prepared by dissolving 21 g of powder in 1 L of distilled water. The 
medium was then sterilized by autoclaving at 121°C for 15 minutes. The 
broth solution thus obtained was clear and yellowish-brown with a pH of 
7.3 ± 0.1 at 25°C. 
This medium was used to prepare the inoculum (Escherichia coli, 
ATCC 25922). It was buffered at pH 7.0 by adding phosphate salts 
(50 mM) to the broth solution, and sterilized by filtration on a Stericup™ 
filtration system (Bedford, USA). 
Preparation of stock solutions of sulfonamides 
Stock solutions of sulfonamides (1 mg/mL or 5 mg/mL) were prepared 
by dissolving the drugs with a minimal amount of NaOH 2.5 M and by 
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diluting with a buffered solution at pH 7.0 (50 mM phosphate salts). These 
solutions were then sterilized by filtration using sterile Millipore filters 
(Millex-GS, syringe driven filter unit, 0.22 µm pore diameter) mounted on 
sterile syringes (Omnifix, Luer lock, 20 ml from Braun, Melsungen, 
Germany), and stored at 4°C until needed. 
Preparation of the inoculum 
The density of inoculum in antimicrobial susceptibility assays is 
critical for the results so that its adjustment has to be carefully achieved 
[36]. The inoculum was prepared from a stock culture of Escherichia coli 
(ATCC 25922) stored at -80°C in a rich nutritive medium containing 10% 
glycerol as antifreeze. An aliquot of the stock culture was streaked onto an 
agar plate supplemented with sheep blood (nonselective medium) and 
incubated overnight at 35°C in an ambient air incubator. This preliminary 
stage was performed to check the purity of the stock culture. Then, one or 
two colonies from overnight growth were suspended in Mueller-Hinton 
broth and incubated overnight at 35°C. For rapidly growing bacteria like 
E. coli, overnight broth cultures reach approximately 109 CFU/mL (CFU 
or colony forming units). 
A portion of the inoculum suspension was diluted 1:1000 in 
NaCl 0.9% so that an intermediate inoculum of 106 CFU/mL was 
obtained. When 10 µL of this dilution were added to each tube containing 
1 mL of diluted antibacterial agent (see below), a final inoculum of 
104 CFU/mL was obtained. 
Two aliquots of the inoculum suspension at 104 CFU/mL were 
diluted 1:10 and 1:100 in NaCl 0.9%, respectively, and 100 µL of each 
solution were streaked onto an agar plate supplemented with sheep blood 
to check for purity and inoculum density (see Fig. 7.4).  
The adjusted inoculum suspension was used within 15 minutes of 
preparation, since longer delays may change the inoculum size.  
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Determination of antibacterial activities 
Experiments were performed as follows: 
1. A series of twofold dilutions was prepared in sterile tubes from 
each stock solution and MHB buffered at pH 7.0 (50 mM 
phosphate salts) to obtain a final volume of 1 mL per tube.  
2. Each tube was inoculated with 10 µL of adjusted inoculum (see 
above) and covered with plastic parafilm®.  
3. All tubes were then incubated overnight at 35°C in an ambient 
air incubator. In addition, two tubes were filled with buffered 
MHB and one of them was inoculated to serve, respectively, as a 
positive and as a negative control for bacterial growth. 
4. The tubes from overnight growth were inspected visually to 
determine where bacteria had grown, as indicated by turbidity. 
The tubes in which the antimicrobial agent was present in 
concentrations sufficient to inhibit bacterial growth remained 
clear (see Fig. 7.5). In experimental terms, the MIC is the 
concentration of antimicrobial agent present in the “last” clear 
tube and the smaller the concentration, the greater the activity. 
5. The pH was verified in each tube after determination of the MIC, 
using an Orion micro pH-electrode (Hügli-Labortec, Abtwil, 
Switzerland). 
6. Growth, purity and inoculum density were checked.  
7.3.4 pKa measurements 
The ionization constants were determined by potentiometric 
titrations using the GLpKa apparatus (Sirius Analytical Instruments Ltd, 
Forrest Row, East Sussex, UK) as previously described [37]. The low 
aqueous solubility of sulfonamides required pKa measurements in the 
presence of methanol as co-solvent. For these compounds, several separate 
20-mL semi-aqueous solutions of ca. 1 mM, in 10-50% (w/w) methanol and 
0.15 M KCl (to adjust ionic strength), were initially alkalinized to an 
appropriately high pH with standardized KOH.  
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Fig. 7.4. Inoculation with bacteria (Escherichia coli ATCC 25922) of an 
agar plate supplemented with sheep blood. Dilution 1:10 (left 
plate) and 1:100 (right plate ) of an adjusted inoculum 
(104 CFU/ml). Each spot represents a colony forming unit 
(CFU). 
 
Fig. 7.5. Determination of the minimal inhibitory concentration (MIC) of 
sulfisoxazole against Escherichia coli (ATCC 25922) in 
Mueller-Hinton broth buffered at pH 7.0 (50 mM phosphate 
salts). 
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The solutions were then titrated with HCl 0.5 M to low pH 
(minimum 1.8). The titrations were conducted under an inert gas 
atmosphere (Ar) at 25.0 ± 0.1°C. The initial estimates of psKa values (the 
apparent ionization constants in the H2O/co-solvent mixture) were 
obtained from Bjerrum plots. These values were refined by a weighted 
non-linear least-squares procedure. The refined values were then 
extrapolated to zero percent of co-solvent by the Yasuda-Shedlovsky 
procedure [38].  
7.3.5 Partition coefficients measurements 
The partition coefficients in octanol/H2O and DCE/H2O were 
determined by the pH-metric method with the GLpKa apparatus. The 
principle of the pH-metric method for pKa and log P measurements has 
been explained in detail elsewhere [37,38]. At least three separate 
titrations of sulfonamides (ca. 1 mM) were carried out in the pH range 1.8 
to 11.0, using various volumes of octanol or DCE (volume ratios of organic 
solvent/H2O ranging from 0.2 to 1.0). All experiments were performed 
under Ar at 25.0 ± 0.1°C. The log P values were estimated from difference 
Bjerrum plots [39] and refined by a non-linear least squares procedure by 
including previous determined pKa values as unrefined contributions. 
7.3.6 Cyclic voltammetry measurements 
The experimental set-up used was a home-made four-electrode 
potentiostat, as described in reference [40], with ohmic drop compensation 
[41]. The scanning of the applied potential was performed by a waveform 
generator (VA-scanner E 612, Metrohm, Herisau, Switzerland), coupled to 
an X-Y recorder (Bausch & Lomb, Rochester, NY, USA). Both the cell and 
the four-electrode potentiostat were housed in a Faraday cage. All 
experiments were carried out at room temperature (25°C). 
The electrochemical cell used in all experiments was described in 
Fig. 7.6. 
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Fig. 7.6. Electrochemical chain. 
Water and 1,2-dichloroethane were mutually saturated. The drugs 
were dissolved in the aqueous phase. The pH of the aqueous solution was 
adjusted to the desired value with H2SO4 or LiOH. 
In this work, an increase of the Galvani potential difference between 
the two phases (noted wo∆ φ ) renders the aqueous phase more positive than 
the organic phase. This increase of wo∆ φ  creates a flow of negative charges 
from 1,2-dichloroethane to water which is taken as a positive current. 
All half-wave potentials measured (noted w 1/2o i∆ φ ) were referred to 
the half-wave potential of the tetramethylammonium cation (TMA). Thus, 
the standard transfer potential of an ion Xi (noted w 0o i∆ φ ) can be calculated 
using Eq. 7.1 [42]: 
1/2 0 1/2 0
i i TMA TMA -  =  - 
α α α αβ β β β∆ φ ∆ φ ∆ φ ∆ φ  Eq. 7.1 
Since the value of w 0o TMA∆ φ  is known (160 mV on the tetraphenylarsonium 
tetraphenylborate scale [43]), the standard Gibbs transfer energy of ion Xi 
( tr, 
0 w o
iG
,∆ → ) and its standard partition coefficient ( 0ilog P ) can be 
calculated using Eqs 7.2 and 7.3 [44]: 
tr, 
0 w o
i0
i
i
G
 =  
z F
,
αβ
∆∆ φ ⋅
→
  Eq. 7.2 
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tr, 
0 w o
i0  i
G
log P =  - 
R T ln10
,∆
⋅ ⋅
→
  Eq. 7.3 
7.4 Results and discussion 
The experimental physicochemical parameters and the antibacterial 
activity of the 24 sulfonamides investigated are summarized in Table 7.1. 
The chemical structures are illustrated in Fig. 7.8. 
7.4.1 Viability of the microorganisms 
The bacterial growth of E. coli (ATCC 25922) in the broth solution 
tempered at 35°C and buffered at pH 7.0 (50 mM phosphate salts) was 
checked spectrophotometrically at 620 nm. As illustrated in Fig. 7.7 the 
absorbance of the solution, corresponding to the bacterial density, 
increases exponentially to reach a steady-state after 5 hours. The 
inoculation of an agar plate with the suspension after 14 hours growth 
indicated that the inoculum reached 109 CFU/mL (CFU or colony forming 
units). These results show that the broth solution is adequate for good and 
fast bacterial growth.  
0 2 4 6 8 10 12 14 16
0.0
0.2
0.4
0.6
0.8
temps [h]
A
bs
or
ba
nc
e
 
Fig. 7.7. Bacterial growth of E.coli (ATCC 25922) measured at 620 nm 
in Mueller-Hinton broth buffered at pH 7.0 (50 mM phosphate 
salts). 
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N1-heterocyclic derivates containing five-membered rings 
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Fig. 7.8. Chemical structures of the sulfonamides studied. 
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N1-heterocyclic derivates containing six-membered rings 
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Fig. 7.8. Continued. 
 
  
Table 7.1.  Experimental and computational physicochemical parameters of sulfonamides. 
N° Physicochemical properties Antibacterial 
activity 
 MW 1apK
a) 2apK
a) Noctlog P  b) CLOGP c) MLPlog P d) Ndcelog P b) ∆ Noct-dcelog P e) 0,Adcelog P  f) N-Adce(log P )diff  g) log (1/MIC) h) 
1 172.21 2.15 10.42 -0.67 -0.57 -1.19 -0.68 0.01 ⎯ ⎯ 1.92 
2 214.24 1.78 5.28 -0.36 -0.98 -1.08 -0.72 0.36 ⎯ ⎯ 2.92 
3 254.31 1.90 5.54 1.08 0.75 -0.53 1.02 0.06 -5.16 6.18 3.00 
4 276.32 1.70 4.18 1.43 1.56 0.05 1.60 -0.17 -3.84 5.44 3.03 
5 215.24 1.77 5.41 -0.65 -0.72 -1.80 -1.47 0.82 ⎯ ⎯ 2.62 
6 214.24 2.79 11.49 -1.22 -1.24 -1.87 ⎯ ⎯ ⎯ ⎯ 2.02 
7 249.30 2.64 8.45 0.01 0.84 0.17 0.40 -0.39 -5.19 5.59 2.99 
8 250.28 1.98 6.43 -0.19 0.07 -0.59 0.36 -0.55 -6.09 6.45 3.89 
9 264.32 2.66 6.79 0.34 0.57 0.02 0.57 -0.23 -5.71 6.28 3.62 
10 278.34 2.73 7.52 0.44 1.07 0.60 0.84 -0.40 -5.25 6.09 3.34 
11 278.34 2.80 7.29 -0.13 1.07 0.45 -0.37 0.24 -5.34 4.97 3.64 
12 280.32 2.07 5.98 0.91 0.94 -0.44 0.76 0.15 -4.62 5.38 3.94 
13 280.32 1.57 6.59 0.46 0.59 -0.33 0.54 -0.08 -5.63 6.17 3.64 
14 280.32 2.09 7.02 0.40 0.96 -0.10 0.82 -0.42 -5.02 5.84 3.64 
15 284.73 1.61 5.16 1.56 0.76 -0.25 1.29 0.27 -3.21 4.50 3.35 
16 294.34 1.97 6.92 -0.22 -0.52 -1.04 0.40 -0.62 ⎯ ⎯ 3.96 
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Table 7.1.  Continued 
N° Physicochemical properties Antibacterial 
activity 
 MW 1apK
a) 2apK
a) Noctlog P  b) CLOGP c) MLPlog P d) Ndcelog P b) ∆ Noct-dcelog P e) 0,Adcelog P  f) N-Adce(log P )diff  g) log (1/MIC) h) 
17 310.34 1.80 5.85 0.83 0.90 -0.10 1.63 -0.80 -4.99 6.62 3.38 
18 310.34 2.24 6.53 1.29 1.80 -0.17 1.19 0.10 -4.00 5.19 3.38 
19 255.32 1.90 7.20 0.08 0.72 -0.59 -0.08 0.16 -4.23 4.15 3.90 
20 253.29 2.28 5.68 0.89 0.55 -1.10 0.95 -0.06 -4.72 5.67 3.90 
21 276.31 1.62 4.83 1.01 0.21 -0.79 0.92 0.09 -4.21 5.13 3.64 
22 267.31 1.76 6.97 0.13 0.50 -0.67 0.29 -0.16 -4.80 5.09 3.32 
23 270.35 2.06 5.23 0.66 0.20 0.21 0.30 0.36 -4.65 4.95 3.32 
24 314.40 1.73 5.89 1.34 2.04 -0.02 1.66 -0.32 -2.99 4.65 3.69 
a) Ionization constants for the basic (1) and acidic (2) group determined by potentiometry; n = 5; SD < 0.1. 
b) Logarithm of n-octanol/water and 1,2-dichloroethane/water partition coefficient of the neutral form determined by potentiometry; n = 3; SD < 0.04. 
c) Calculated by the CLOGP algorithm [45]. 
d) Logarithm of n-octanol/water partition coefficient of the neutral form back-calculated from MLP [46]. 
e) ∆ N N Noctoct-dce dcelog P ) = log P  - log P . 
f) Standard partition coefficient of the anionic form measured by cyclic voltammetry; n = 6; SD < 0.1. 
g) N-A N 0,Adce dce dce(log P ) = log P  - log Pdiff . 
h) MIC is the minimal inhibitory concentration in [M] (see section 7.3.3). 
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7.4.2 Antibacterial activity of sulfonamides 
Due to the small range of activity (two log units) covered by the set of 
sulfonamides, a qualitative analysis of the results instead of a 
quantitative multi-linear analysis was performed. 
Effect of pKa 
The relationship between antibacterial activity and pKa2 of the 
investigated sulfonamides is illustrated in Fig. 7.9. For convenience in 
plotting the graph, log (1/MIC) is used rather than MIC. These results do 
not seem to correlate with the relationship previously described by Bell 
and Roblin [19], despite the experiments being performed with the same 
bacterial strain (E. coli) and at the same pH (7.0). Bell and Roblin 
observed a parabolic response between the antibacterial activity and the 
acid ionization constant with a maximum laying between pKa 6 and 7.4 
(Fig. 7.10).  
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Fig. 7.9. Antibacterial activity of the investigated sulfonamides as a 
function of 2apK  (•) N1-acyl derivates, ({) N1-heterocyclic 
derivates containing six-membered rings and (c) 
five-membered rings, respectively. 
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Fig. 7.10. Relationship of in vitro antibacterial activity of sulfonamides 
to 2apK . The data are taken from Bell and Roblin [19]. 
The discrepancy observed between the results may come from the 
non-equivalence of the biological activity. However, as depicted in 
Fig. 7.11 the comparison of the antibacterial activities of 9  compounds 
measured in common highlights the same qualitative trend. The 
quantitative differences may be due to variation in experimental 
conditions, such as broth solution or inoculum density. 
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Fig. 7.11. Comparison of the antibacterial activity measured in this 
study (•) with those measured by Bell and Roblin ({)[19]. 
Compound numbering follows that in Table 7.1. 
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Based on a set of 50 N1-substituted sulfonamides, Bell and Roblin 
emphasized the value of this relationship for predicting the MIC of new 
sulfonamides and thus the 2apK  of most of the active sulfonamides 
discovered since then falls in this range. In our study, most of the selected 
compounds have a 2apK  value corresponding to an optimal activity and 
are thus clustered in the top of the parabolic curve depicted in Fig. 7.10. 
Effect of lipophilicity 
To inhibit their enzymatic target, namely dihydropteroate synthase 
which localized inside the bacteria, sulfonamides must cross biological 
membranes. Some physicochemical parameters have proven particularly 
useful for predicting drug permeation, but none has attracted as much 
interest as lipophilicity [47]. The n-octanol/water system has been one of 
the most suitable models of lipidic biological membranes, because of the 
analogy of n-octanol with lipids ⎯ its long alkyl chain and the polar 
hydroxy group.  
The antibacterial activity of sulfonamides was thus investigated in 
terms of lipophilicity measured in the n-octanol/water system. As shown in 
Fig. 7.12A, an optimal range of lipophilicity corresponding to a good 
antibacterial activity is observed with compounds having a Noctlog P  > 0. 
Below this Noctlog P  value, the compounds are too polar and their 
permeation is thus strongly hindered. Although the inhibition of 
dihydropteroate synthase is due to the anionic form of sulfonamides, the 
penetration component is the rate-limiting step for bacteriostasis. 
Other different solvent systems yielding partitioning information 
complementary to n-octanol/water data have been suggested for the 
modeling of various membranes and tissues [48]. Recently, the 
1,2-dichloroethane/water system has been used as an inert solvent 
intended to mimic the highly hydrophobic region of membranes [49]. The 
relationship between antibacterial activity and lipophilicity expressed by 
the 1,2-dichloroethane/water partitioning (Fig. 7.12B) shows the same 
trend as those described with n-octanol/water system. An optimal range of 
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lipophilicity ( Ndcelog P  > 0) is also observed, thus confirming the 
importance of this parameter in permeation. 
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Fig. 7.12. Antibacterial activity of the investigated sulfonamides as a 
function of lipophilicity measured in terms of n-octanol/water 
partitioning (A) and 1,2-dichloroethane/water partitioning (B). 
(•) N1-acyl derivates, ({) N1-heterocyclic derivates containing 
six-membered rings and (c) five-membered rings, respectively. 
The dashed line stands for borderline of optimal lipophilicity. 
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The ∆ Noct-dcelog P parameter, which derives from lipophilicity and 
encodes the hydrogen-bond donor capacity of a solute, has found useful 
applications in predicting bio-membrane permeation [50,51]. As revealed 
by Fig. 7.13, this parameter however is not pertinent to predict 
antibacterial activity. The ∆ Noct-dcelog P  parameter varies slightly between 
the different sulfonamides due to the shedding effect of R-substituent on 
the hydrogen linked to the amido group (Fig. 7.3). The aromatic amino 
group, being identical in the investigated compounds, does not account for 
variation. The largest ∆ Noct-dcelog P  value observed with sulfacarbamide (5) 
may be due to the accessibility of the hydrogen linked to the amido group 
and to the presence of an additional H-bond forming substituent. 
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Fig. 7.13. Antibacterial activity of the investigated sulfonamides as a 
function of lipophilicity measured by the difference between 
n-octanol/water and 1,2-dichloroethane/water systems.  
(•) N1-acyl derivates, ({) N1-heterocyclic derivates containing 
six-membered rings and (c) five-membered rings, respectively. 
As the anionic form of sulfonamides is responsible for bacteriostasis 
by inhibiting dihydropteroate synthase, the influence of lipophilicity, 
measured in terms of the standard ionic partition coefficient ( 0,Adcelog P ), 
was also investigated (Fig. 7.14). While a large variation in anionic 
lipophilicity data (3 log units) is observed, the 0,Adcelog P  parameter is not 
relevant to predict antibacterial activity. This result supports the view of 
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the predominant role of the neutral form partitioning in permeation. In 
fact, the intracellular ionic concentration of sulfonamides, which is limited 
by the permeation of unionized compounds, governs activity. 
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Fig. 7.14. Antibacterial activity of the investigated sulfonamides as a 
function of their standard ionic partition coefficient measured 
in 1,2-dichloroethane/water. (•) N1-acyl derivates, ({) 
N1-heterocyclic derivates containing six-membered rings and 
(c) five-membered rings, respectively.  
7.4.3 Experimental versus theoretical lipophilicity 
Among the computational methods to calculate the n-octanol/water 
partition coefficient of neutral form ( Noctlog P ) [52], two were investigated 
in terms of predictivity. The first one is the CLOGP algorithm or the Leo 
and Hansch approach which is based on the additivity of molecular 
fragments and the use of numerous correction factors [53]. The second 
method is based on back-calculated lipophilicity from the Molecular 
Lipophilicity Potential or MLP (see chapter 6) [46]. 
CLOGP was calculated for each sulfonamide using the Daylight 
software 4.41 [45]. The correlation between Noctlog P  and CLOGP 
(Fig. 7.15) is not as good as those obtained earlier with other homologous 
series of compounds [54]. These results may be due to badly parameterized 
fragmental values for this set of compounds or to the limitation of the 
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method in predicting conformational effects that occur experimentally in 
solution. Besides these hypotheses, it might also be possible that the 
partition coefficients of compounds with Noctlog P  values lower than 1.0 
were underestimated using the potentiometric method. An overestimated 
N
octlog P  value with this method seems less probable.  
Here, it is interesting to note that whereas the large and increasing 
number of correction factors continues to improve the precision of CLOGP 
for calculating partition coefficients, this number of factors makes it 
difficult to unravel the origin of discrepancies between experimental and 
calculated partition coefficients [55].  
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Fig. 7.15. Relationship between experimental lipophilicity measured in 
the n-octanol/water system and the calculated CLOGP value. 
The correlation between Noctlog P  and the back-calculated lipophilicity 
from MLP ( MLPlog P ), as depicted in Fig. 7.16, is not good. It seems that 
the larger the R-substituent in sulfonamide derivates, the worst the 
prediction. Moreover, the results indicate that the atomic system used in 
MLP is inadequate to predict the lipophilicity of sulfonamide derivates 
[52]. 
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Fig. 7.16. Relationship between experimental lipophilicity measured in 
the n-octanol/water system and the back-calculated value from 
MLP. 
7.5 Conclusion 
Sufonamides have to penetrate inside the bacteria in order to inhibit 
their enzymatic target and produce their bacteriostatic activity. 
Lipophilicity plays a critical role in this process, being the rate-limiting 
step. An optimal lipophilicity of the neutral form ( Noctlog P  and 
N
dcelog P  > 1) is needed so that sufonamides penetrate the bacteria. 
Moreover, acidity is another parameter which strongly influences activity. 
It follows that a weak acidity is favorable for permeation. However, once 
inside the bacteria sulfonamides act on dihydropteroate synthase as 
competitive inhibitors of para-aminobenzoate. This effect being specific for 
the anionic form, a high acidity is hence desirable. As a result of these two 
opposite conditions, the most active sulfonamides are moderately acidic, 
with a compromise pKa around 6.0. As most of the therapeutic 
sulfonamides used in this study falls in this range, the investigations are 
thus limited in terms of acidity properties.  
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8 General conclusion and perspectives 
Interest in transdermal drug delivery has increased in recent years 
owing to its many advantages over other routes of administration. 
However, during the preclinical development of transdermal devices, it is 
difficult as well as unethical to test products in humans initially due to the 
potential toxicity of pharmaceutical agents. Therefore, traditional skin 
models from animals have been used for in vitro and in vivo studies. 
Practically, it would be advantageous to use human skin for permeation 
studies but, for most investigators, this skin type is not readily available. 
Also, skin samples are typically obtained from a variety of anatomical 
sites and under different disease states, which might alter the 
percutaneous permeability of drugs. 
Most transdermal studies are performed using hairless mouse skin. 
However, other models are also used including rat, guinea pig, rabbit and 
shed snake skin, artificial composite membranes, and, more recently, 
living skin equivalents. Although no model has yet been tested that fully 
mimics the results obtained with human skin, there are many similar 
features between these models and human skin.  
Because the determination of absorption of chemicals into and 
through the skin involves ethical difficulties with experiments on animals 
and human skin, the quantification of transdermal penetration raises 
great interest in pharmaceutical, toxicological and cosmetic studies. 
Quantitative structure-permeation relationships (QSPeRs) relate 
variations in the permeation of a series of compounds with variations in 
their physicochemical and/or structural properties. QSPeRs provide 
insights into permeation mechanisms, prediction of the permeation of 
novel compounds and allow to limit in vivo experiments. Certain 
limitations of these models, however, have been pinpointed in this thesis. 
First, an inherent problem lies in the fact that their applicability is 
restricted by the limited range of polarity and size of the permeants on 
which they are based. In addition, most of the models use large 
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compilations of data from various investigators and laboratories 
employing different experimental protocols. Thus, these models show fair 
explanation of variance in the lower molecular size and the middle range 
of lipophilicity, while the divergences for both very hydrophilic and very 
lipophilic compounds become conspicuous. Finally, rigorous statistics show 
that some models are based on non-significant descriptors. As such, they 
do not afford mechanistic insights and may lead to an over-interpretation 
of the data. 
Understanding the physicochemical factors that control passive skin 
permeation is a topic of current interest. In this respect, when human or 
animal skin is difficult to obtain, or when a large number of experiments 
are to be carried out, synthetic membranes have been widely used. Among 
them, silicone membranes have been particularly relevant to mimic the 
hydrophobic nature of the stratum corneum, the outermost epidermal 
layer being considered as the rate-determining step in skin permeation. 
In this thesis, the mechanisms of permeation across silicone 
membranes were characterized by emphasizing the most distinctive 
structural parameters in a series of permeants. The results show that the 
permeation of xenobiotics across silicone membranes is controlled 
primarily by their H-bond donor capacity, in turn strongly influenced by 
intramolecular interactions. Thus, a single H-bond donor parameter is 
shown to correlate with silicone membrane permeability for a congeneric 
set of phenols, whereas a lipophilicity term must be added when 
heterogeneous drugs are included in the correlation. Interestingly, the 
permeation of the extended set is also well described by lipophilicity in the 
1,2-dichloroethane/water system, which encodes a strong contribution 
from H-bond donor capacity, in contrast to the n-octanol/water system 
which does not. 
While traditional QSPeRs in skin permeation are based on 
descriptors for hydrophobic, steric and electronic effects, they usually do 
not take into account the fact that biological and physicochemical 
properties of a compound are strongly dependent on its tri-dimensional 
shape. Moreover, 3D-QSPeRs are often applied to more diverse sets of 
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compounds than traditional approaches, since molecules are described by 
properties calculated directly from their tri-dimensional structures, 
instead of experimental determinations. 3D-QSPeR methods define 
molecular properties in terms of 3D molecular interaction fields (MIFs).  
In this context, a new method called VolSurf, which is able to 
transform the information present in 3D-MIFs into a limited number of 
quantitative descriptors, was used to correlate 3D molecular structures of 
a large and heterogeneous set of compounds with skin permeation. Three 
different MIFs were investigated, namely GRID which is based on the 
total energy of interaction between a probe and a target molecule, MLP 
which is a molecular field of lipophilicity, and MHBPs which take into 
account hydrogen-bonding capacity. The results indicate that while the 
models obtained from both MxPs (MLP and MHBPs) and GRID fields are 
statistically equivalent, MxPs fields are better in terms of mechanistic 
interpretation for skin permeation. 
While this computational method is easy to apply, the interpretation 
of the results must be made carefully. As illustrated in this thesis, a 
detailed knowledge of the information encoded in MIFs is needed to 
correctly interpret the models. In addition, it must be underlined that 
rational drug design from VolSurf models is a very difficult task. Indeed 
the large number of non-equivalent parameters coming from different 
MIFs produces very complex predictive models and renders nearly 
impossible the back-translation of the balance of all contributions into 3D 
structures. 
To reach their site of action, drugs have to cross biological 
membranes. As exemplified in this study with sulfonamides, these 
compounds must cross bacterial membranes to inhibit their enzymatic 
target, namely dihydropteroate synthase which is localized inside the 
bacteria. Lipophilicity plays a critical role in this process since an optimal 
lipophilicity of the neutral form is needed so that sulfonamides penetrate 
the bacteria. Moreover, acidity is another parameter which strongly 
influences activity since the anionic form of sulfonamides acts on 
dihydropteroate synthase. As a result, the most active sulfonamides are 
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moderately acidic, with a compromise pKa around 6.0. As most of the 
therapeutic sulfonamides used in our study falls in this range, the 
investigations are thus limited in terms of acidity properties. 
The ultimate outcome of any model system is obviously its ability to 
yield observations in agreement with the more complex process it is meant 
to mimic. This study has shown that silicone membranes may be a useful 
trend-predictive model for skin permeation. These models, however, do not 
incorporate all the structural features needed to evaluate interactions 
occurring during percutaneous transport. Thus, other polymeric 
membranes, based on co-polymerization of hydrophilic and hydrophobic 
constituents, are worthy of further investigations. 
Today, the use of combinatorial chemistry in hit and lead finding 
generates huge numbers of compounds. This in turn produces a need for 
the fast and reliable characterization of physicochemical properties 
governing a specific way of permeation. The use of computational tool to 
predict skin permeation such the VolSurf approach may be very attractive, 
but a careful analysis of conformational effects should be taken into 
account since it may influence the predictivity of a model. 
Finally, to better characterize the antibacterial activity of 
sulfonamides, investigations based on the separation of permeation and 
enzymatic inhibition phenomenon should be carried out. Permeation could 
be quantified by the determination of sulfonamide uptake after incubation 
with bacteria, while inhibition constants could be obtained from enzymatic 
kinetics with isolated dihydropteroate synthase. Such tests should be more 
precise than the determination of the minimal inhibitory concentration 
(MIC), for which small differences in bacteriostatic activity (factor of 2) are 
within experimental error. 
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Summary 
In order to exert its pharmacological and therapeutic effects, a drug 
must reach its target sites in sufficient concentration, and it is well 
recognized that the biological activity of drugs mainly depends on their 
interaction with biological membranes. In this context, the aim of this 
thesis is to highlight the relevant physicochemical properties responsible 
for drug permeation across both human skin and into bacteria. 
The first part of this work is dedicated to a critical review of skin 
permeation. The predictive capacity of the different in vivo and in vitro 
models used to estimate skin permeation is discussed and it is shown that 
while no model has yet been tested that fully mimics the results obtained 
with human skin, some models may be trend-predictive. Our studies based 
on permeation across silicone membranes showed that the mechanism was 
controlled primarily by the H-bond donor capacity of permeants, which is 
in turn strongly influenced by intramolecular interactions. Other models 
to predict skin permeation based on quantitative structure-permeation 
relationships (QSPeRs) in predicting skin permeation were reviewed and 
analyzed in terms of their statistical reliability. These models showed fair 
explanation of variance in the lower molecular size and the middle range 
of lipophilicity, while divergences for both very hydrophilic and very 
lipophilic compounds are conspicuous. 
As the experimental measurement of transdermal drug permeation is 
fraught with difficulties, including problems to obtain human skin 
samples, various computational methods for predicting skin permeation 
have been developed. In this context a new procedure called VolSurf was 
investigated. Specific considerations on the nature of molecular interaction 
fields used in this method were discussed. 
In the last part, the antibacterial activity of sulfonamides was 
investigated in terms of their physicochemical properties. The results 
indicated that both lipophilicity of the neutral form and acidity were 
relevant for activity. 
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Résumé 
Pour exercer ses effets pharmacologiques et thérapeutiques, un 
médicament doit atteindre son site d’action en concentrations suffisantes. 
Ce processus dépend essentiellement des interactions entre le médicament 
et les membranes biologiques. Ainsi, le but de cette thèse est d’identifier 
les propriétés physico-chimiques les plus pertinentes pour la perméation 
médicamenteuse, tant à travers la peau humaine qu’au travers de 
bactéries. 
La première partie de ce travail consiste en une revue critique de la 
perméation cutanée. Les limites d’application de différents modèles in vivo 
et in vitro sont abordées en soulignant le fait que bien qu’aucun modèle ne 
rende entièrement compte de la complexité de la peau humaine, certains 
d’entre eux sont utiles comme outils prédictifs. Nos études basées sur la 
perméation au travers de membranes en silicone ont montré que ce 
mécanisme dépendait avant tout de la capacité d’un soluté à former des 
liaisons hydrogènes intramoléculaires. Dans le but de prédire la 
perméation cutanée, plusieurs modèles basés sur des relations entre la 
structure et le passage membranaire ont été passés en revue et examinés 
en fonction de leur fiabilité statistique. Bien que ces modèles soient 
pertinents pour prédire la perméation de composés de faible poids 
moléculaire et de lipophilie moyenne, ils sont en revanche peu fiables pour 
prédire le devenir de composés sortant de ces critères. 
Pour faire face aux problèmes liés à l’obtention de tissu cutané 
d’origine humaine, des méthodes de calculs prévisionnels se sont 
développées parallèlement aux mesures expérimentales. Dans cette étude, 
l’algorithme VolSurf a été utilisé et des observations importantes sur la 
nature des champs moléculaires d’interaction ont été relevées. 
Finalement, un travail basé sur l’identification au sein d’une classe 
de sulfamidés de propriétés physico-chimiques jouant un rôle dans leur 
activité antibactérienne a montré que tant la lipophilie de la forme neutre 
que l’acidité de ces composés sont des paramètres importants. 
 
